

Sonder Health Plans, Inc.
Dual Complete (HMO D-SNP)
2024 Formulary
List of Covered Drugs

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File Submission ID 24457, Version Number 6

This formulary was updated on 08/25/2023. For more recent information or other questions, please contact us, Sonder Health Plans Member Service at 1-833-684-7263 (TTY users should call 711), 24 hours a day, 7 days a week, or visit www.sonderhealthplans.com.

- **Important Message About What You Pay for Insulin** - You won't pay more than \$35 for a one-month supply of each insulin product covered by our plan, no matter what cost-sharing tier it's on, even if you haven't paid your deductible.
- **Important Message About What You Pay for Vaccines** - Our plan covers most Part D vaccines at no cost to you, even if you haven't paid your deductible. Call Member Services for more information.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to "we," "us", or "our," it means Sonder Health Plans. When it refers to "plan" or "our plan," it means Sonder Dual Complete (HMO D-SNP).

This document includes a list of the drugs (formulary) for our plan which is current as of 08/25/2023. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2024, and from time to time during the year.

What is the Sonder Health Plans Dual Complete (HMO D-SNP) Formulary?

A formulary is a list of covered drugs selected by Sonder Health Plans Dual Complete (HMO D-SNP) in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. We will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Sonder Health Plans Dual Complete (HMO D-SNP) network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

For a complete listing of all prescription drugs covered by our plan, please visit our website or call us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand-name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand-name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand-name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can find information in the section below titled “How do I request an exception to the Sonder Health Plans Dual Complete (HMO D-SNP)’s Formulary?”

Drugs removed from the market. If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.

- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to the market to replace a brand-name drug currently on the formulary or add new restrictions to the brand-name drug or move it to a different cost-sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.
 - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand-name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Sonder Health Plans Dual Complete (HMO D-SNP)’s Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2024 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2024 coverage year except as described above. This means these drugs will

remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of August 25, 2023. To get updated information about the drugs covered by our plan please contact us. Our contact information appears on the front and back cover pages. If we make certain non-routine changes to coverage for drugs, we will send members an errata sheet to update the formulary they received.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 4. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, Cardiovascular Agents. If you know what your drug is used for, look for the category name in the list that begins on 1. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page 94. The Index provides an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Our plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs cost less than brand-name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plan requires you [or your physician] to get prior authorization for certain drugs. This means that you will need to get approval from us before you fill your prescriptions. If you don't get approval, we may not cover the drug.
- **Quantity Limits:** For certain drugs, our plan limits the amount of the drug that we will cover. For example, our plan provides 240 tablets per 30-day prescription for Tramadol HCl Tablet 50MG. This may be in addition to a standard one-month or three-month supply.

- **Step Therapy:** In some cases, our plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 4. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask us to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the Sonder Health Plans Dual Complete (HMO D-SNP)’s formulary?” on page iv for information about how to request an exception.

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Member Services for a list of similar drugs that are covered by our plan. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Sonder Health Plans Dual Complete (HMO D-SNP)’s Formulary?

You can ask us to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.

- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, our plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, we will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, tier, or utilization restriction exception. **When you request a formulary, tier, or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

If you experience a change in your level of care, such as a move from a home to a long-term care setting, and need a drug that is not on our formulary (or if your ability to get your drugs is limited), we may cover a onetime temporary supply from a network long-term care pharmacy for up to 31 days unless you have a prescription for fewer days. If you experience a change in your level of care, such as a move from a hospital to home, and need a drug that is not on our formulary (or if your ability to get your drugs is limited), we may cover a one-time temporary supply from a network pharmacy for up to 31 days unless you have a prescription for fewer days. You should use the plan's exception process if you wish to have continued coverage of the drug after the temporary supply is finished.

For more information

For more detailed information about your plan’s prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about our plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

Drug tier copay levels

This 2024 comprehensive formulary is a listing of brand-name and generic drugs. Sonder Health Plans Dual Complete (HMO D-SNP)’s 2024 formulary covers most drugs identified by Medicare as Part D drugs. If you qualify for “Extra Help”, you pay nothing for your prescription drug costs as long as you follow our rules. If you no longer qualify for Extra Help, your drug costs may change.

| Cost-Sharing Tier | Retail Pharmacy Cost-sharing In-Network, up to 30-day or 1 month supply | Retail Pharmacy Cost-sharing In-Network, 90-day or 3-month supply | Long-Term Care (LTC) Cost-Sharing In-Network, up to 31-day or 1 month supply | Mail Order Cost-Sharing 90-day or 3-month supply |
|--------------------------|--|--|---|---|
| Tier 1 | 25% | 25% | 25% | 25% |
| Tier 2 | 25% | 25% | 25% | 25% |
| Tier 3 | 25% | 25% | 25% | 25% |
| Tier 4 | 25% | 25% | 25% | 25% |
| Tier 5 | 25% | 25% | 25% | 25% |

Sonder Health Plans Dual Complete (HMO D-SNP) Formulary

The formulary below provides coverage information about the drugs covered by our plan. If you have trouble finding your drug in the list, turn to the Index that begins on page 94.

The first column of the chart lists the drug name. Brand-name drugs are capitalized (e.g., SYNTHROID) and generic drugs are listed in lower-case italics (e.g., levothyroxine).

The information in the Requirements/Limits column tells you if our plan has any special requirements for coverage of your drug.

Sonder Health Plans Dual Complete (HMO D-SNP)
2024 5-Tier (List of Covered Drugs)
List of Drugs by Medical Condition

| | |
|---|----|
| ANALGESICS | 4 |
| ANESTHETICS | 6 |
| ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS | 6 |
| ANTIBACTERIALS | 7 |
| ANTICONVULSANTS | 13 |
| ANTIDEMENTIA AGENTS | 16 |
| ANTIDEPRESSANTS | 17 |
| ANTIEMETICS | 20 |
| ANTIFUNGALS | 21 |
| ANTIGOUT AGENTS | 22 |
| ANTIMIGRAINE AGENTS | 23 |
| ANTIMYASTHENIC AGENTS | 24 |
| ANTIMYCOBACTERIALS | 24 |
| ANTINEOPLASTICS | 24 |
| ANTIPARASITICS | 32 |
| ANTIPARKINSON AGENTS | 33 |
| ANTIPSYCHOTICS | 34 |
| ANTISPASTICITY AGENTS | 37 |
| ANTIVIRALS | 37 |
| ANXIOLYTICS | 42 |
| BIPOLAR AGENTS | 43 |
| BLOOD GLUCOSE REGULATORS | 43 |
| BLOOD PRODUCTS AND MODIFIERS | 47 |
| CARDIOVASCULAR AGENTS | 48 |
| CENTRAL NERVOUS SYSTEM AGENTS | 56 |
| DENTAL AND ORAL AGENTS | 58 |
| DERMATOLOGICAL AGENTS | 59 |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | 62 |
| EXCLUDED DRUG COVERAGE | 66 |
| GASTROINTESTINAL AGENTS | 66 |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | 68 |
| GENITOURINARY AGENTS | 68 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | 70 |

| | |
|---|----|
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY) | 70 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | 71 |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) | 76 |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | 77 |
| HORMONAL AGENTS, SUPPRESSANT (THYROID) | 78 |
| IMMUNOLOGICAL AGENTS | 78 |
| INFLAMMATORY BOWEL DISEASE AGENTS | 84 |
| METABOLIC BONE DISEASE AGENTS | 85 |
| OPHTHALMIC AGENTS | 85 |
| OTIC AGENTS | 88 |
| RESPIRATORY TRACT/ PULMONARY AGENTS | 89 |
| SKELETAL MUSCLE RELAXANTS | 93 |
| SLEEP DISORDER AGENTS | 93 |

Legend

1: Preferred Generics

2: Generics

3: Preferred Brands

4: Non-Preferred Drugs

5: Specialty

BvD: Part B vs. Part D- This prescription drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

E: Excluded Drug - This prescription drug is not normally covered in a Medicare Prescription Drug Plan and is considered enhanced coverage. The amount you pay when you fill a prescription for this drug does not count toward your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug. Quantity limits apply and this drug will not be covered during the gap period per individual plan design.

MO: Mail Order Eligible - This prescription may also be available via mail.

PA: Prior Authorization- You (or your physician) are required to get prior authorization before you fill your prescription for this drug. Without prior approval, we may not cover this drug.

QL: Quantity Limit- There is a limit on the amount of this drug that is covered per prescription, or within a specific time frame.

ST: Step Therapy - In some cases, you may be required to first try certain drugs to treat your medical condition before we will cover another drug for that condition.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| ANALGESICS | | |
| <i>Analgesics</i> | | |
| <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| <i>butalbital-asa-caff-codeine oral capsule 50-325-40-30 mg</i> | 4 | MO; QL (180 EA per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| Nonsteroidal Anti-Inflammatory Drugs | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | 2 | MO |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | MO |
| <i>diclofenac sodium er oral tablet extended release 24 hour 100 mg</i> | 1 | MO |
| <i>diclofenac sodium external gel 1 %</i> | 2 | MO |
| <i>diclofenac sodium oral tablet delayed release 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>diflunisal oral tablet 500 mg</i> | 2 | MO |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | MO |
| <i>etodolac oral tablet 400 mg, 500 mg</i> | 2 | MO |
| <i>flurbiprofen oral tablet 100 mg</i> | 1 | MO |
| IBU ORAL TABLET 600 MG, 800 MG | 1 | MO |
| <i>ibuprofen oral suspension 100 mg/5ml</i> | 1 | MO |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | MO |
| <i>indomethacin er oral capsule extended release 75 mg</i> | 2 | MO |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 1 | MO |
| <i>ketorolac tromethamine oral tablet 10 mg</i> | 1 | MO |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | MO |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 1 | MO |
| <i>naproxen oral suspension 125 mg/5ml</i> | 2 | MO |
| <i>naproxen oral tablet 250 mg, 375 mg, 500 mg</i> | 1 | MO |
| <i>naproxen oral tablet delayed release 375 mg, 500 mg</i> | 2 | MO |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | 2 | MO |
| <i>oxaprozin oral tablet 600 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| <i>piroxicam oral capsule 10 mg, 20 mg</i> | 2 | MO |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 1 | MO |
| Opioid Analgesics, Long-Acting | | |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hr, 50 mcg/hr, 62.5 mcg/hr, 75 mcg/hr, 87.5 mcg/hr</i> | 4 | PA; MO; QL (10 EA per 30 days) |
| <i>methadone hcl oral tablet 10 mg, 5 mg</i> | 2 | MO; QL (240 EA per 30 days) |
| <i>morphine sulfate er oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>oxycodone hcl er oral tablet er 12 hour abuse-deterrent 10 mg, 20 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| Opioid Analgesics, Short-Acting | | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5ml</i> | 2 | MO; QL (5000 ML per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg, 300-60 mg</i> | 2 | MO; QL (360 EA per 30 days) |
| <i>codeine sulfate oral tablet 15 mg, 30 mg, 60 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1200 mcg, 1600 mcg, 600 mcg, 800 mcg</i> | 5 | PA; QL (120 EA per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg, 400 mcg</i> | 4 | PA; MO; QL (120 EA per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15ml</i> | 2 | MO; QL (5500 ML per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | MO; QL (360 EA per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | 2 | MO; QL (150 EA per 30 days) |
| <i>hydromorphone hcl oral liquid 1 mg/ml</i> | 4 | MO; QL (1920 ML per 30 days) |
| <i>hydromorphone hcl oral tablet 2 mg, 4 mg</i> | 2 | MO; QL (360 EA per 30 days) |
| <i>hydromorphone hcl oral tablet 8 mg</i> | 2 | MO; QL (240 EA per 30 days) |
| <i>morphine sulfate (concentrate) oral solution 20 mg/ml</i> | 2 | MO; QL (600 ML per 30 days) |
| <i>morphine sulfate oral solution 10 mg/5ml</i> | 2 | MO; QL (1800 ML per 30 days) |
| <i>morphine sulfate oral solution 20 mg/5ml</i> | 2 | MO; QL (1500 ML per 30 days) |
| <i>morphine sulfate oral tablet 15 mg, 30 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| <i>oxycodone hcl oral concentrate 100 mg/5ml</i> | 4 | MO; QL (180 ML per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>oxycodone hcl oral solution 5 mg/5ml</i> | 4 | MO; QL (1080 ML per 30 days) |
| <i>oxycodone hcl oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| <i>oxycodone-acetaminophen oral solution 5-325 mg/5ml</i> | 2 | MO; QL (1080 ML per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg, 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | 2 | MO; QL (360 EA per 30 days) |
| <i>tramadol hcl oral tablet 100 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>tramadol hcl oral tablet 50 mg</i> | 1 | MO; QL (240 EA per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | 2 | MO; QL (240 EA per 30 days) |
| ANESTHETICS | | |
| <i>Local Anesthetics</i> | | |
| <i>lidocaine external patch 5 %</i> | 4 | PA; MO; QL (90 EA per 30 days) |
| <i>lidocaine hcl external solution 4 %</i> | 2 | MO; QL (50 ML per 30 days) |
| <i>lidocaine viscous hcl mouth/throat solution 2 %</i> | 4 | MO |
| <i>lidocaine-prilocaine external cream 2.5-2.5 %</i> | 2 | MO; QL (30 GM per 30 days) |
| ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS | | |
| <i>Alcohol Deterrents/Anti-Craving</i> | | |
| <i>acamprosate calcium oral tablet delayed release 333 mg</i> | 2 | MO |
| <i>disulfiram oral tablet 250 mg</i> | 2 | MO |
| <i>naltrexone hcl oral tablet 50 mg</i> | 2 | MO |
| VIVITROL INTRAMUSCULAR SUSPENSION RECONSTITUTED 380 MG | 5 | |
| <i>Opioid Dependence</i> | | |
| <i>buprenorphine hcl sublingual tablet sublingual 2 mg, 8 mg</i> | 2 | MO |
| <i>buprenorphine hcl-naloxone hcl sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg</i> | 1 | MO |
| <i>buprenorphine hcl-naloxone hcl sublingual tablet sublingual 2-0.5 mg, 8-2 mg</i> | 2 | MO |
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 2-0.5 MG, 4-1 MG, 8-2 MG | 4 | MO |
| <i>Opioid Reversal Agents</i> | | |
| KLOXXADO NASAL LIQUID 8 MG/0.1ML | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>naloxone hcl injection solution 0.4 mg/ml</i> | 2 | MO |
| <i>naloxone hcl injection solution cartridge 0.4 mg/ml</i> | 2 | MO |
| <i>naloxone hcl injection solution prefilled syringe 2 mg/2ml</i> | 2 | MO |
| <i>naloxone hcl nasal liquid 4 mg/0.1ml</i> | 2 | MO |
| NARCAN NASAL LIQUID 4 MG/0.1ML | 3 | MO |
| ZIMHI INJECTION SOLUTION PREFILLED SYRINGE 5 MG/0.5ML | 3 | MO |
| Smoking Cessation Agents | | |
| <i>bupropion hcl er (smoking det) oral tablet extended release 12 hour 150 mg</i> | 1 | MO |
| NICOTROL INHALATION INHALER 10 MG | 4 | MO |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i> | 3 | MO |
| <i>varenicline tartrate oral tablet therapy pack 0.5 mg x 11 & 1 mg x 42</i> | 3 | MO |
| ANTIBACTERIALS | | |
| Aminoglycosides | | |
| <i>amikacin sulfate injection solution 500 mg/2ml</i> | 4 | BvD; MO |
| ARIKAYCE INHALATION SUSPENSION 590 MG/8.4ML | 4 | PA; MO |
| <i>gentamicin in saline intravenous solution 0.8-0.9 mg/ml-%, 1-0.9 mg/ml-%, 1.2-0.9 mg/ml-%, 1.6-0.9 mg/ml-%</i> | 2 | MO |
| <i>gentamicin sulfate external cream 0.1 %</i> | 2 | MO |
| <i>gentamicin sulfate external ointment 0.1 %</i> | 2 | MO |
| <i>gentamicin sulfate injection solution 40 mg/ml</i> | 2 | MO |
| <i>neomycin sulfate oral tablet 500 mg</i> | 2 | MO |
| <i>paromomycin sulfate oral capsule 250 mg</i> | 4 | MO |
| <i>tobramycin sulfate injection solution 10 mg/ml, 80 mg/2ml</i> | 4 | BvD; MO |
| ZEMDRI INTRAVENOUS SOLUTION 500 MG/10ML | 5 | |
| Antibacterials, Other | | |
| <i>aztreonam injection solution reconstituted 1 gm</i> | 2 | BvD; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>aztreonam injection solution reconstituted 2 gm</i> | 4 | BvD; MO |
| <i>clindamycin hcl oral capsule 150 mg, 75 mg</i> | 1 | MO |
| <i>clindamycin hcl oral capsule 300 mg</i> | 2 | MO |
| <i>clindamycin palmitate hcl oral solution reconstituted 75 mg/5ml</i> | 4 | MO |
| <i>clindamycin phosphate in d5w intravenous solution 300 mg/50ml, 600 mg/50ml, 900 mg/50ml</i> | 4 | MO |
| <i>clindamycin phosphate injection solution 300 mg/2ml, 600 mg/4ml, 900 mg/6ml</i> | 4 | BvD; MO |
| <i>clindamycin phosphate vaginal cream 2 %</i> | 2 | MO |
| <i>colistimethate sodium (cba) injection solution reconstituted 150 mg</i> | 4 | BvD; MO |
| <i>daptomycin intravenous solution reconstituted 350 mg</i> | 4 | MO |
| <i>daptomycin intravenous solution reconstituted 500 mg</i> | 5 | |
| FIRVANQ ORAL SOLUTION RECONSTITUTED 25 MG/ML, 50 MG/ML | 4 | MO |
| <i>linezolid intravenous solution 600 mg/300ml</i> | 4 | PA; MO |
| <i>linezolid oral tablet 600 mg</i> | 4 | PA; MO |
| <i>methenamine hippurate oral tablet 1 gm</i> | 2 | MO |
| <i>metronidazole external cream 0.75 %</i> | 2 | MO |
| <i>metronidazole external gel 0.75 %, 1 %</i> | 2 | MO |
| <i>metronidazole external lotion 0.75 %</i> | 2 | MO |
| <i>metronidazole intravenous solution 500 mg/100ml</i> | 2 | BvD; MO |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 2 | MO |
| <i>metronidazole vaginal gel 0.75 %</i> | 3 | MO |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>nitrofurantoin monohyd macro oral capsule 100 mg</i> | 2 | MO |
| <i>tigecycline intravenous solution reconstituted 50 mg</i> | 5 | BvD |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | MO |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>vancomycin hcl intravenous solution reconstituted 1 gm, 10 gm, 500 mg, 750 mg</i> | 4 | MO |
| <i>vancomycin hcl oral capsule 125 mg, 250 mg</i> | 4 | MO |
| <i>vancomycin hcl oral solution reconstituted 25 mg/ml, 250 mg/5ml</i> | 4 | MO |
| XIFAXAN ORAL TABLET 200 MG, 550 MG | 4 | MO |
| Beta-Lactam, Cephalosporins | | |
| <i>cefaclor er oral tablet extended release 12 hour 500 mg</i> | 4 | MO |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | MO |
| <i>cefaclor oral suspension reconstituted 125 mg/5ml, 250 mg/5ml, 375 mg/5ml</i> | 4 | MO |
| <i>cefadroxil oral capsule 500 mg</i> | 1 | MO |
| <i>cefadroxil oral suspension reconstituted 250 mg/5ml, 500 mg/5ml</i> | 2 | MO |
| <i>cefadroxil oral tablet 1 gm</i> | 2 | MO |
| <i>cefazolin sodium injection solution reconstituted 1 gm, 10 gm, 500 mg</i> | 4 | MO |
| <i>cefdinir oral capsule 300 mg</i> | 2 | MO |
| <i>cefdinir oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | MO |
| <i>cefepime hcl injection solution reconstituted 1 gm</i> | 4 | MO |
| <i>cefepime hcl intravenous solution reconstituted 2 gm</i> | 4 | MO |
| <i>cefixime oral capsule 400 mg</i> | 4 | MO |
| <i>cefixime oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 4 | MO |
| <i>cefotetan disodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | BvD; MO |
| <i>cefoxitin sodium intravenous solution reconstituted 1 gm, 10 gm, 2 gm</i> | 4 | BvD; MO |
| <i>cefpodoxime proxetil oral suspension reconstituted 100 mg/5ml, 50 mg/5ml</i> | 4 | MO |
| <i>cefpodoxime proxetil oral tablet 100 mg, 200 mg</i> | 4 | MO |
| <i>cefprozil oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | MO |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ceftazidime injection solution reconstituted 1 gm, 6 gm</i> | 4 | MO |
| <i>ceftazidime intravenous solution reconstituted 2 gm</i> | 4 | MO |
| <i>ceftriaxone sodium injection solution reconstituted 1 gm, 2 gm, 250 mg, 500 mg</i> | 4 | MO |
| <i>ceftriaxone sodium intravenous solution reconstituted 10 gm</i> | 4 | MO |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | MO |
| <i>cefuroxime sodium injection solution reconstituted 750 mg</i> | 4 | BvD; MO |
| <i>cefuroxime sodium intravenous solution reconstituted 1.5 gm</i> | 4 | BvD; MO |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | MO |
| <i>cephalexin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | MO |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 2 | MO |
| TEFLARO INTRAVENOUS SOLUTION RECONSTITUTED 400 MG, 600 MG | 5 | BvD |
| <i>Beta-Lactam, Penicillins</i> | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | MO |
| <i>amoxicillin oral suspension reconstituted 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml</i> | 1 | MO |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | MO |
| <i>amoxicillin oral tablet chewable 125 mg, 250 mg</i> | 1 | MO |
| <i>amoxicillin-pot clavulanate er oral tablet extended release 12 hour 1000-62.5 mg</i> | 4 | MO |
| <i>amoxicillin-pot clavulanate oral suspension reconstituted 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml, 600-42.9 mg/5ml</i> | 2 | MO |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 500-125 mg, 875-125 mg</i> | 2 | MO |
| <i>amoxicillin-pot clavulanate oral tablet chewable 200-28.5 mg, 400-57 mg</i> | 2 | MO |
| <i>ampicillin oral capsule 500 mg</i> | 1 | MO |
| <i>ampicillin sodium injection solution reconstituted 1 gm, 125 mg</i> | 4 | BvD; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ampicillin sodium intravenous solution reconstituted 10 gm</i> | 4 | BvD; MO |
| <i>ampicillin-sulbactam sodium injection solution reconstituted 1.5 (1-0.5) gm, 3 (2-1) gm</i> | 4 | MO |
| <i>ampicillin-sulbactam sodium intravenous solution reconstituted 15 (10-5) gm</i> | 4 | MO |
| BICILLIN L-A INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1200000 UNIT/2ML, 2400000 UNIT/4ML, 600000 UNIT/ML | 4 | MO |
| <i>dicloxacillin sodium oral capsule 250 mg, 500 mg</i> | 2 | MO |
| <i>nafcillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | BvD; MO |
| <i>nafcillin sodium intravenous solution reconstituted 10 gm</i> | 4 | BvD; MO |
| <i>oxacillin sodium in dextrose intravenous solution 1 gm/50ml, 2 gm/50ml</i> | 4 | BvD; MO |
| <i>oxacillin sodium injection solution reconstituted 1 gm, 2 gm</i> | 4 | BvD; MO |
| <i>oxacillin sodium intravenous solution reconstituted 10 gm</i> | 4 | BvD; MO |
| <i>penicillin g pot in dextrose intravenous solution 40000 unit/ml, 60000 unit/ml</i> | 4 | MO |
| <i>penicillin g potassium injection solution reconstituted 20000000 unit</i> | 4 | BvD; MO |
| <i>penicillin g procaine intramuscular suspension 600000 unit/ml</i> | 4 | MO |
| <i>penicillin g sodium injection solution reconstituted 5000000 unit</i> | 4 | BvD; MO |
| <i>penicillin v potassium oral solution reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | MO |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | MO |
| <i>piperacillin sod-tazobactam so intravenous solution reconstituted 2.25 (2-0.25) gm, 3.375 (3-0.375) gm, 4.5 (4-0.5) gm</i> | 4 | MO |
| Carbapenems | | |
| <i>ertapenem sodium injection solution reconstituted 1 gm</i> | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>imipenem-cilastatin intravenous solution reconstituted 250 mg, 500 mg</i> | 4 | MO |
| <i>meropenem intravenous solution reconstituted 1 gm, 500 mg</i> | 4 | MO |
| Macrolides | | |
| <i>azithromycin intravenous solution reconstituted 500 mg</i> | 2 | BvD; MO |
| <i>azithromycin oral packet 1 gm</i> | 2 | MO |
| <i>azithromycin oral suspension reconstituted 100 mg/5ml, 200 mg/5ml</i> | 2 | MO |
| <i>azithromycin oral tablet 250 mg, 250 mg (6 pack)</i> | 1 | MO |
| <i>azithromycin oral tablet 500 mg, 500 mg (3 pack), 600 mg</i> | 2 | MO |
| <i>clarithromycin er oral tablet extended release 24 hour 500 mg</i> | 2 | MO |
| <i>clarithromycin oral suspension reconstituted 125 mg/5ml, 250 mg/5ml</i> | 2 | MO |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | MO |
| DIFICID ORAL SUSPENSION RECONSTITUTED 40 MG/ML | 5 | PA; QL (136 ML per 10 days) |
| DIFICID ORAL TABLET 200 MG | 5 | PA; QL (20 EA per 10 days) |
| ERYTHROCIN LACTOBIONATE INTRAVENOUS SOLUTION RECONSTITUTED 500 MG | 4 | BvD; MO |
| <i>erythromycin base oral capsule delayed release particles 250 mg</i> | 4 | MO |
| <i>erythromycin base oral tablet 250 mg, 500 mg</i> | 4 | MO |
| <i>erythromycin ethylsuccinate oral suspension reconstituted 200 mg/5ml, 400 mg/5ml</i> | 4 | MO |
| <i>erythromycin ethylsuccinate oral tablet 400 mg</i> | 4 | MO |
| <i>erythromycin oral tablet delayed release 250 mg, 333 mg, 500 mg</i> | 4 | MO |
| Quinolones | | |
| <i>ciprofloxacin hcl ophthalmic solution 0.3 %</i> | 1 | MO |
| <i>ciprofloxacin hcl oral tablet 100 mg, 750 mg</i> | 2 | MO |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>ciprofloxacin in d5w intravenous solution 200 mg/100ml</i> | 4 | BvD; MO |
| <i>levofloxacin in d5w intravenous solution 500 mg/100ml, 750 mg/150ml</i> | 4 | MO |
| <i>levofloxacin oral solution 25 mg/ml</i> | 4 | MO |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 2 | MO |
| <i>moxifloxacin hcl in nacl intravenous solution 400 mg/250ml</i> | 4 | BvD; MO |
| <i>moxifloxacin hcl oral tablet 400 mg</i> | 4 | MO |
| <i>ofloxacin oral tablet 300 mg, 400 mg</i> | 2 | MO |
| Sulfonamides | | |
| <i>sulfacetamide sodium (acne) external lotion 10 %</i> | 2 | MO |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | MO |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5ml</i> | 2 | MO |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg, 800-160 mg</i> | 1 | MO |
| Tetracyclines | | |
| DOXY 100 INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 4 | BvD; MO |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> | 2 | MO |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | MO |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | 1 | MO |
| <i>doxycycline monohydrate oral tablet 100 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>minocycline hcl oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>minocycline hcl oral tablet 100 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>tetracycline hcl oral capsule 250 mg, 500 mg</i> | 2 | MO |
| ANTICONVULSANTS | | |
| Anticonvulsants, Other | | |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 4 | MO; QL (600 ML per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 4 | MO; QL (60 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| DIACOMIT ORAL CAPSULE 250 MG, 500 MG | 4 | PA; MO |
| DIACOMIT ORAL PACKET 250 MG, 500 MG | 4 | PA; MO |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 4 | PA; MO |
| <i>felbamate oral suspension 600 mg/5ml</i> | 5 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | 4 | MO |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 4 | PA; MO |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 4 | ST; MO; QL (720 ML per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | 5 | ST; QL (30 EA per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 4 | ST; MO; QL (30 EA per 30 days) |
| <i>lamotrigine er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | 4 | MO |
| <i>lamotrigine oral kit 21 x 25 mg & 7 x 50 mg, 25 & 50 & 100 mg, 42 x 50 mg & 14x100 mg</i> | 2 | MO |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | MO |
| <i>lamotrigine oral tablet chewable 25 mg, 5 mg</i> | 2 | MO |
| <i>lamotrigine oral tablet dispersible 100 mg, 200 mg, 25 mg, 50 mg</i> | 4 | MO |
| <i>lamotrigine starter kit-blue oral kit 35 x 25 mg</i> | 2 | MO |
| <i>lamotrigine starter kit-green oral kit 84 x 25 mg & 14x100 mg</i> | 2 | MO |
| <i>lamotrigine starter kit-orange oral kit 42 x 25 mg & 7 x 100 mg</i> | 2 | MO |
| <i>levetiracetam er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 2 | MO |
| <i>levetiracetam oral solution 100 mg/ml</i> | 2 | MO |
| <i>levetiracetam oral tablet 1000 mg, 250 mg, 500 mg, 750 mg</i> | 1 | MO |
| <i>phenobarbital oral elixir 20 mg/5ml</i> | 2 | MO; QL (1500 ML per 30 days) |
| <i>phenobarbital oral tablet 100 mg, 16.2 mg, 32.4 mg, 64.8 mg, 97.2 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>phenobarbital oral tablet 15 mg, 60 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>phenobarbital oral tablet 30 mg</i> | 2 | MO; QL (300 EA per 30 days) |
| <i>primidone oral tablet 125 mg, 250 mg, 50 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 1000 MG | 4 | ST; MO; QL (90 EA per 30 days) |
| SPRITAM ORAL TABLET DISINTEGRATING SOLUBLE 250 MG, 500 MG, 750 MG | 4 | ST; MO; QL (120 EA per 30 days) |
| <i>valproic acid oral capsule 250 mg</i> | 2 | MO |
| <i>valproic acid oral solution 250 mg/5ml</i> | 2 | MO |
| XCOPRI (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 100 & 150 MG | 4 | MO; QL (56 EA per 28 days) |
| XCOPRI (350 MG DAILY DOSE) ORAL TABLET THERAPY PACK 150 & 200 MG | 4 | MO; QL (56 EA per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 4 | MO; QL (60 EA per 30 days) |
| XCOPRI ORAL TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG, 14 X 150 MG & 14 X 200 MG, 14 X 50 MG & 14 X 100 MG | 4 | MO; QL (28 EA per 28 days) |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA; QL (1100 ML per 30 days) |
| <i>Calcium Channel Modifying Agents</i> | | |
| <i>ethosuximide oral capsule 250 mg</i> | 2 | MO |
| <i>ethosuximide oral solution 250 mg/5ml</i> | 2 | MO |
| <i>methsuximide oral capsule 300 mg</i> | 4 | MO |
| ZONISADE ORAL SUSPENSION 100 MG/5ML | 4 | MO; QL (900 ML per 30 days) |
| <i>zonisamide oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>Gamma-Aminobutyric Acid (Gaba) Augmenting Agents</i> | | |
| <i>clobazam oral suspension 2.5 mg/ml</i> | 4 | MO; QL (480 ML per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>diazepam rectal gel 10 mg, 2.5 mg, 20 mg</i> | 4 | MO |
| <i>gabapentin oral capsule 100 mg, 300 mg, 400 mg</i> | 1 | MO; QL (270 EA per 30 days) |
| <i>gabapentin oral solution 250 mg/5ml</i> | 2 | MO |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| NAYZILAM NASAL SOLUTION 5 MG/0.1ML | 4 | MO |
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 5 | ST; QL (60 EA per 30 days) |
| <i>tiagabine hcl oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 4 | MO |
| VALTOCO 10 MG DOSE NASAL LIQUID 10 MG/0.1ML | 4 | ST; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| VALTOCO 15 MG DOSE NASAL LIQUID THERAPY PACK 7.5 MG/0.1ML | 4 | ST; MO |
| VALTOCO 20 MG DOSE NASAL LIQUID THERAPY PACK 10 MG/0.1ML | 4 | ST; MO |
| VALTOCO 5 MG DOSE NASAL LIQUID 5 MG/0.1ML | 4 | ST; MO |
| <i>vigabatrin oral packet 500 mg</i> | 5 | PA; QL (180 EA per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> | 5 | PA; QL (180 EA per 30 days) |
| <i>Sodium Channel Agents</i> | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | 5 | ST; QL (30 EA per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | 5 | ST; QL (60 EA per 30 days) |
| <i>carbamazepine er oral capsule extended release 12 hour 100 mg, 200 mg, 300 mg</i> | 2 | MO |
| <i>carbamazepine er oral tablet extended release 12 hour 100 mg, 200 mg, 400 mg</i> | 2 | MO |
| <i>carbamazepine oral suspension 100 mg/5ml</i> | 2 | MO |
| <i>carbamazepine oral tablet 200 mg</i> | 2 | MO |
| <i>carbamazepine oral tablet chewable 100 mg</i> | 1 | MO |
| DILANTIN ORAL CAPSULE 30 MG | 4 | ST; MO |
| EPITOL ORAL TABLET 200 MG | 2 | MO |
| <i>lacosamide oral solution 10 mg/ml</i> | 4 | MO; QL (1395 ML per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5ml</i> | 4 | MO |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | 1 | MO |
| <i>phenytoin oral suspension 125 mg/5ml</i> | 1 | MO |
| <i>phenytoin oral tablet chewable 50 mg</i> | 1 | MO |
| <i>phenytoin sodium extended oral capsule 100 mg, 200 mg, 300 mg</i> | 1 | MO |
| <i>rufinamide oral suspension 40 mg/ml</i> | 5 | QL (2760 ML per 30 days) |
| <i>rufinamide oral tablet 200 mg</i> | 4 | MO; QL (480 EA per 30 days) |
| <i>rufinamide oral tablet 400 mg</i> | 5 | QL (240 EA per 30 days) |

ANTIDEMENTIA AGENTS

Antidementia Agents, Other

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>memantine hcl er oral capsule extended release 24 hour 14 mg, 21 mg, 28 mg, 7 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>memantine hcl oral solution 2 mg/ml</i> | 2 | MO; QL (360 ML per 30 days) |
| <i>memantine hcl oral tablet 10 mg, 5 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>memantine hcl oral tablet 28 x 5 mg & 21 x 10 mg</i> | 2 | MO; QL (49 EA per 28 days) |
| NAMZARIC ORAL CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG | 3 | PA; MO |
| NAMZARIC ORAL CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 3 | PA; MO |
| Cholinesterase Inhibitors | | |
| <i>donepezil hcl oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet 23 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>donepezil hcl oral tablet dispersible 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide er oral capsule extended release 24 hour 16 mg, 24 mg, 8 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>galantamine hydrobromide oral solution 4 mg/ml</i> | 2 | MO; QL (200 ML per 30 days) |
| <i>galantamine hydrobromide oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24hr, 4.6 mg/24hr, 9.5 mg/24hr</i> | 2 | MO; QL (30 EA per 30 days) |
| ANTIDEPRESSANTS | | |
| Antidepressants, Other | | |
| AUVELITY ORAL TABLET EXTENDED RELEASE 45-105 MG | 4 | ST; MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 100 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 150 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (sr) oral tablet extended release 12 hour 200 mg</i> | 1 | MO; QL (60 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 150 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 300 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>bupropion hcl er (xl) oral tablet extended release 24 hour 450 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>bupropion hcl oral tablet 100 mg</i> | 1 | MO; QL (180 EA per 30 days) |
| <i>bupropion hcl oral tablet 75 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>mirtazapine oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>mirtazapine oral tablet 7.5 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>mirtazapine oral tablet dispersible 15 mg, 30 mg, 45 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 12-25 mg, 12-50 mg, 6-50 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>olanzapine-fluoxetine hcl oral capsule 3-25 mg, 6-25 mg</i> | 4 | MO; QL (90 EA per 30 days) |
| <i>Monoamine Oxidase Inhibitors</i> | | |
| <i>EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24HR, 6 MG/24HR, 9 MG/24HR</i> | 5 | ST; QL (30 EA per 30 days) |
| <i>MARPLAN ORAL TABLET 10 MG</i> | 4 | ST; MO; QL (180 EA per 30 days) |
| <i>phenelzine sulfate oral tablet 15 mg</i> | 2 | MO |
| <i>tranylcypromine sulfate oral tablet 10 mg</i> | 4 | MO |
| <i>Ssris/Snris (Selective Serotonin Reuptake Inhibitor/Serotonin And Norepinephrine Reuptake Inhibitor)</i> | | |
| <i>citalopram hydrobromide oral capsule 30 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral solution 10 mg/5ml</i> | 2 | MO; QL (600 ML per 30 days) |
| <i>citalopram hydrobromide oral tablet 10 mg, 40 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>citalopram hydrobromide oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>desvenlafaxine er oral tablet extended release 24 hour 100 mg, 50 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>desvenlafaxine succinate er oral tablet extended release 24 hour 100 mg, 25 mg, 50 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>duloxetine hcl oral capsule delayed release particles 20 mg, 30 mg, 40 mg, 60 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5ml</i> | 2 | MO; QL (600 ML per 30 days) |
| <i>escitalopram oxalate oral tablet 10 mg</i> | 1 | MO; QL (45 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>escitalopram oxalate oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| FETZIMA ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 20 MG, 40 MG, 80 MG | 3 | MO; QL (30 EA per 30 days) |
| FETZIMA TITRATION ORAL CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG | 3 | MO; QL (28 EA per 28 days) |
| <i>fluoxetine hcl oral capsule 10 mg, 20 mg, 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral solution 20 mg/5ml</i> | 2 | MO; QL (600 ML per 30 days) |
| <i>fluoxetine hcl oral tablet 10 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>fluoxetine hcl oral tablet 20 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>fluvoxamine maleate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>nefazodone hcl oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 4 | MO |
| <i>paroxetine hcl oral suspension 10 mg/5ml</i> | 4 | MO; QL (900 ML per 30 days) |
| <i>paroxetine hcl oral tablet 10 mg, 20 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>paroxetine hcl oral tablet 30 mg, 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral capsule 150 mg, 200 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>sertraline hcl oral concentrate 20 mg/ml</i> | 1 | MO; QL (300 ML per 30 days) |
| <i>sertraline hcl oral tablet 100 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>sertraline hcl oral tablet 25 mg, 50 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>trazodone hcl oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | MO |
| <i>trazodone hcl oral tablet 300 mg</i> | 2 | MO |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 4 | ST; MO; QL (30 EA per 30 days) |
| <i>venlafaxine besylate er oral tablet extended release 24 hour 112.5 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl er oral capsule extended release 24 hour 150 mg, 37.5 mg, 75 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>venlafaxine hcl er oral tablet extended release 24 hour 150 mg, 225 mg, 37.5 mg, 75 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>venlafaxine hcl oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| VIIIBRYD STARTER PACK ORAL KIT 10 & 20 MG | 3 | MO; QL (30 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| <i>vilazodone hcl oral tablet 10 mg, 20 mg, 40 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| Tricyclics | | |
| <i>amitriptyline hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>clomipramine hcl oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | MO |
| <i>desipramine hcl oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>doxepin hcl oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | MO |
| <i>doxepin hcl oral concentrate 10 mg/ml</i> | 2 | MO |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>nortriptyline hcl oral capsule 10 mg, 25 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>nortriptyline hcl oral solution 10 mg/5ml</i> | 2 | MO |
| <i>protriptyline hcl oral tablet 10 mg, 5 mg</i> | 4 | MO |
| <i>trimipramine maleate oral capsule 100 mg, 25 mg, 50 mg</i> | 4 | MO |
| ANTIEMETICS | | |
| Antiemetics, Other | | |
| <i>meclizine hcl oral tablet 12.5 mg, 25 mg</i> | 1 | MO |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> | 1 | BvD; MO |
| <i>prochlorperazine rectal suppository 25 mg</i> | 4 | MO |
| <i>promethazine hcl oral syrup 6.25 mg/5ml</i> | 2 | MO |
| <i>promethazine hcl oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>promethazine hcl rectal suppository 12.5 mg, 25 mg</i> | 2 | MO |
| <i>scopolamine transdermal patch 72 hour 1 mg/3days</i> | 4 | MO |
| Emetogenic Therapy Adjuncts | | |
| <i>aprepitant oral capsule 125 mg, 40 mg, 80 mg</i> | 4 | BvD; MO; QL (30 EA per 30 days) |
| <i>aprepitant oral capsule 80 & 125 mg</i> | 4 | BvD; MO; QL (12 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> | 4 | PA; MO; QL (60 EA per 30 days) |
| <i>granisetron hcl oral tablet 1 mg</i> | 4 | BvD; MO; QL (60 EA per 30 days) |
| <i>ondansetron hcl oral solution 4 mg/5ml</i> | 2 | BvD; MO |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 1 | BvD; MO |
| <i>ondansetron oral tablet dispersible 4 mg, 8 mg</i> | 2 | BvD; MO |
| VARUBI (180 MG DOSE) ORAL TABLET THERAPY PACK 2 X 90 MG | 3 | BvD; MO |

ANTIFUNGALS

Antifungals

| | | |
|--|---|---------|
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | BvD; MO |
| AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG | 5 | BvD |
| <i>amphotericin b intravenous solution reconstituted 50 mg</i> | 4 | BvD; MO |
| <i>caspofungin acetate intravenous solution reconstituted 50 mg</i> | 5 | |
| <i>caspofungin acetate intravenous solution reconstituted 70 mg</i> | 4 | MO |
| <i>ciclopirox olamine external cream 0.77 %</i> | 2 | MO |
| <i>ciclopirox olamine external suspension 0.77 %</i> | 2 | MO |
| <i>clotrimazole external cream 1 %</i> | 1 | MO |
| <i>clotrimazole external solution 1 %</i> | 2 | MO |
| <i>clotrimazole mouth/throat troche 10 mg</i> | 2 | MO |
| <i>econazole nitrate external cream 1 %</i> | 2 | MO |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 100 MG | 5 | BvD |
| ERAXIS INTRAVENOUS SOLUTION RECONSTITUTED 50 MG | 4 | BvD; MO |
| <i>fluconazole in sodium chloride intravenous solution 200-0.9 mg/100ml-%, 400-0.9 mg/200ml- %</i> | 2 | BvD; MO |
| <i>fluconazole oral suspension reconstituted 10 mg/ml, 40 mg/ml</i> | 2 | MO |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | 5 | |
| <i>griseofulvin microsize oral suspension 125 mg/5ml</i> | 2 | MO |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 2 | MO |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 2 | MO |
| <i>itraconazole oral capsule 100 mg</i> | 4 | PA; MO |
| <i>itraconazole oral solution 10 mg/ml</i> | 4 | PA; MO |
| JUBLIA EXTERNAL SOLUTION 10 % | 4 | MO |
| <i>ketoconazole external cream 2 %</i> | 2 | MO |
| <i>ketoconazole external shampoo 2 %</i> | 1 | MO |
| <i>ketoconazole oral tablet 200 mg</i> | 1 | MO |
| NOXAFIL ORAL PACKET 300 MG | 5 | PA |
| NYAMYC EXTERNAL POWDER 100000 UNIT/GM | 3 | MO |
| <i>nystatin external cream 100000 unit/gm</i> | 1 | MO |
| <i>nystatin external ointment 100000 unit/gm</i> | 1 | MO |
| <i>nystatin external powder 100000 unit/gm</i> | 2 | MO |
| <i>nystatin mouth/throat suspension 100000 unit/ml</i> | 2 | MO |
| <i>nystatin oral tablet 500000 unit</i> | 2 | MO |
| NYSTOP EXTERNAL POWDER 100000 UNIT/GM | 3 | MO |
| <i>posaconazole oral suspension 40 mg/ml</i> | 5 | PA |
| <i>posaconazole oral tablet delayed release 100 mg</i> | 4 | PA; MO |
| <i>terbinafine hcl oral tablet 250 mg</i> | 2 | MO |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | MO |
| <i>terconazole vaginal suppository 80 mg</i> | 2 | MO |
| <i>voriconazole intravenous solution reconstituted 200 mg</i> | 5 | PA |
| <i>voriconazole oral suspension reconstituted 40 mg/ml</i> | 5 | PA |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | 4 | PA; MO |

ANTIGOUT AGENTS

Antigout Agents

| | | |
|---|---|----|
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | 1 | MO |
|---|---|----|

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>colchicine oral capsule 0.6 mg</i> | 3 | MO |
| <i>colchicine oral tablet 0.6 mg</i> | 3 | MO |
| <i>colchicine-probenecid oral tablet 0.5-500 mg</i> | 3 | MO |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | 3 | PA; MO |
| <i>probenecid oral tablet 500 mg</i> | 2 | MO |
| ANTIMIGRAINE AGENTS | | |
| <i>Ergot Alkaloids</i> | | |
| <i>dihydroergotamine mesylate nasal solution 4 mg/ml</i> | 5 | |
| <i>ergotamine-caffeine oral tablet 1-100 mg</i> | 2 | MO; QL (40 EA per 28 days) |
| <i>Prophylactic</i> | | |
| EMGALITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 120 MG/ML | 3 | PA; MO |
| EMGALITY SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 3 | PA; MO |
| EPRONTIA ORAL SOLUTION 25 MG/ML | 3 | MO |
| <i>propranolol hcl er oral capsule extended release 24 hour 80 mg</i> | 2 | MO |
| <i>propranolol hcl oral tablet 80 mg</i> | 1 | MO |
| <i>topiramate er oral capsule er 24 hour sprinkle 100 mg, 150 mg, 200 mg, 25 mg, 50 mg</i> | 4 | MO |
| <i>topiramate oral capsule sprinkle 15 mg, 25 mg</i> | 2 | MO |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 4 | PA; MO; QL (16 EA per 30 days) |
| <i>Serotonin (5-Ht) Receptor Agonist</i> | | |
| <i>naratriptan hcl oral tablet 1 mg, 2.5 mg</i> | 2 | MO; QL (9 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet 10 mg, 5 mg</i> | 2 | MO; QL (12 EA per 30 days) |
| <i>rizatriptan benzoate oral tablet dispersible 10 mg, 5 mg</i> | 2 | MO; QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 20 mg/act</i> | 4 | MO; QL (12 EA per 30 days) |
| <i>sumatriptan nasal solution 5 mg/act</i> | 4 | MO; QL (18 EA per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO; QL (9 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>sumatriptan succinate refill subcutaneous solution cartridge 4 mg/0.5ml, 6 mg/0.5ml</i> | 2 | MO; QL (4 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5ml</i> | 2 | MO; QL (4 ML per 30 days) |
| <i>sumatriptan succinate subcutaneous solution auto-injector 4 mg/0.5ml, 6 mg/0.5ml</i> | 2 | MO; QL (4 ML per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> | 2 | MO; QL (6 EA per 30 days) |
| <i>zolmitriptan oral tablet dispersible 2.5 mg, 5 mg</i> | 2 | MO; QL (6 EA per 30 days) |
| ANTIMYASTHENIC AGENTS | | |
| <i>Parasympathomimetics</i> | | |
| <i>pyridostigmine bromide oral solution 60 mg/5ml</i> | 2 | MO |
| <i>pyridostigmine bromide oral tablet 30 mg, 60 mg</i> | 2 | MO |
| ANTIMYCOBACTERIALS | | |
| <i>Antimycobacterials, Other</i> | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | MO |
| PRIFTIN ORAL TABLET 150 MG | 4 | MO |
| <i>rifabutin oral capsule 150 mg</i> | 4 | MO |
| <i>Antituberculars</i> | | |
| <i>ethambutol hcl oral tablet 100 mg, 400 mg</i> | 2 | MO |
| <i>isoniazid oral syrup 50 mg/5ml</i> | 1 | MO |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | MO |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | MO |
| <i>rifampin intravenous solution reconstituted 600 mg</i> | 4 | MO |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | MO |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA |
| TRECTOR ORAL TABLET 250 MG | 4 | MO |
| ANTINEOPLASTICS | | |
| <i>Alkylating Agents</i> | | |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 4 | BvD; MO |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 2 | BvD; MO |
| GLEOSTINE ORAL CAPSULE 10 MG, 100 MG, 40 MG | 4 | PA; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| LEUKERAN ORAL TABLET 2 MG | 4 | MO |
| MATULANE ORAL CAPSULE 50 MG | 5 | PA |
| VALCHLOR EXTERNAL GEL 0.016 % | 5 | PA; QL (60 GM per 14 days) |
| <i>Antiandrogens</i> | | |
| <i>abiraterone acetate oral tablet 250 mg, 500 mg</i> | 5 | PA; QL (120 EA per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> | 1 | MO |
| ERLEADA ORAL TABLET 240 MG | 5 | PA; QL (30 EA per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA; QL (120 EA per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | |
| <i>nilutamide oral tablet 150 mg</i> | 5 | QL (60 EA per 30 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA; QL (120 EA per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA; QL (90 EA per 30 days) |
| YONSA ORAL TABLET 125 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>Antiangiogenic Agents</i> | | |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> | 5 | PA; QL (28 EA per 28 days) |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA; QL (21 EA per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 200 MG, 50 MG | 5 | PA; QL (30 EA per 30 days) |
| THALOMID ORAL CAPSULE 150 MG | 5 | PA; QL (60 EA per 30 days) |
| <i>Antiestrogens/Modifiers</i> | | |
| EMCYT ORAL CAPSULE 140 MG | 3 | MO |
| ORSERDU ORAL TABLET 345 MG | 5 | PA; QL (30 EA per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA; QL (90 EA per 30 days) |
| SOLTAMOX ORAL SOLUTION 10 MG/5ML | 4 | PA; MO |
| <i>tamoxifen citrate oral tablet 10 mg, 20 mg</i> | 1 | MO |
| <i>toremifene citrate oral tablet 60 mg</i> | 5 | PA |
| <i>Antimetabolites</i> | | |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>hydroxyurea oral capsule 500 mg</i> | 1 | MO |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | MO |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA |
| PURIXAN ORAL SUSPENSION 2000 MG/100ML | 5 | |
| TABLOID ORAL TABLET 40 MG | 4 | PA; MO |
| <i>Antineoplastics, Other</i> | | |
| IDHIFA ORAL TABLET 100 MG | 5 | PA; QL (30 EA per 30 days) |
| IDHIFA ORAL TABLET 50 MG | 5 | PA; QL (60 EA per 30 days) |
| KISQALI FEMARA (200 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA |
| KISQALI FEMARA (400 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA |
| KISQALI FEMARA (600 MG DOSE) ORAL TABLET THERAPY PACK 200 & 2.5 MG | 5 | PA |
| KRAZATI ORAL TABLET 200 MG | 5 | PA; QL (180 EA per 30 days) |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | MO |
| LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG | 5 | PA |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA; QL (240 EA per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA; QL (90 EA per 30 days) |
| LYNPARZA ORAL TABLET 100 MG | 5 | PA; QL (180 EA per 30 days) |
| LYNPARZA ORAL TABLET 150 MG | 5 | PA; QL (120 EA per 30 days) |
| MESNEX ORAL TABLET 400 MG | 5 | |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA; QL (60 EA per 30 days) |
| SYNRIBO SUBCUTANEOUS SOLUTION RECONSTITUTED 3.5 MG | 5 | PA |
| WELIREG ORAL TABLET 40 MG | 5 | PA; QL (90 EA per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | BvD; MO |
| XPOVIO (100 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 50 MG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| XPOVIO (40 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA |
| XPOVIO (40 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA |
| XPOVIO (60 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 60 MG | 5 | PA |
| XPOVIO (60 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA |
| XPOVIO (80 MG ONCE WEEKLY) ORAL TABLET THERAPY PACK 40 MG | 5 | PA |
| XPOVIO (80 MG TWICE WEEKLY) ORAL TABLET THERAPY PACK 20 MG | 5 | PA |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>Aromatase Inhibitors, 3Rd Generation</i> | | |
| <i>anastrozole oral tablet 1 mg</i> | 1 | MO |
| <i>exemestane oral tablet 25 mg</i> | 4 | MO |
| <i>letrozole oral tablet 2.5 mg</i> | 1 | MO |
| <i>Molecular Target Inhibitors</i> | | |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA |
| ALUNBRIG ORAL TABLET 180 MG | 5 | PA; QL (30 EA per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA; QL (180 EA per 30 days) |
| ALUNBRIG ORAL TABLET 90 MG | 5 | PA; QL (60 EA per 30 days) |
| ALUNBRIG ORAL TABLET THERAPY PACK 90 & 180 MG | 5 | PA; QL (30 EA per 30 days) |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA; QL (30 EA per 30 days) |
| BALVERSA ORAL TABLET 3 MG | 5 | PA; QL (90 EA per 30 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA; QL (60 EA per 30 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA; QL (30 EA per 30 days) |
| BOSULIF ORAL TABLET 100 MG | 5 | PA; QL (120 EA per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA; QL (30 EA per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA; QL (180 EA per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA; QL (120 EA per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA; QL (60 EA per 30 days) |
| CALQUENCE ORAL TABLET 100 MG | 5 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 100 MG | 5 | PA; QL (60 EA per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA; QL (30 EA per 30 days) |
| COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG | 5 | PA; QL (56 EA per 28 days) |
| COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG | 5 | PA; QL (112 EA per 28 days) |
| COMETRIQ (60 MG DAILY DOSE) ORAL KIT 20 MG | 5 | PA; QL (84 EA per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA; QL (60 EA per 30 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA; QL (63 EA per 28 days) |
| DAURISMO ORAL TABLET 100 MG, 25 MG | 5 | PA |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA |
| <i>erlotinib hcl oral tablet 100 mg, 150 mg</i> | 5 | PA; QL (30 EA per 30 days) |
| <i>erlotinib hcl oral tablet 25 mg</i> | 5 | PA; QL (90 EA per 30 days) |
| <i>everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 5 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 2 mg, 3 mg</i> | 5 | PA; QL (30 EA per 30 days) |
| <i>everolimus oral tablet soluble 5 mg</i> | 5 | PA; QL (60 EA per 30 days) |
| EXKIVITY ORAL CAPSULE 40 MG | 5 | PA |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5 | PA; QL (21 EA per 28 days) |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> | 5 | PA |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA; QL (30 EA per 30 days) |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA |
| ICLUSIG ORAL TABLET 10 MG, 30 MG, 45 MG | 5 | PA; QL (30 EA per 30 days) |
| ICLUSIG ORAL TABLET 15 MG | 5 | PA; QL (60 EA per 30 days) |
| <i>imatinib mesylate oral tablet 100 mg</i> | 5 | PA; QL (90 EA per 30 days) |
| <i>imatinib mesylate oral tablet 400 mg</i> | 5 | PA; QL (60 EA per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA; QL (120 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA; QL (28 EA per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA; QL (240 ML per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG | 5 | PA; QL (28 EA per 28 days) |
| INLYTA ORAL TABLET 1 MG | 5 | PA; QL (180 EA per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA; QL (60 EA per 30 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA; QL (120 EA per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA; QL (60 EA per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA; QL (60 EA per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA; QL (30 EA per 30 days) |
| KISQALI (200 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA |
| KISQALI (400 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA |
| KISQALI (600 MG DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA; QL (240 EA per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>lapatinib ditosylate oral tablet 250 mg</i> | 5 | PA; QL (180 EA per 30 days) |
| LENVIMA (10 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG | 5 | PA |
| LENVIMA (12 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 3 X 4 MG | 5 | PA |
| LENVIMA (14 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 & 4 MG | 5 | PA |
| LENVIMA (18 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 10 MG & 2 X 4 MG | 5 | PA |
| LENVIMA (20 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG | 5 | PA |
| LENVIMA (24 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 10 MG & 4 MG | 5 | PA |
| LENVIMA (4 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 4 MG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| LENVIMA (8 MG DAILY DOSE) ORAL CAPSULE THERAPY PACK 2 X 4 MG | 5 | PA |
| LORBRENA ORAL TABLET 100 MG | 5 | PA; QL (30 EA per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA; QL (120 EA per 30 days) |
| LYTGOBI (12 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA; QL (84 EA per 28 days) |
| LYTGOBI (16 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA; QL (112 EA per 28 days) |
| LYTGOBI (20 MG DAILY DOSE) ORAL TABLET THERAPY PACK 4 MG | 5 | PA; QL (140 EA per 28 days) |
| MEKINIST ORAL SOLUTION RECONSTITUTED 0.05 MG/ML | 5 | PA; QL (1260 ML per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA; QL (120 EA per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA; QL (30 EA per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA; QL (180 EA per 30 days) |
| NERLYNX ORAL TABLET 40 MG | 5 | PA; QL (180 EA per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA; QL (14 EA per 21 days) |
| PIQRAY (200 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 MG | 5 | PA |
| PIQRAY (250 MG DAILY DOSE) ORAL TABLET THERAPY PACK 200 & 50 MG | 5 | PA |
| PIQRAY (300 MG DAILY DOSE) ORAL TABLET THERAPY PACK 2 X 150 MG | 5 | PA |
| QINLOCK ORAL TABLET 50 MG | 5 | PA; QL (90 EA per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA; QL (120 EA per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA; QL (180 EA per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA; QL (60 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA; QL (150 EA per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA; QL (90 EA per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA; QL (240 EA per 30 days) |
| SCSEMBLIX ORAL TABLET 20 MG, 40 MG | 5 | PA |
| <i>sorafenib tosylate oral tablet 200 mg</i> | 5 | PA; QL (120 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| SPRYCEL ORAL TABLET 100 MG, 50 MG, 70 MG, 80 MG | 5 | PA; QL (60 EA per 30 days) |
| SPRYCEL ORAL TABLET 140 MG | 5 | PA; QL (30 EA per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 5 | PA; QL (90 EA per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA; QL (84 EA per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> | 5 | PA; QL (28 EA per 28 days) |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA; QL (120 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 50 MG | 5 | PA; QL (180 EA per 30 days) |
| TAFINLAR ORAL CAPSULE 75 MG | 5 | PA; QL (120 EA per 30 days) |
| TAFINLAR ORAL TABLET SOLUBLE 10 MG | 5 | PA; QL (900 EA per 30 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG | 5 | PA |
| TALZENNA ORAL CAPSULE 0.25 MG | 5 | PA; QL (120 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.5 MG | 5 | PA; QL (60 EA per 30 days) |
| TALZENNA ORAL CAPSULE 0.75 MG, 1 MG | 5 | PA; QL (30 EA per 30 days) |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG, 50 MG | 5 | PA; QL (120 EA per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA; QL (240 EA per 30 days) |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA; QL (60 EA per 30 days) |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA; QL (60 EA per 30 days) |
| TUKYSA ORAL TABLET 150 MG, 50 MG | 5 | PA; QL (120 EA per 30 days) |
| TURALIO ORAL CAPSULE 125 MG | 5 | PA; QL (120 EA per 30 days) |
| VENCLEXTA ORAL TABLET 10 MG, 50 MG | 4 | PA; MO |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA |
| VENCLEXTA STARTING PACK ORAL TABLET THERAPY PACK 10 & 50 & 100 MG | 3 | PA; MO |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA; QL (60 EA per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA; QL (180 EA per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA; QL (310 ML per 30 days) |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA; QL (30 EA per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA; QL (120 EA per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 5 | PA; QL (120 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA; QL (120 EA per 30 days) |
| XOSPATA ORAL TABLET 40 MG | 5 | PA; QL (90 EA per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA; QL (90 EA per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA; QL (240 EA per 30 days) |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA; QL (60 EA per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA; QL (150 EA per 30 days) |
| Retinoids | | |
| <i>bexarotene external gel 1 %</i> | 5 | PA |
| <i>bexarotene oral capsule 75 mg</i> | 5 | PA; QL (300 EA per 30 days) |
| <i>tretinoin oral capsule 10 mg</i> | 5 | |
| ANTIPARASITICS | | |
| Anthelmintics | | |
| <i>albendazole oral tablet 200 mg</i> | 4 | MO |
| EMVERM ORAL TABLET CHEWABLE 100 MG | 5 | |
| <i>ivermectin oral tablet 3 mg</i> | 2 | PA; MO |
| Antiprotozoals | | |
| <i>atovaquone oral suspension 750 mg/5ml</i> | 5 | |
| <i>atovaquone-proguanil hcl oral tablet 250-100 mg, 62.5-25 mg</i> | 2 | MO |
| <i>benznidazole oral tablet 100 mg, 12.5 mg</i> | 2 | MO |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | MO |
| COARTEM ORAL TABLET 20-120 MG | 4 | MO |
| <i>hydroxychloroquine sulfate oral tablet 100 mg, 200 mg, 300 mg, 400 mg</i> | 2 | MO |
| LAMPIT ORAL TABLET 120 MG, 30 MG | 4 | MO |
| <i>mefloquine hcl oral tablet 250 mg</i> | 2 | MO |
| <i>nitazoxanide oral tablet 500 mg</i> | 4 | MO; QL (40 EA per 30 days) |
| <i>pentamidine isethionate inhalation solution reconstituted 300 mg</i> | 4 | BvD; MO |
| <i>pentamidine isethionate injection solution reconstituted 300 mg</i> | 4 | BvD; MO |
| <i>primaquine phosphate oral tablet 26.3 (15 base) mg</i> | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>quinine sulfate oral capsule 324 mg</i> | 2 | PA; MO |
| ANTIPARKINSON AGENTS | | |
| <i>Anticholinergics</i> | | |
| <i>benztropine mesylate oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral solution 0.4 mg/ml</i> | 1 | MO |
| <i>trihexyphenidyl hcl oral tablet 2 mg, 5 mg</i> | 1 | MO |
| <i>Antiparkinson Agents, Other</i> | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | MO |
| <i>amantadine hcl oral solution 50 mg/5ml</i> | 2 | MO |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | MO |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | MO |
| <i>entacapone oral tablet 200 mg</i> | 2 | MO |
| <i>Dopamine Agonists</i> | | |
| <i>bromocriptine mesylate oral capsule 5 mg</i> | 2 | MO |
| <i>bromocriptine mesylate oral tablet 2.5 mg</i> | 2 | MO |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24HR, 2 MG/24HR, 3 MG/24HR, 4 MG/24HR, 6 MG/24HR, 8 MG/24HR | 4 | MO |
| <i>pramipexole dihydrochloride oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 1 | MO |
| <i>ropinirole hcl oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 1 | MO |
| <i>Dopamine Precursors And/Or L-Amino Acid Decarboxylase Inhibitors</i> | | |
| <i>carbidopa oral tablet 25 mg</i> | 2 | MO |
| <i>carbidopa-levodopa er oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | MO |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | MO |
| <i>carbidopa-levodopa oral tablet dispersible 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | MO |
| INBRIJA INHALATION CAPSULE 42 MG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| RYTARY ORAL CAPSULE EXTENDED RELEASE 23.75-95 MG, 36.25-145 MG, 48.75-195 MG, 61.25-245 MG | 4 | ST; MO |
| <i>Monoamine Oxidase B (Mao-B) Inhibitors</i> | | |
| <i>rasagiline mesylate oral tablet 0.5 mg, 1 mg</i> | 4 | MO |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | MO |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | MO |
| ANTIPSYCHOTICS | | |
| <i>1St Generation/Typical</i> | | |
| <i>chlorpromazine hcl oral concentrate 100 mg/ml, 30 mg/ml</i> | 4 | BvD; MO |
| <i>chlorpromazine hcl oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 4 | BvD; MO |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 4 | MO |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 4 | MO |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | MO |
| <i>fluphenazine hcl oral elixir 2.5 mg/5ml</i> | 2 | MO |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | MO |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml 1 ml, 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | MO |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 4 | MO |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 1 | MO |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | MO |
| <i>molindone hcl oral tablet 10 mg, 25 mg, 5 mg</i> | 2 | MO |
| <i>perphenazine oral tablet 16 mg, 2 mg</i> | 2 | MO |
| <i>perphenazine oral tablet 4 mg, 8 mg</i> | 2 | BvD; MO |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | MO |
| <i>thioridazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>trifluoperazine hcl oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | MO |
| 2Nd Generation/Atypical | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR PREFILLED SYRINGE 720 MG/2.4ML, 960 MG/3.2ML | 5 | |
| ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE 300 MG, 400 MG | 5 | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 300 MG, 400 MG | 5 | |
| <i>aripiprazole oral solution 1 mg/ml</i> | 4 | MO; QL (750 ML per 30 days) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 10 mg</i> | 5 | QL (90 EA per 30 days) |
| <i>aripiprazole oral tablet dispersible 15 mg</i> | 5 | QL (60 EA per 30 days) |
| <i>asenapine maleate sublingual tablet sublingual 10 mg, 2.5 mg, 5 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; QL (60 EA per 30 days) |
| FANAPT TITRATION PACK ORAL TABLET 1 & 2 & 4 & 6 MG | 4 | ST; MO; QL (60 EA per 30 days) |
| INVEGA HAFYERA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1092 MG/3.5ML, 1560 MG/5ML | 5 | |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 117 MG/0.75ML, 156 MG/ML, 234 MG/1.5ML, 78 MG/0.5ML | 5 | |
| INVEGA SUSTENNA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 39 MG/0.25ML | 4 | MO |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML | 5 | |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>lurasidone hcl oral tablet 120 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 5 | |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | ST; QL (30 EA per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA |
| <i>olanzapine intramuscular solution reconstituted 10 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>olanzapine oral tablet 20 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 10 mg, 5 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>olanzapine oral tablet dispersible 15 mg, 20 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 9 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>paliperidone er oral tablet extended release 24 hour 6 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 150 mg</i> | 4 | MO; QL (90 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 200 mg, 300 mg, 400 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>quetiapine fumarate er oral tablet extended release 24 hour 50 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>quetiapine fumarate oral tablet 100 mg, 150 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 12.5 MG | 4 | MO |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER 25 MG, 37.5 MG, 50 MG | 5 | |
| <i>risperidone oral solution 1 mg/ml</i> | 2 | MO; QL (480 ML per 30 days) |
| <i>risperidone oral tablet 0.25 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet 0.5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>risperidone oral tablet dispersible 0.25 mg, 1 mg, 2 mg</i> | 2 | MO; QL (60 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>risperidone oral tablet dispersible 0.5 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>risperidone oral tablet dispersible 3 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>risperidone oral tablet dispersible 4 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24HR, 5.7 MG/24HR, 7.6 MG/24HR | 5 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG | 5 | ST; QL (60 EA per 30 days) |
| VRAYLAR ORAL CAPSULE 3 MG, 4.5 MG, 6 MG | 5 | ST; QL (30 EA per 30 days) |
| VRAYLAR ORAL CAPSULE THERAPY PACK 1.5 & 3 MG | 4 | ST; MO; QL (7 EA per 28 days) |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>ziprasidone mesylate intramuscular solution reconstituted 20 mg</i> | 4 | MO; QL (6 EA per 3 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION RECONSTITUTED 210 MG | 4 | ST; MO |
| <i>Treatment-Resistant</i> | | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>clozapine oral tablet dispersible 100 mg, 12.5 mg, 150 mg, 25 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>clozapine oral tablet dispersible 200 mg</i> | 5 | QL (120 EA per 30 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; QL (540 ML per 30 days) |
| ANTISPASTICITY AGENTS | | |
| <i>Antispasticity Agents</i> | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>tizanidine hcl oral tablet 2 mg, 4 mg</i> | 2 | MO |
| ANTIVIRALS | | |
| <i>Anti-Cytomegalovirus (Cmv) Agents</i> | | |
| LIVTENCITY ORAL TABLET 200 MG | 5 | PA |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; QL (28 EA per 28 days) |
| <i>valganciclovir hcl oral solution reconstituted 50 mg/ml</i> | 4 | MO |
| <i>valganciclovir hcl oral tablet 450 mg</i> | 3 | MO |
| ZIRGAN OPHTHALMIC GEL 0.15 % | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>Anti-Hepatitis B (Hbv) Agents</i> | | |
| <i>adefovir dipivoxil oral tablet 10 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| BARACLUDGE ORAL SOLUTION 0.05 MG/ML | 5 | QL (600 ML per 30 days) |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>lamivudine oral tablet 100 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| VEMLIDY ORAL TABLET 25 MG | 5 | QL (30 EA per 30 days) |
| <i>Anti-Hepatitis C (Hcv) Agents</i> | | |
| MAVYRET ORAL PACKET 50-20 MG | 5 | PA |
| MAVYRET ORAL TABLET 100-40 MG | 5 | PA |
| <i>ribavirin oral capsule 200 mg</i> | 4 | MO |
| <i>ribavirin oral tablet 200 mg</i> | 2 | MO |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> | 5 | PA |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA |
| <i>Antitherpetic Agents</i> | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | MO |
| <i>acyclovir oral suspension 200 mg/5ml</i> | 2 | MO |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 1 | MO |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | BvD; MO |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | MO |
| <i>trifluridine ophthalmic solution 1 %</i> | 2 | MO |
| <i>valacyclovir hcl oral tablet 1 gm, 500 mg</i> | 2 | MO |
| <i>Anti-Hiv Agents, Integrase Inhibitors (Insti)</i> | | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | QL (30 EA per 30 days) |
| DOVATO ORAL TABLET 50-300 MG | 5 | QL (30 EA per 30 days) |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | QL (30 EA per 30 days) |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | QL (60 EA per 30 days) |
| ISENTRESS ORAL PACKET 100 MG | 4 | MO; QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET 400 MG | 5 | QL (60 EA per 30 days) |
| ISENTRESS ORAL TABLET CHEWABLE 100 MG, 25 MG | 4 | MO; QL (180 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | QL (30 EA per 30 days) |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | QL (30 EA per 30 days) |
| TIVICAY ORAL TABLET 10 MG | 4 | MO; QL (60 EA per 30 days) |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | QL (60 EA per 30 days) |
| TIVICAY PD ORAL TABLET SOLUBLE 5 MG | 4 | MO; QL (360 EA per 30 days) |
| <i>Anti-Hiv Agents, Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrti)</i> | | |
| COMPLERA ORAL TABLET 200-25-300 MG | 5 | QL (30 EA per 30 days) |
| EDURANT ORAL TABLET 25 MG | 5 | QL (30 EA per 30 days) |
| <i>efavirenz oral capsule 200 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>efavirenz oral capsule 50 mg</i> | 4 | MO; QL (360 EA per 30 days) |
| <i>efavirenz oral tablet 600 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>etravirine oral tablet 100 mg</i> | 5 | QL (120 EA per 30 days) |
| <i>etravirine oral tablet 200 mg</i> | 5 | QL (60 EA per 30 days) |
| INTELENCE ORAL TABLET 25 MG | 4 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 100 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>nevirapine er oral tablet extended release 24 hour 400 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>nevirapine oral suspension 50 mg/5ml</i> | 4 | MO; QL (1200 ML per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| PIFELTRO ORAL TABLET 100 MG | 5 | QL (30 EA per 30 days) |
| <i>Anti-Hiv Agents, Nucleoside And Nucleotide Reverse Transcriptase Inhibitors (Nrti)</i> | | |
| <i>abacavir sulfate oral solution 20 mg/ml</i> | 4 | MO; QL (960 ML per 30 days) |
| <i>abacavir sulfate oral tablet 300 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>abacavir sulfate-lamivudine oral tablet 600-300 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | QL (30 EA per 30 days) |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | QL (30 EA per 30 days) |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | QL (30 EA per 30 days) |
| <i>efavirenz-emtricitab-tenofo df oral tablet 600-200-300 mg</i> | 5 | QL (30 EA per 30 days) |
| <i>efavirenz-lamivudine-tenofovir oral tablet 400-300-300 mg, 600-300-300 mg</i> | 5 | QL (30 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>emtricitabine oral capsule 200 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 5 | QL (30 EA per 30 days) |
| <i>emtricitabine-tenofovir df oral tablet 200-300 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | MO; QL (680 ML per 28 days) |
| JULUCA ORAL TABLET 50-25 MG | 5 | QL (30 EA per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> | 4 | MO; QL (900 ML per 30 days) |
| <i>lamivudine oral tablet 150 mg</i> | 3 | MO; QL (60 EA per 30 days) |
| <i>lamivudine oral tablet 300 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | QL (30 EA per 30 days) |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | QL (60 EA per 30 days) |
| VIREAD ORAL POWDER 40 MG/GM | 5 | QL (240 GM per 30 days) |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | QL (30 EA per 30 days) |
| <i>zidovudine oral capsule 100 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| <i>zidovudine oral syrup 50 mg/5ml</i> | 2 | MO; QL (1680 ML per 28 days) |
| <i>zidovudine oral tablet 300 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| Anti-Hiv Agents, Other | | |
| FUZEON SUBCUTANEOUS SOLUTION RECONSTITUTED 90 MG | 5 | QL (60 EA per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> | 5 | QL (120 EA per 30 days) |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HOUR 600 MG | 5 | QL (60 EA per 30 days) |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | QL (1800 ML per 30 days) |
| SELZENTRY ORAL TABLET 25 MG | 3 | MO; QL (240 EA per 30 days) |
| SELZENTRY ORAL TABLET 75 MG | 5 | QL (60 EA per 30 days) |
| SUNLENCA ORAL TABLET THERAPY PACK 4 X 300 MG | 5 | QL (4 EA per 180 days) |
| SUNLENCA ORAL TABLET THERAPY PACK 5 X 300 MG | 5 | QL (5 EA per 180 days) |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | QL (30 EA per 30 days) |
| TRIUMEQ PD ORAL TABLET SOLUBLE 60-5-30 MG | 5 | QL (180 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| TYBOST ORAL TABLET 150 MG | 3 | MO; QL (30 EA per 30 days) |
| <i>Anti-Hiv Agents, Protease Inhibitors (Pi)</i> | | |
| APTIVUS ORAL CAPSULE 250 MG | 5 | QL (120 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 150 mg, 200 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>atazanavir sulfate oral capsule 300 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>darunavir oral tablet 600 mg</i> | 5 | QL (60 EA per 30 days) |
| <i>darunavir oral tablet 800 mg</i> | 5 | QL (30 EA per 30 days) |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | QL (30 EA per 30 days) |
| <i>fosamprenavir calcium oral tablet 700 mg</i> | 5 | QL (120 EA per 30 days) |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | MO; QL (1575 ML per 28 days) |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5ml</i> | 4 | MO; QL (400 ML per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | 4 | MO; QL (300 EA per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | 4 | MO; QL (150 EA per 30 days) |
| NORVIR ORAL PACKET 100 MG | 4 | MO; QL (360 EA per 30 days) |
| PREZCOBIX ORAL TABLET 800-150 MG | 5 | QL (30 EA per 30 days) |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | QL (360 ML per 30 days) |
| PREZISTA ORAL TABLET 150 MG | 4 | MO; QL (240 EA per 30 days) |
| PREZISTA ORAL TABLET 75 MG | 4 | MO; QL (480 EA per 30 days) |
| REYATAZ ORAL PACKET 50 MG | 4 | MO; QL (180 EA per 30 days) |
| <i>ritonavir oral tablet 100 mg</i> | 3 | MO; QL (360 EA per 30 days) |
| VIRACEPT ORAL TABLET 250 MG | 5 | QL (300 EA per 30 days) |
| VIRACEPT ORAL TABLET 625 MG | 5 | QL (120 EA per 30 days) |
| <i>Anti-Influenza Agents</i> | | |
| <i>oseltamivir phosphate oral capsule 30 mg, 45 mg, 75 mg</i> | 2 | MO |
| <i>oseltamivir phosphate oral suspension reconstituted 6 mg/ml</i> | 2 | MO |
| RELENZA DISKHALER INHALATION AEROSOL POWDER BREATH ACTIVATED 5 MG/ACT | 4 | MO |
| <i>rimantadine hcl oral tablet 100 mg</i> | 2 | MO |
| XOFLUZA (40 MG DOSE) ORAL TABLET THERAPY PACK 1 X 40 MG | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| XOFLUZA (80 MG DOSE) ORAL TABLET THERAPY PACK 1 X 80 MG | 3 | MO |
| ANXIOLYTICS | | |
| Anxiolytics, Other | | |
| <i>buspirone hcl oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | MO |
| <i>hydroxyzine hcl oral syrup 10 mg/5ml</i> | 4 | MO |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg</i> | 1 | MO |
| <i>hydroxyzine hcl oral tablet 50 mg</i> | 2 | MO |
| <i>hydroxyzine pamoate oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| Benzodiazepines | | |
| ALPRAZOLAM INTENSOL ORAL CONCENTRATE 1 MG/ML | 2 | MO; QL (300 ML per 30 days) |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>alprazolam oral tablet 1 mg</i> | 2 | MO; QL (240 EA per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> | 2 | MO; QL (150 EA per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | 1 | MO; QL (90 EA per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | 1 | MO; QL (300 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>clonazepam oral tablet dispersible 2 mg</i> | 2 | MO; QL (300 EA per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 2 | MO; QL (180 EA per 30 days) |
| DIAZEPAM INTENSOL ORAL CONCENTRATE 5 MG/ML | 2 | MO; QL (240 ML per 30 days) |
| <i>diazepam oral solution 5 mg/5ml</i> | 2 | MO; QL (1200 ML per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>diazepam oral tablet 5 mg</i> | 1 | MO; QL (240 EA per 30 days) |
| LORAZEPAM INTENSOL ORAL CONCENTRATE 2 MG/ML | 2 | MO; QL (240 ML per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | MO; QL (150 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| BIPOLAR AGENTS | | |
| <i>Mood Stabilizers</i> | | |
| <i>divalproex sodium er oral tablet extended release 24 hour 250 mg, 500 mg</i> | 2 | MO |
| <i>divalproex sodium oral capsule delayed release sprinkle 125 mg</i> | 2 | MO |
| <i>divalproex sodium oral tablet delayed release 125 mg, 250 mg, 500 mg</i> | 1 | MO |
| <i>lithium carbonate er oral tablet extended release 300 mg, 450 mg</i> | 1 | MO |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | MO |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | MO |
| BLOOD GLUCOSE REGULATORS | | |
| <i>Antidiabetic Agents</i> | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>glimepiride oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | MO |
| <i>glipizide er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>glipizide oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>glipizide-metformin hcl oral tablet 2.5-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | MO |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 1 | MO |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | MO |
| INVOKAMET ORAL TABLET 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 3 | MO |
| INVOKAMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 150-1000 MG, 150-500 MG, 50-1000 MG, 50-500 MG | 3 | MO |
| INVOKANA ORAL TABLET 100 MG, 300 MG | 3 | MO |
| JANUMET ORAL TABLET 50-1000 MG, 50-500 MG | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| JANUMET XR ORAL TABLET EXTENDED RELEASE 24 HOUR 100-1000 MG, 50-1000 MG, 50-500 MG | 3 | MO |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | MO |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | MO |
| <i>metformin hcl er oral tablet extended release 24 hour 500 mg, 750 mg</i> | 1 | MO |
| <i>metformin hcl oral tablet 1000 mg, 500 mg, 850 mg</i> | 1 | MO |
| <i>migliitol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| MOUNJARO SUBCUTANEOUS SOLUTION PEN-INJECTOR 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML, 2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML | 3 | PA; MO; QL (2 ML per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 1 | MO |
| OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML | 3 | PA; MO; QL (3 ML per 28 days) |
| OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML | 3 | PA; MO; QL (3 ML per 28 days) |
| OZEMPIC (2 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 8 MG/3ML | 3 | PA; MO; QL (3 ML per 28 days) |
| <i>pioglitazone hcl oral tablet 15 mg, 30 mg, 45 mg</i> | 1 | MO |
| <i>pioglitazone hcl-metformin hcl oral tablet 15-500 mg, 15-850 mg</i> | 1 | MO |
| <i>repaglinide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 3 | PA; MO; QL (30 EA per 30 days) |
| SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR 2700 MCG/2.7ML | 4 | PA; MO |
| SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR 1500 MCG/1.5ML | 4 | PA; MO |
| SYNJARDY ORAL TABLET 12.5-1000 MG, 12.5-500 MG, 5-1000 MG, 5-500 MG | 3 | MO |
| SYNJARDY XR ORAL TABLET EXTENDED RELEASE 24 HOUR 10-1000 MG, 12.5-1000 MG, 25-1000 MG, 5-1000 MG | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| TRULICITY SUBCUTANEOUS SOLUTION PEN-INJECTOR 0.75 MG/0.5ML, 1.5 MG/0.5ML, 3 MG/0.5ML, 4.5 MG/0.5ML | 3 | PA; MO; QL (2 ML per 28 days) |
| VICTOZA SUBCUTANEOUS SOLUTION PEN-INJECTOR 18 MG/3ML | 4 | PA; MO; QL (9 ML per 28 days) |
| XULTOPHY SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-3.6 UNIT-MG/ML | 3 | MO |
| <i>Glycemic Agents</i> | | |
| BAQSIMI ONE PACK NASAL POWDER 3 MG/DOSE | 3 | MO |
| <i>diazoxide oral suspension 50 mg/ml</i> | 5 | |
| GLUCAGEN HYPOKIT INJECTION SOLUTION RECONSTITUTED 1 MG | 3 | MO |
| KORLYM ORAL TABLET 300 MG | 5 | PA |
| <i>Insulins</i> | | |
| ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML | 1 | MO |
| COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML | 1 | MO |
| <i>cvs gauze sterile pad 2"x2"</i> | 1 | MO |
| EXEL COMFORT POINT PEN NEEDLE 29G X 12MM | 1 | MO |
| FIASP FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | MO |
| FIASP INJECTION SOLUTION 100 UNIT/ML | 3 | MO |
| FIASP PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 3 | MO |
| <i>insulin glargine solostar subcutaneous solution pen-injector 100 unit/ml</i> | 3 | MO |
| <i>insulin glargine subcutaneous solution 100 unit/ml</i> | 3 | MO |
| LANTUS SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | MO |
| LANTUS SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | MO |
| LEVEMIR FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| LEVEMIR SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | MO |
| NOVOLIN 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | MO |
| NOVOLIN 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | MO |
| NOVOLIN N FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR 100 UNIT/ML | 3 | MO |
| NOVOLIN N SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | MO |
| NOVOLIN R FLEXPEN INJECTION SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | MO |
| NOVOLIN R INJECTION SOLUTION 100 UNIT/ML | 3 | MO |
| NOVOLOG FLEXPEN SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML | 3 | MO |
| NOVOLOG INJECTION SOLUTION 100 UNIT/ML | 3 | MO |
| NOVOLOG MIX 70/30 FLEXPEN SUBCUTANEOUS SUSPENSION PEN-INJECTOR (70-30) 100 UNIT/ML | 3 | MO |
| NOVOLOG MIX 70/30 SUBCUTANEOUS SUSPENSION (70-30) 100 UNIT/ML | 3 | MO |
| NOVOLOG PENFILL SUBCUTANEOUS SOLUTION CARTRIDGE 100 UNIT/ML | 3 | MO |
| <i>preferred plus insulin syringe 28g x 1/2" 0.5 ml</i> | 1 | MO |
| RELI-ON INSULIN SYRINGE 29G 0.3 ML | 1 | MO |
| SOLIQUA SUBCUTANEOUS SOLUTION PEN-INJECTOR 100-33 UNT-MCG/ML | 3 | MO |
| TOUJEO MAX SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 3 | MO |
| TOUJEO SOLOSTAR SUBCUTANEOUS SOLUTION PEN-INJECTOR 300 UNIT/ML | 3 | MO |
| TRESIBA FLEXTOUCH SUBCUTANEOUS SOLUTION PEN-INJECTOR 100 UNIT/ML, 200 UNIT/ML | 3 | MO |
| TRESIBA SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| BLOOD PRODUCTS AND MODIFIERS | | |
| <i>Anticoagulants</i> | | |
| ELIQUIS DVT/PE STARTER PACK ORAL TABLET THERAPY PACK 5 MG | 3 | MO |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 3 | MO |
| <i>enoxaparin sodium injection solution prefilled syringe 100 mg/ml, 150 mg/ml</i> | 4 | MO; QL (60 ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 120 mg/0.8ml, 80 mg/0.8ml</i> | 4 | MO; QL (48 ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 30 mg/0.3ml</i> | 4 | MO; QL (18 ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 40 mg/0.4ml</i> | 4 | MO; QL (24 ML per 30 days) |
| <i>enoxaparin sodium injection solution prefilled syringe 60 mg/0.6ml</i> | 4 | MO; QL (36 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 10 mg/0.8ml</i> | 5 | QL (24 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 2.5 mg/0.5ml</i> | 4 | MO; QL (15 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 5 mg/0.4ml</i> | 5 | QL (12 ML per 30 days) |
| <i>fondaparinux sodium subcutaneous solution 7.5 mg/0.6ml</i> | 5 | QL (18 ML per 30 days) |
| <i>heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 20000 unit/ml, 5000 unit/ml</i> | 2 | BvD; MO |
| JANTOVEN ORAL TABLET 1 MG, 10 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG | 1 | MO |
| <i>warfarin sodium oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> | 1 | MO |
| XARELTO ORAL SUSPENSION RECONSTITUTED 1 MG/ML | 3 | MO |
| XARELTO ORAL TABLET 10 MG, 15 MG, 2.5 MG, 20 MG | 3 | MO |
| XARELTO STARTER PACK ORAL TABLET THERAPY PACK 15 & 20 MG | 3 | MO |
| <i>Blood Products And Modifiers, Other</i> | | |
| <i>anagrelide hcl oral capsule 0.5 mg, 1 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| LEUKINE INJECTION SOLUTION RECONSTITUTED 250 MCG | 5 | PA |
| PROMACTA ORAL PACKET 12.5 MG | 5 | PA; QL (360 EA per 30 days) |
| PROMACTA ORAL PACKET 25 MG | 5 | PA; QL (180 EA per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG | 5 | PA; QL (60 EA per 30 days) |
| RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 20000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML | 4 | PA; MO; QL (12 ML per 28 days) |
| RETACRIT INJECTION SOLUTION 2000 UNIT/ML | 4 | PA; MO; QL (23 ML per 30 days) |
| RETACRIT INJECTION SOLUTION 3000 UNIT/ML | 4 | PA; MO; QL (16 ML per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | MO |
| ZARXIO INJECTION SOLUTION PREFILLED SYRINGE 300 MCG/0.5ML, 480 MCG/0.8ML | 5 | PA |
| ZIEXTENZO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 6 MG/0.6ML | 5 | PA |
| <i>Platelet Modifying Agents</i> | | |
| <i>aspirin-dipyridamole er oral capsule extended release 12 hour 25-200 mg</i> | 2 | MO |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | MO |
| CABLIVI INJECTION KIT 11 MG | 5 | PA |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | MO |
| <i>clopidogrel bisulfate oral tablet 75 mg</i> | 2 | MO |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> | 4 | MO |
| CARDIOVASCULAR AGENTS | | |
| <i>Alpha-Adrenergic Agonists</i> | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | MO |
| <i>clonidine transdermal patch weekly 0.1 mg/24hr, 0.2 mg/24hr, 0.3 mg/24hr</i> | 2 | MO; QL (4 EA per 28 days) |
| <i>droxidopa oral capsule 100 mg, 200 mg, 300 mg</i> | 5 | PA; QL (180 EA per 30 days) |
| <i>guanfacine hcl oral tablet 1 mg, 2 mg</i> | 1 | MO |
| <i>midodrine hcl oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | MO |
| <i>Alpha-Adrenergic Blocking Agents</i> | | |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>doxazosin mesylate oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> | 1 | MO |
| <i>prazosin hcl oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | MO |
| <i>terazosin hcl oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | MO |
| Angiotensin Ii Receptor Antagonists | | |
| <i>candesartan cilexetil oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 1 | MO |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> | 1 | MO |
| <i>losartan potassium oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>olmesartan medoxomil oral tablet 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | MO |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 1 | MO |
| Angiotensin-Converting Enzyme (Ace) Inhibitors | | |
| <i>benazepril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 2 | MO |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | MO |
| <i>fosinopril sodium oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | MO |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>moexipril hcl oral tablet 15 mg, 7.5 mg</i> | 1 | MO |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 1 | MO |
| <i>quinapril hcl oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | MO |
| Antiarrhythmics | | |
| <i>amiodarone hcl oral tablet 100 mg, 200 mg, 400 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> | 2 | MO |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> | 4 | MO |
| <i>flecainide acetate oral tablet 100 mg, 150 mg, 50 mg</i> | 1 | MO |
| <i>mexiletine hcl oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | MO |
| MULTAQ ORAL TABLET 400 MG | 3 | MO |
| <i>propafenone hcl oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | MO |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 1 | MO |
| <i>sotalol hcl (af) oral tablet 120 mg, 160 mg, 80 mg</i> | 2 | MO |
| <i>sotalol hcl oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 1 | MO |
| <i>Beta-Adrenergic Blocking Agents</i> | | |
| <i>acebutolol hcl oral capsule 200 mg, 400 mg</i> | 1 | MO |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>betaxolol hcl oral tablet 10 mg, 20 mg</i> | 1 | MO |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> | 1 | MO |
| <i>carvedilol phosphate er oral capsule extended release 24 hour 10 mg, 20 mg, 40 mg, 80 mg</i> | 2 | MO |
| <i>labetalol hcl oral tablet 100 mg, 200 mg, 300 mg</i> | 1 | MO |
| <i>metoprolol succinate er oral tablet extended release 24 hour 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>metoprolol tartrate oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 1 | MO |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | MO |
| <i>nebivolol hcl oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 4 | MO |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | MO |
| <i>propranolol hcl er oral capsule extended release 24 hour 120 mg, 160 mg, 60 mg</i> | 2 | MO |
| <i>propranolol hcl oral solution 20 mg/5ml, 40 mg/5ml</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>propranolol hcl oral tablet 10 mg, 20 mg, 40 mg, 60 mg</i> | 1 | MO |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| Calcium Channel Blocking Agents, Dihydropyridines | | |
| <i>amlodipine besylate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>felodipine er oral tablet extended release 24 hour 10 mg, 2.5 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 2 | MO |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | MO |
| <i>nicardipine hcl oral capsule 20 mg, 30 mg</i> | 2 | MO |
| <i>nifedipine er oral tablet extended release 24 hour 30 mg, 60 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er oral tablet extended release 24 hour 90 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 30 mg, 60 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>nifedipine er osmotic release oral tablet extended release 24 hour 90 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>nifedipine oral capsule 10 mg, 20 mg</i> | 2 | MO |
| Calcium Channel Blocking Agents, Nondihydropyridines | | |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 2 | MO; QL (60 EA per 30 days) |
| CARTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG | 2 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er beads oral capsule extended release 24 hour 360 mg, 420 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>diltiazem hcl er coated beads oral capsule extended release 24 hour 300 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>diltiazem hcl er oral capsule extended release 12 hour 120 mg, 60 mg, 90 mg</i> | 2 | MO |
| <i>diltiazem hcl er oral tablet extended release 24 hour 180 mg, 240 mg, 300 mg, 360 mg</i> | 2 | MO |
| <i>diltiazem hcl oral tablet 120 mg, 90 mg</i> | 2 | MO |
| <i>diltiazem hcl oral tablet 30 mg, 60 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>dilt-xr oral capsule extended release 24 hour 120 mg, 180 mg, 240 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| MATZIM LA ORAL TABLET EXTENDED RELEASE 24 HOUR 180 MG, 240 MG, 300 MG, 360 MG, 420 MG | 2 | MO |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 2 | MO; QL (60 EA per 30 days) |
| TAZTIA XT ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG | 2 | MO; QL (30 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 120 MG, 180 MG, 240 MG | 2 | MO; QL (60 EA per 30 days) |
| TIADYLT ER ORAL CAPSULE EXTENDED RELEASE 24 HOUR 300 MG, 360 MG, 420 MG | 2 | MO; QL (30 EA per 30 days) |
| <i>verapamil hcl er oral capsule extended release 24 hour 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg</i> | 2 | MO |
| <i>verapamil hcl er oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 1 | MO |
| <i>verapamil hcl oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | MO |
| Cardiovascular Agents, Other | | |
| <i>aliskiren fumarate oral tablet 150 mg, 300 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 1 | MO |
| <i>amlodipine besy-benazepril hcl oral capsule 10-20 mg, 10-40 mg, 2.5-10 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> | 1 | MO |
| <i>amlodipine besylate-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> | 1 | MO |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 2.5-10 mg, 2.5-20 mg, 2.5-40 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> | 1 | MO |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg, 50-25 mg</i> | 1 | MO |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg, 5-6.25 mg</i> | 1 | MO |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG | 5 | PA; QL (30 EA per 30 days) |
| <i>candesartan cilexetil-hctz oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 1 | MO |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 4 | PA; MO |
| <i>digoxin oral solution 0.05 mg/ml</i> | 2 | MO; QL (255 ML per 30 days) |
| <i>digoxin oral tablet 125 mcg, 250 mcg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>digoxin oral tablet 62.5 mcg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg, 5-12.5 mg</i> | 1 | MO |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 3 | MO |
| FILSPARI ORAL TABLET 200 MG, 400 MG | 5 | PA; QL (30 EA per 30 days) |
| <i>fosinopril sodium-hctz oral tablet 10-12.5 mg, 20-12.5 mg</i> | 1 | MO |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 1 | MO |
| <i>isosorb dinitrate-hydralazine oral tablet 20-37.5 mg</i> | 1 | MO |
| LANOXIN ORAL TABLET 125 MCG, 250 MCG, 62.5 MCG | 4 | MO; QL (30 EA per 30 days) |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 1 | MO |
| <i>losartan potassium-hctz oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | MO |
| <i>metoprolol-hydrochlorothiazide oral tablet 100-25 mg, 100-50 mg, 50-25 mg</i> | 1 | MO |
| <i>metyrosine oral capsule 250 mg</i> | 5 | |
| <i>olmesartan medoxomil-hctz oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 1 | MO |
| <i>olmesartan-amlodipine-hctz oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 1 | MO |
| <i>pentoxifylline er oral tablet extended release 400 mg</i> | 1 | MO |
| <i>ranolazine er oral tablet extended release 12 hour 1000 mg, 500 mg</i> | 3 | MO |
| <i>spironolactone-hctz oral tablet 25-25 mg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 1 | MO |
| <i>telmisartan-hctz oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 1 | MO |
| <i>trandolapril-verapamil hcl er oral tablet extended release 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 1 | MO |
| <i>triamterene-hctz oral capsule 37.5-25 mg</i> | 1 | MO |
| <i>triamterene-hctz oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | MO |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> | 1 | MO |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; MO |
| Diuretics, Loop | | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 2 | MO |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | MO |
| <i>furosemide injection solution 10 mg/ml</i> | 2 | BvD; MO |
| <i>furosemide oral solution 10 mg/ml, 8 mg/ml</i> | 1 | MO |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> | 1 | MO |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | MO |
| Diuretics, Potassium-Sparing | | |
| <i>amiloride hcl oral tablet 5 mg</i> | 1 | MO |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> | 2 | MO |
| KERENDIA ORAL TABLET 10 MG, 20 MG | 3 | MO; QL (30 EA per 30 days) |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| Diuretics, Thiazide | | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | MO |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | MO |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| Dyslipidemics, Fibric Acid Derivatives | | |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 67 mg</i> | 2 | MO; QL (30 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>fenofibrate micronized oral capsule 43 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral capsule 150 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral capsule 50 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>fenofibrate oral tablet 145 mg, 160 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>fenofibrate oral tablet 48 mg, 54 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>fenofibric acid oral capsule delayed release 135 mg, 45 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>gemfibrozil oral tablet 600 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>Dyslipidemics, Hmg Coa Reductase Inhibitors</i> | | |
| <i>atorvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>fluvastatin sodium er oral tablet extended release 24 hour 80 mg</i> | 2 | MO |
| <i>fluvastatin sodium oral capsule 20 mg, 40 mg</i> | 1 | MO |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 3 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 10 mg</i> | 1 | MO; QL (45 EA per 30 days) |
| <i>lovastatin oral tablet 20 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>lovastatin oral tablet 40 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>pravastatin sodium oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>rosuvastatin calcium oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg, 80 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>Dyslipidemics, Other</i> | | |
| <i>cholestyramine light oral packet 4 gm</i> | 2 | MO |
| <i>cholestyramine oral packet 4 gm</i> | 2 | MO |
| <i>colestipol hcl oral packet 5 gm</i> | 2 | MO |
| <i>colestipol hcl oral tablet 1 gm</i> | 2 | MO |
| <i>ezetimibe oral tablet 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg</i> | 2 | MO |
| <i>icosapent ethyl oral capsule 0.5 gm, 1 gm</i> | 4 | MO |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>niacin er (antihyperlipidemic) oral tablet extended release 1000 mg, 500 mg, 750 mg</i> | 2 | MO |
| <i>omega-3-acid ethyl esters oral capsule 1 gm</i> | 2 | MO |
| REPATHA PUSHTRONEX SYSTEM SUBCUTANEOUS SOLUTION CARTRIDGE 420 MG/3.5ML | 3 | PA; MO |
| REPATHA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 140 MG/ML | 3 | PA; MO |
| REPATHA SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 140 MG/ML | 3 | PA; MO |
| VASCEPA ORAL CAPSULE 0.5 GM, 1 GM | 3 | MO |
| <i>Vasodilators, Direct-Acting Arterial/ Venous</i> | | |
| <i>hydralazine hcl oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | MO |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg, 5 mg</i> | 1 | MO |
| <i>isosorbide mononitrate er oral tablet extended release 24 hour 120 mg, 30 mg, 60 mg</i> | 1 | MO |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 1 | MO |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 1 | MO |
| NITRO-BID TRANSDERMAL OINTMENT 2 % | 3 | MO |
| <i>nitroglycerin sublingual tablet sublingual 0.3 mg, 0.4 mg, 0.6 mg</i> | 1 | MO |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | 1 | MO |
| <i>nitroglycerin translingual solution 0.4 mg/spray</i> | 2 | MO |
| RECTIV RECTAL OINTMENT 0.4 % | 4 | MO |
| CENTRAL NERVOUS SYSTEM AGENTS | | |
| <i>Attention Deficit Hyperactivity Disorder Agents, Amphetamines</i> | | |
| <i>amphetamine-dextroamphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>amphetamine-dextroamphetamine oral tablet 30 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 10 mg</i> | 4 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 15 mg</i> | 4 | MO; QL (120 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>dextroamphetamine sulfate er oral capsule extended release 24 hour 5 mg</i> | 4 | MO; QL (360 EA per 30 days) |
| <i>dextroamphetamine sulfate oral solution 5 mg/5ml</i> | 4 | MO; QL (1800 ML per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 4 | MO; QL (180 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg</i> | 4 | MO; QL (90 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 30 mg</i> | 4 | MO; QL (60 EA per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 5 mg</i> | 4 | MO; QL (150 EA per 30 days) |
| Attention Deficit Hyperactivity Disorder Agents, Non-Amphetamines | | |
| <i>atomoxetine hcl oral capsule 10 mg, 100 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 10 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 2.5 mg</i> | 1 | MO; QL (240 EA per 30 days) |
| <i>dexmethylphenidate hcl oral tablet 5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>guanfacine hcl er oral tablet extended release 24 hour 1 mg, 2 mg, 3 mg, 4 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| Central Nervous System, Other | | |
| AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG | 5 | PA; QL (120 EA per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 6 MG | 5 | PA; QL (90 EA per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 24 MG | 5 | PA; QL (60 EA per 30 days) |
| EVRYSDI ORAL SOLUTION RECONSTITUTED 0.75 MG/ML | 5 | PA |
| NUEDEXTA ORAL CAPSULE 20-10 MG | 4 | PA; MO |
| <i>riluzole oral tablet 50 mg</i> | 4 | PA; MO |
| <i>tetrabenazine oral tablet 12.5 mg</i> | 5 | PA; QL (240 EA per 30 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | 5 | PA; QL (120 EA per 30 days) |
| Fibromyalgia Agents | | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg</i> | 2 | MO; QL (90 EA per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | 2 | MO; QL (60 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>pregabalin oral capsule 75 mg</i> | 2 | MO; QL (120 EA per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> | 2 | MO; QL (900 ML per 30 days) |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 3 | MO; QL (60 EA per 30 days) |
| SAVELLA TITRATION PACK ORAL 12.5 & 25 & 50 MG | 3 | MO; QL (55 EA per 28 days) |
| <i>Multiple Sclerosis Agents</i> | | |
| AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT 30 MCG/0.5ML | 5 | PA |
| AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT 30 MCG/0.5ML | 5 | PA |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA |
| COPAXONE SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 20 MG/ML, 40 MG/ML | 5 | PA |
| <i>dalfampridine er oral tablet extended release 12 hour 10 mg</i> | 3 | PA; MO; QL (60 EA per 30 days) |
| <i>dimethyl fumarate oral capsule delayed release 120 mg, 240 mg</i> | 5 | PA |
| <i>dimethyl fumarate starter pack oral 120 & 240 mg</i> | 5 | PA |
| <i>fingolimod hcl oral capsule 0.5 mg</i> | 5 | PA |
| KESIMPTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 20 MG/0.4ML | 5 | PA |
| MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG | 5 | PA |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 12 X 0.25 MG | 5 | PA |
| MAYZENT STARTER PACK ORAL TABLET THERAPY PACK 7 X 0.25 MG | 4 | PA; MO |
| DENTAL AND ORAL AGENTS | | |
| <i>Dental And Oral Agents</i> | | |
| <i>chlorhexidine gluconate mouth/throat solution 0.12 %</i> | 1 | MO |
| PERIOGARD MOUTH/THROAT SOLUTION 0.12 % | 1 | MO |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | 2 | MO |
| <i>triamcinolone acetonide mouth/throat paste 0.1 %</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| DERMATOLOGICAL AGENTS | | |
| <i>Acne And Rosacea Agents</i> | | |
| ACUTANE ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG | 3 | MO |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 4 | PA; MO |
| AMNESTEEM ORAL CAPSULE 10 MG, 20 MG, 40 MG | 4 | MO |
| <i>benzoyl peroxide-erythromycin external gel 5-3 %</i> | 2 | MO |
| CLARAVIS ORAL CAPSULE 10 MG, 20 MG, 30 MG, 40 MG | 4 | MO |
| <i>clindamycin phos-benzoyl perox external gel 1.2-5 %</i> | 2 | MO |
| <i>isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | 4 | MO |
| <i>tazarotene external cream 0.1 %</i> | 2 | PA; MO |
| <i>tazarotene external gel 0.05 %, 0.1 %</i> | 4 | PA; MO |
| TAZORAC EXTERNAL CREAM 0.05 % | 4 | PA; MO |
| <i>tretinoin external cream 0.025 %, 0.05 %, 0.1 %</i> | 2 | PA; MO |
| <i>tretinoin external gel 0.01 %, 0.025 %, 0.05 %</i> | 2 | PA; MO |
| <i>Dermatitis And Pruitus Agents</i> | | |
| <i>alclometasone dipropionate external cream 0.05 %</i> | 2 | MO |
| <i>alclometasone dipropionate external ointment 0.05 %</i> | 2 | MO |
| <i>amcinonide external ointment 0.1 %</i> | 4 | MO |
| <i>ammonium lactate external cream 12 %</i> | 1 | MO |
| <i>ammonium lactate external lotion 12 %</i> | 1 | MO |
| <i>betamethasone dipropionate aug external cream 0.05 %</i> | 1 | MO |
| <i>betamethasone dipropionate aug external lotion 0.05 %</i> | 2 | MO |
| <i>betamethasone dipropionate aug external ointment 0.05 %</i> | 2 | MO |
| <i>betamethasone dipropionate external cream 0.05 %</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>betamethasone dipropionate external lotion 0.05 %</i> | 2 | MO |
| <i>betamethasone dipropionate external ointment 0.05 %</i> | 2 | MO |
| <i>betamethasone valerate external cream 0.1 %</i> | 2 | MO |
| <i>betamethasone valerate external lotion 0.1 %</i> | 2 | MO |
| <i>betamethasone valerate external ointment 0.1 %</i> | 2 | MO |
| <i>clobetasol propionate e external cream 0.05 %</i> | 4 | MO |
| <i>clobetasol propionate external cream 0.05 %</i> | 4 | MO |
| <i>clobetasol propionate external gel 0.05 %</i> | 4 | MO |
| <i>clobetasol propionate external ointment 0.05 %</i> | 4 | MO |
| <i>clobetasol propionate external solution 0.05 %</i> | 2 | MO |
| <i>desonide external cream 0.05 %</i> | 4 | MO |
| <i>desonide external lotion 0.05 %</i> | 4 | MO |
| <i>desonide external ointment 0.05 %</i> | 2 | MO |
| <i>desoximetasone external cream 0.05 %, 0.25 %</i> | 4 | MO |
| <i>desoximetasone external gel 0.05 %</i> | 4 | MO |
| <i>desoximetasone external ointment 0.05 %, 0.25 %</i> | 4 | MO |
| EUCRISA EXTERNAL OINTMENT 2 % | 4 | MO |
| <i>fluocinolone acetonide external cream 0.01 %, 0.025 %</i> | 2 | MO |
| <i>fluocinolone acetonide external ointment 0.025 %</i> | 2 | MO |
| <i>fluocinolone acetonide external solution 0.01 %</i> | 4 | MO |
| <i>fluocinonide emulsified base external cream 0.05 %</i> | 2 | MO |
| <i>fluocinonide external gel 0.05 %</i> | 4 | MO |
| <i>fluocinonide external ointment 0.05 %</i> | 2 | MO |
| <i>fluocinonide external solution 0.05 %</i> | 2 | MO |
| <i>fluticasone propionate external cream 0.05 %</i> | 1 | MO |
| <i>fluticasone propionate external ointment 0.005 %</i> | 1 | MO |
| <i>halobetasol propionate external cream 0.05 %</i> | 4 | MO |
| <i>halobetasol propionate external ointment 0.05 %</i> | 2 | MO |
| <i>hydrocortisone (perianal) external cream 2.5 %</i> | 1 | MO |
| <i>hydrocortisone external cream 1 %</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>hydrocortisone external lotion 2.5 %</i> | 1 | MO |
| <i>hydrocortisone external ointment 1 %</i> | 2 | MO |
| <i>hydrocortisone external ointment 2.5 %</i> | 1 | MO |
| <i>hydrocortisone valerate external cream 0.2 %</i> | 2 | MO |
| <i>hydrocortisone valerate external ointment 0.2 %</i> | 2 | MO |
| HYFTOR EXTERNAL GEL 0.2 % | 5 | PA |
| <i>mometasone furoate external cream 0.1 %</i> | 2 | MO |
| <i>mometasone furoate external ointment 0.1 %</i> | 2 | MO |
| <i>mometasone furoate external solution 0.1 %</i> | 2 | MO |
| <i>pimecrolimus external cream 1 %</i> | 4 | MO |
| PROCTO-MED HC EXTERNAL CREAM 2.5 % | 4 | MO |
| PROCTOSOL HC EXTERNAL CREAM 2.5 % | 4 | MO |
| PROCTOZONE-HC EXTERNAL CREAM 2.5 % | 3 | MO |
| <i>selenium sulfide external lotion 2.5 %</i> | 1 | MO |
| <i>tacrolimus external ointment 0.03 %, 0.1 %</i> | 4 | MO |
| <i>triamcinolone acetonide external cream 0.025 %, 0.1 %, 0.5 %</i> | 1 | MO |
| <i>triamcinolone acetonide external lotion 0.025 %, 0.1 %</i> | 2 | MO |
| <i>triamcinolone acetonide external ointment 0.025 %, 0.1 %, 0.5 %</i> | 1 | MO |
| <i>Dermatological Agents, Other</i> | | |
| <i>calcipotriene external solution 0.005 %</i> | 4 | MO |
| <i>clotrimazole-betamethasone external cream 1-0.05 %</i> | 2 | MO |
| <i>clotrimazole-betamethasone external lotion 1-0.05 %</i> | 2 | MO |
| <i>diclofenac sodium external gel 3 %</i> | 4 | PA; MO |
| <i>fluorouracil external cream 5 %</i> | 3 | MO |
| <i>fluorouracil external solution 2 %, 5 %</i> | 2 | MO |
| <i>global alcohol prep ease pad 70 %</i> | 1 | MO |
| <i>hydrocortisone ace-pramoxine external cream 1-1 %</i> | 2 | MO |
| <i>imiquimod external cream 5 %</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>nystatin-triamcinolone external cream 100000-0.1 unit/gm-%</i> | 2 | MO |
| <i>nystatin-triamcinolone external ointment 100000-0.1 unit/gm-%</i> | 2 | MO |
| PANRETIN EXTERNAL GEL 0.1 % | 5 | PA |
| <i>podofilox external solution 0.5 %</i> | 2 | MO |
| REGRANEX EXTERNAL GEL 0.01 % | 5 | PA |
| SANTYL EXTERNAL OINTMENT 250 UNIT/GM | 4 | MO |
| <i>silver sulfadiazine external cream 1 %</i> | 2 | MO |
| SSD EXTERNAL CREAM 1 % | 1 | MO |
| <i>Pediculicides/Scabicides</i> | | |
| <i>malathion external lotion 0.5 %</i> | 4 | MO |
| <i>permethrin external cream 5 %</i> | 2 | MO |
| <i>Topical Anti-Infectives</i> | | |
| <i>ciclopirox external gel 0.77 %</i> | 2 | MO |
| <i>ciclopirox external shampoo 1 %</i> | 2 | MO |
| <i>ciclopirox external solution 8 %</i> | 2 | MO |
| <i>clindamycin phosphate external gel 1 %</i> | 2 | MO |
| <i>clindamycin phosphate external lotion 1 %</i> | 2 | MO |
| <i>clindamycin phosphate external solution 1 %</i> | 2 | MO |
| <i>ery external pad 2 %</i> | 3 | MO |
| <i>erythromycin external gel 2 %</i> | 2 | MO |
| <i>erythromycin external solution 2 %</i> | 2 | MO |
| <i>mupirocin calcium external cream 2 %</i> | 4 | MO |
| <i>mupirocin external ointment 2 %</i> | 1 | MO |
| ELECTROLYTES/MINERALS/METALS/VITAMINS | | |
| <i>Electrolyte/ Mineral Replacement</i> | | |
| <i>carglumic acid oral tablet soluble 200 mg</i> | 5 | PA |
| ISOLYTE-S PH 7.4 INTRAVENOUS SOLUTION | 4 | BvD; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>kcl in dextrose-nacl intravenous solution 10-5-0.45 meq/l-%-%, 20-5-0.2 meq/l-%-%, 20-5-0.45 meq/l-%-%, 20-5-0.9 meq/l-%-%, 30-5-0.45 meq/l-%-%, 40-5-0.45 meq/l-%-%, 40-5-0.9 meq/l-%-%</i> | 2 | BvD; MO |
| <i>kcl-lactated ringers-d5w intravenous solution 20 meq/l</i> | 2 | BvD; MO |
| KLOR-CON 10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M10 ORAL TABLET EXTENDED RELEASE 10 MEQ | 1 | MO |
| KLOR-CON M15 ORAL TABLET EXTENDED RELEASE 15 MEQ | 1 | MO |
| KLOR-CON M20 ORAL TABLET EXTENDED RELEASE 20 MEQ | 1 | MO |
| KLOR-CON ORAL PACKET 20 MEQ | 2 | MO |
| KLOR-CON ORAL TABLET EXTENDED RELEASE 8 MEQ | 1 | MO |
| <i>magnesium sulfate injection solution 50 %, 50 % (10ml syringe)</i> | 2 | MO |
| PLASMA-LYTE 148 INTRAVENOUS SOLUTION | 3 | BvD; MO |
| PLASMA-LYTE A INTRAVENOUS SOLUTION | 3 | BvD; MO |
| <i>potassium chloride crys er oral tablet extended release 10 meq, 15 meq, 20 meq</i> | 1 | MO |
| <i>potassium chloride er oral capsule extended release 10 meq, 8 meq</i> | 2 | MO |
| <i>potassium chloride er oral tablet extended release 10 meq, 20 meq, 8 meq</i> | 1 | MO |
| <i>potassium chloride in nacl intravenous solution 20-0.45 meq/l-%, 20-0.9 meq/l-%, 40-0.9 meq/l-%</i> | 3 | BvD; MO |
| <i>potassium chloride intravenous solution 10 meq/100ml, 2 meq/ml, 2 meq/ml (20 ml), 20 meq/100ml, 40 meq/100ml</i> | 2 | BvD; MO |
| <i>potassium chloride oral packet 20 meq</i> | 2 | MO |
| <i>potassium chloride oral solution 20 meq/15ml (10%), 40 meq/15ml (20%)</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>potassium citrate er oral tablet extended release 10 meq (1080 mg), 15 meq (1620 mg), 5 meq (540 mg)</i> | 2 | MO |
| <i>potassium cl in dextrose 5% intravenous solution 20 meq/l</i> | 2 | BvD; MO |
| <i>sodium chloride intravenous solution 0.45 %, 0.9 %, 3 %, 5 %</i> | 2 | MO |
| <i>sodium chloride irrigation solution 0.9 %</i> | 1 | MO |
| <i>sodium fluoride oral tablet 2.2 (1 f) mg</i> | 2 | MO |
| <i>Electrolyte/Mineral/Metal Modifiers</i> | | |
| <i>deferasirox granules oral packet 180 mg, 360 mg, 90 mg</i> | 5 | PA |
| <i>deferasirox oral tablet 180 mg, 360 mg</i> | 5 | PA |
| <i>deferasirox oral tablet 90 mg</i> | 4 | PA; MO |
| <i>deferasirox oral tablet soluble 125 mg</i> | 4 | PA; MO |
| <i>deferasirox oral tablet soluble 250 mg, 500 mg</i> | 5 | PA |
| <i>deferiprone oral tablet 1000 mg, 500 mg</i> | 5 | PA |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 5 | PA |
| FERRIPROX TWICE-A-DAY ORAL TABLET 1000 MG | 5 | PA |
| LOKELMA ORAL PACKET 10 GM, 5 GM | 4 | MO |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | MO |
| SPS ORAL SUSPENSION 15 GM/60ML | 3 | MO |
| <i>tolvaptan oral tablet 15 mg</i> | 5 | PA; QL (120 EA per 30 days) |
| <i>tolvaptan oral tablet 30 mg</i> | 5 | PA; QL (60 EA per 30 days) |
| <i>trientine hcl oral capsule 250 mg</i> | 5 | PA |
| <i>Electrolytes/Minerals/Metals/Vitamins</i> | | |
| CLINIMIX E/DEXTROSE (2.75/5) INTRAVENOUS SOLUTION 2.75 % | 3 | BvD; MO |
| CLINIMIX E/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % | 3 | BvD; MO |
| CLINIMIX E/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % | 3 | BvD; MO |
| CLINIMIX E/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % | 3 | BvD; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| CLINIMIX E/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % | 3 | BvD; MO |
| CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % | 4 | BvD; MO |
| CLINIMIX/DEXTROSE (4.25/5) INTRAVENOUS SOLUTION 4.25 % | 4 | BvD; MO |
| CLINIMIX/DEXTROSE (5/15) INTRAVENOUS SOLUTION 5 % | 4 | BvD; MO |
| CLINIMIX/DEXTROSE (5/20) INTRAVENOUS SOLUTION 5 % | 4 | BvD; MO |
| <i>dextrose intravenous solution 10 %, 5 %</i> | 2 | BvD; MO |
| <i>dextrose-nacl intravenous solution 10-0.2 %, 10- 0.45 %, 2.5-0.45 %, 5-0.2 %, 5-0.45 %, 5-0.9 %</i> | 3 | BvD; MO |
| DOJOLVI ORAL LIQUID 100 % | 5 | PA |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 4 | BvD; MO |
| ISOLYTE-P IN D5W INTRAVENOUS SOLUTION | 4 | BvD; MO |
| <i>levocarnitine oral solution 1 gm/10ml</i> | 2 | MO |
| <i>levocarnitine oral tablet 330 mg</i> | 2 | MO |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 4 | BvD; MO |
| PREMASOL INTRAVENOUS SOLUTION 10 % | 4 | BvD; MO |
| <i>prenatal oral tablet 27-1 mg</i> | 2 | MO |
| PROSOL INTRAVENOUS SOLUTION 20 % | 4 | BvD; MO |
| TPN ELECTROLYTES INTRAVENOUS CONCENTRATE | 2 | BvD; MO |
| TRAVASOL INTRAVENOUS SOLUTION 10 % | 4 | BvD; MO |
| TROPHAMINE INTRAVENOUS SOLUTION 10 % | 4 | BvD; MO |
| <i>Phosphate Binders</i> | | |
| AURYXIA ORAL TABLET 1 GM 210 MG(Fe) | 4 | PA; MO |
| <i>calcium acetate (phos binder) oral capsule 667 mg</i> | 2 | MO |
| <i>calcium acetate oral tablet 667 mg</i> | 2 | MO |
| <i>sevelamer carbonate oral packet 0.8 gm</i> | 4 | MO; QL (540 EA per 30 days) |
| <i>sevelamer carbonate oral packet 2.4 gm</i> | 4 | MO; QL (180 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>sevelamer carbonate oral tablet 800 mg</i> | 4 | MO; QL (540 EA per 30 days) |
| VELPHORO ORAL TABLET CHEWABLE 500 MG | 4 | MO |
| EXCLUDED DRUG COVERAGE | | |
| <i>Non-Part D Enhancement</i> | | |
| <i>sildenafil citrate oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | E; MO; QL (6 EA per 30 days) |
| GASTROINTESTINAL AGENTS | | |
| <i>Anti-Constipation Agents</i> | | |
| <i>constulose oral solution 10 gm/15ml</i> | 1 | MO |
| <i>enulose oral solution 10 gm/15ml</i> | 1 | MO |
| <i>generlac oral solution 10 gm/15ml</i> | 1 | MO |
| <i>lactulose oral solution 10 gm/15ml</i> | 1 | MO |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | MO; QL (30 EA per 30 days) |
| <i>lubiprostone oral capsule 24 mcg, 8 mcg</i> | 3 | MO; QL (60 EA per 30 days) |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | MO; QL (30 EA per 30 days) |
| <i>Anti-Diarrheal Agents</i> | | |
| <i>alosetron hcl oral tablet 0.5 mg, 1 mg</i> | 5 | QL (60 EA per 30 days) |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5ml</i> | 4 | MO |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | 2 | MO |
| <i>loperamide hcl oral capsule 2 mg</i> | 1 | MO |
| XERMELO ORAL TABLET 250 MG | 5 | QL (90 EA per 30 days) |
| <i>Antispasmodics, Gastrointestinal</i> | | |
| <i>dicyclomine hcl oral capsule 10 mg</i> | 1 | MO |
| <i>dicyclomine hcl oral solution 10 mg/5ml</i> | 2 | MO |
| <i>dicyclomine hcl oral tablet 20 mg</i> | 1 | MO |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | MO |
| <i>Gastrointestinal Agents, Other</i> | | |
| BYLVAY (PELLETS) ORAL CAPSULE SPRINKLE 200 MCG, 600 MCG | 5 | PA |
| BYLVAY ORAL CAPSULE 1200 MCG, 400 MCG | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| CLENPIQ ORAL SOLUTION 10-3.5-12 MG-GM -GM/160ML, 10-3.5-12 MG-GM -GM/175ML | 4 | MO |
| GATTEX SUBCUTANEOUS KIT 5 MG | 5 | PA |
| GAVILYTE-C ORAL SOLUTION RECONSTITUTED 240 GM | 1 | MO |
| GAVILYTE-G ORAL SOLUTION RECONSTITUTED 236 GM | 1 | MO |
| LIVMARLI ORAL SOLUTION 9.5 MG/ML | 5 | PA |
| <i>metoclopramide hcl oral solution 5 mg/5ml</i> | 1 | MO |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>na sulfate-k sulfate-mg sulf oral solution 17.5-3.13-1.6 gm/177ml</i> | 4 | MO |
| <i>peg 3350-kcl-na bicarb-nacl oral solution reconstituted 420 gm</i> | 2 | MO |
| <i>peg-3350/electrolytes oral solution reconstituted 236 gm</i> | 2 | MO |
| SUTAB ORAL TABLET 1479-225-188 MG | 4 | MO |
| <i>ursodiol oral capsule 300 mg</i> | 2 | MO |
| <i>ursodiol oral tablet 250 mg, 500 mg</i> | 2 | MO |
| <i>Histamine2 (H2) Receptor Antagonists</i> | | |
| <i>famotidine oral suspension reconstituted 40 mg/5ml</i> | 2 | MO |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | 1 | MO |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | MO |
| <i>Protectants</i> | | |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> | 2 | MO |
| <i>sucralfate oral suspension 1 gm/10ml</i> | 4 | MO |
| <i>sucralfate oral tablet 1 gm</i> | 1 | MO |
| <i>Proton Pump Inhibitors</i> | | |
| <i>dexlansoprazole oral capsule delayed release 30 mg, 60 mg</i> | 3 | MO |
| <i>esomeprazole magnesium oral capsule delayed release 20 mg, 40 mg</i> | 2 | MO |
| <i>lansoprazole oral capsule delayed release 15 mg, 30 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>omeprazole oral capsule delayed release 10 mg, 20 mg, 40 mg</i> | 1 | MO |
| <i>pantoprazole sodium oral tablet delayed release 20 mg, 40 mg</i> | 1 | MO |
| GENETIC OR ENZYME OR PROTEIN DISORDER: REPLACEMENT, MODIFIERS, TREATMENT | | |
| <i>Genetic Or Enzyme Or Protein Disorder: Replacement, Modifiers, Treatment</i> | | |
| <i>betaine oral powder</i> | 5 | |
| CREON ORAL CAPSULE DELAYED RELEASE PARTICLES 12000-38000 UNIT, 24000-76000 UNIT, 3000-9500 UNIT, 36000-114000 UNIT, 6000-19000 UNIT | 3 | MO |
| <i>cromolyn sodium oral concentrate 100 mg/5ml</i> | 4 | MO |
| CYSTAGON ORAL CAPSULE 150 MG, 50 MG | 4 | PA; MO |
| ENDARI ORAL PACKET 5 GM | 4 | PA; MO |
| GALAFOLD ORAL CAPSULE 123 MG | 5 | PA |
| <i>miglustat oral capsule 100 mg</i> | 5 | PA |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> | 5 | PA |
| PROLASTIN-C INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG | 5 | PA |
| RAVICTI ORAL LIQUID 1.1 GM/ML | 5 | PA |
| <i>sapropterin dihydrochloride oral packet 100 mg, 500 mg</i> | 5 | PA |
| <i>sapropterin dihydrochloride oral tablet 100 mg</i> | 5 | PA |
| TEGSEDI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 284 MG/1.5ML | 5 | PA |
| VIJOICE ORAL TABLET THERAPY PACK 125 MG, 200 & 50 MG, 50 MG | 5 | PA |
| VYNDAMAX ORAL CAPSULE 61 MG | 5 | PA; QL (30 EA per 30 days) |
| XURIDEN ORAL PACKET 2 GM | 5 | PA |
| ZENPEP ORAL CAPSULE DELAYED RELEASE PARTICLES 10000-32000 UNIT, 15000-47000 UNIT, 20000-63000 UNIT, 25000-79000 UNIT, 3000-10000 UNIT, 40000-126000 UNIT, 5000-24000 UNIT | 3 | MO |
| ZOKINVY ORAL CAPSULE 50 MG, 75 MG | 5 | PA |

GENITOURINARY AGENTS

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| Antispasmodics, Urinary | | |
| <i>darifenacin hydrobromide er oral tablet extended release 24 hour 15 mg, 7.5 mg</i> | 4 | MO |
| <i>fesoterodine fumarate er oral tablet extended release 24 hour 4 mg, 8 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| MYRBETRIQ ORAL SUSPENSION RECONSTITUTED ER 8 MG/ML | 3 | MO; QL (300 ML per 30 days) |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HOUR 25 MG, 50 MG | 3 | MO; QL (30 EA per 30 days) |
| <i>oxybutynin chloride er oral tablet extended release 24 hour 10 mg, 15 mg, 5 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>oxybutynin chloride oral syrup 5 mg/5ml</i> | 2 | MO; QL (600 ML per 30 days) |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 1 | MO; QL (120 EA per 30 days) |
| <i>solifenacin succinate oral tablet 10 mg, 5 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate er oral capsule extended release 24 hour 2 mg, 4 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>tolterodine tartrate oral tablet 1 mg, 2 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| <i>trospium chloride er oral capsule extended release 24 hour 60 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>trospium chloride oral tablet 20 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| Benign Prostatic Hypertrophy Agents | | |
| <i>alfuzosin hcl er oral tablet extended release 24 hour 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| CARDURA XL ORAL TABLET EXTENDED RELEASE 24 HOUR 4 MG, 8 MG | 3 | MO |
| <i>dutasteride oral capsule 0.5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>dutasteride-tamsulosin hcl oral capsule 0.5-0.4 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>finasteride oral tablet 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>silodosin oral capsule 4 mg, 8 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>tamsulosin hcl oral capsule 0.4 mg</i> | 1 | MO; QL (60 EA per 30 days) |
| Genitourinary Agents, Other | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | MO |
| ELMIRON ORAL CAPSULE 100 MG | 4 | MO |
| <i>penicillamine oral tablet 250 mg</i> | 5 | |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------|
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (ADRENAL) | | |
| <i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Adrenal)</i> | | |
| <i>dexamethasone oral solution 0.5 mg/5ml</i> | 2 | MO |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 1 | MO |
| <i>fludrocortisone acetate oral tablet 0.1 mg</i> | 1 | MO |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> | 1 | MO |
| ISTURISA ORAL TABLET 1 MG | 5 | PA; QL (240 EA per 30 days) |
| ISTURISA ORAL TABLET 10 MG | 5 | PA; QL (180 EA per 30 days) |
| ISTURISA ORAL TABLET 5 MG | 5 | PA; QL (120 EA per 30 days) |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | BvD; MO |
| <i>methylprednisolone oral tablet therapy pack 4 mg</i> | 2 | MO |
| <i>prednisolone oral solution 15 mg/5ml</i> | 2 | BvD; MO |
| <i>prednisolone sodium phosphate oral solution 10 mg/5ml, 20 mg/5ml, 25 mg/5ml, 6.7 (5 base) mg/5ml</i> | 4 | BvD; MO |
| <i>prednisolone sodium phosphate oral tablet dispersible 10 mg, 15 mg, 30 mg</i> | 2 | BvD; MO |
| PREDNISONO INTENSOL ORAL CONCENTRATE 5 MG/ML | 2 | BvD; MO |
| <i>prednisone oral solution 5 mg/5ml</i> | 2 | BvD; MO |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | BvD; MO |
| <i>prednisone oral tablet therapy pack 10 mg (21), 10 mg (48), 5 mg (21), 5 mg (48)</i> | 1 | MO |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (PITUITARY) | | |
| <i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Pituitary)</i> | | |
| <i>desmopressin acetate oral tablet 0.1 mg, 0.2 mg</i> | 2 | MO |
| <i>desmopressin acetate spray nasal solution 0.01 %</i> | 2 | MO |
| INCRELEX SUBCUTANEOUS SOLUTION 40 MG/4ML | 5 | PA |
| NOCDURNA SUBLINGUAL TABLET SUBLINGUAL 27.7 MCG, 55.3 MCG | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE 10 MG/1.5ML, 5 MG/1.5ML | 5 | PA |
| OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED 5.8 MG | 5 | PA |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (SEX HORMONES/ MODIFIERS) | | |
| Androgens | | |
| <i>danazol oral capsule 100 mg, 50 mg</i> | 2 | MO |
| <i>danazol oral capsule 200 mg</i> | 4 | MO |
| <i>testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | 2 | MO |
| <i>testosterone enanthate intramuscular solution 200 mg/ml</i> | 2 | MO |
| <i>testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)</i> | 3 | MO |
| <i>testosterone transdermal solution 30 mg/act</i> | 3 | MO |
| Estrogens | | |
| DUAVEE ORAL TABLET 0.45-20 MG | 3 | MO |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | MO |
| <i>estradiol transdermal patch twice weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | MO |
| <i>estradiol transdermal patch weekly 0.025 mg/24hr, 0.0375 mg/24hr, 0.05 mg/24hr, 0.06 mg/24hr, 0.075 mg/24hr, 0.1 mg/24hr</i> | 2 | MO |
| <i>estradiol vaginal cream 0.1 mg/gm</i> | 4 | MO |
| <i>estradiol vaginal tablet 10 mcg</i> | 4 | MO |
| IMVEXXY MAINTENANCE PACK VAGINAL INSERT 10 MCG, 4 MCG | 4 | MO |
| IMVEXXY STARTER PACK VAGINAL INSERT 10 MCG, 4 MCG | 4 | MO |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG, 2.5 MG | 4 | MO |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| PREMARIN VAGINAL CREAM 0.625 MG/GM | 3 | MO |
| <i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Sex Hormones/ Modifiers)</i> | | |
| ALTAVERA ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| <i>alyacen 1/35 oral tablet 1-35 mg-mcg</i> | 1 | MO |
| APRI ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| ARANELLE ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | MO |
| AUBRA EQ ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| AVIANE ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| BALZIVA ORAL TABLET 0.4-35 MG-MCG | 2 | MO |
| BLISOVI FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 2 | MO |
| CRYSSELLE-28 ORAL TABLET 0.3-30 MG-MCG | 2 | MO |
| CYRED EQ ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.02/0.01 mg (21/5)</i> | 2 | MO |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-30 mg-mcg</i> | 1 | MO |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg, 3-0.03 mg</i> | 2 | MO |
| ELURYNG VAGINAL RING 0.12-0.015 MG/24HR | 4 | MO |
| ENPRESSE-28 ORAL TABLET 50-30/75-40/125-30 MCG | 1 | MO |
| ENSKYCE ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| ESTARYLLA ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | 2 | MO |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24hr</i> | 4 | MO |
| FALMINA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| ICLEVIA ORAL TABLET 0.15-0.03 MG | 2 | MO |
| INTRAROSA VAGINAL INSERT 6.5 MG | 3 | PA; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| INTROVALE ORAL TABLET 0.15-0.03 MG | 2 | MO |
| ISIBLOOM ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| JASMIEL ORAL TABLET 3-0.02 MG | 2 | MO |
| JULEBER ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| JUNEL 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | MO |
| JUNEL 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| JUNEL FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| JUNEL FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| KARIVA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | MO |
| KELNOR 1/35 ORAL TABLET 1-35 MG-MCG | 1 | MO |
| KELNOR 1/50 ORAL TABLET 1-50 MG-MCG | 1 | MO |
| KURVELO ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| LARIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | MO |
| LARIN 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| LARIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 1 | MO |
| LARIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| LEENA ORAL TABLET 0.5/1/0.5-35 MG-MCG | 2 | MO |
| LESSINA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| LEVONEST ORAL TABLET 50-30/75-40/ 125-30 MCG | 1 | MO |
| <i>levonorgest-eth estrad 91-day oral tablet 0.15-0.03 mg</i> | 2 | MO |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg, 0.15-30 mg-mcg</i> | 1 | MO |
| <i>levonorg-eth estrad triphasic oral tablet 50-30/75-40/ 125-30 mcg</i> | 1 | MO |
| LEVORA 0.15/30 (28) ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| LORYNA ORAL TABLET 3-0.02 MG | 2 | MO |
| LOW-OGESTREL ORAL TABLET 0.3-30 MG-MCG | 2 | MO |
| LUTERA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| <i>marlissa oral tablet 0.15-30 mg-mcg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| MICROGESTIN 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | MO |
| MICROGESTIN 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| MICROGESTIN FE 1.5/30 ORAL TABLET 1.5-30 MG-MCG | 2 | MO |
| MICROGESTIN FE 1/20 ORAL TABLET 1-20 MG-MCG | 1 | MO |
| MILI ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| NECON 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | MO |
| NIKKI ORAL TABLET 3-0.02 MG | 2 | MO |
| <i>norethin ace-eth estrad-fe oral tablet 1-20 mg-mcg</i> | 1 | MO |
| <i>norethindrone acet-ethinyl est oral tablet 1-20 mg-mcg</i> | 2 | MO |
| <i>norethindrone-eth estradiol oral tablet 1-5 mg-mcg</i> | 2 | MO |
| <i>norgestimate-eth estradiol oral tablet 0.25-35 mg-mcg</i> | 1 | MO |
| <i>norgestim-eth estrad triphasic oral tablet 0.18/0.215/0.25 mg-35 mcg</i> | 1 | MO |
| NORTREL 0.5/35 (28) ORAL TABLET 0.5-35 MG-MCG | 2 | MO |
| NORTREL 1/35 (21) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| NORTREL 1/35 (28) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| NORTREL 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 1 | MO |
| NYLIA 1/35 ORAL TABLET 1-35 MG-MCG | 1 | MO |
| NYLIA 7/7/7 ORAL TABLET 0.5/0.75/1-35 MG-MCG | 1 | MO |
| NYMYO ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| OCELLA ORAL TABLET 3-0.03 MG | 2 | MO |
| OSPHENA ORAL TABLET 60 MG | 3 | PA; MO |
| PIMTREA ORAL TABLET 0.15-0.02/0.01 MG (21/5) | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| PORTIA-28 ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| PREMPHASE ORAL TABLET 0.625-5 MG | 3 | MO |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | MO |
| RECLIPSEN ORAL TABLET 0.15-30 MG-MCG | 1 | MO |
| SETLAKIN ORAL TABLET 0.15-0.03 MG | 2 | MO |
| SPRINTEC 28 ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| SRONYX ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| SYEDA ORAL TABLET 3-0.03 MG | 2 | MO |
| TARINA FE 1/20 EQ ORAL TABLET 1-20 MG-MCG | 1 | MO |
| TRI-ESTARYLLA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-MILI ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-NYMYO ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRI-SPRINTEC ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| TRIVORA (28) ORAL TABLET 50-30/75-40/125-30 MCG | 1 | MO |
| TRI-VYLIBRA ORAL TABLET 0.18/0.215/0.25 MG-35 MCG | 1 | MO |
| VELIVET ORAL TABLET 0.1/0.125/0.15 -0.025 MG | 2 | MO |
| VESTURA ORAL TABLET 3-0.02 MG | 2 | MO |
| VIENVA ORAL TABLET 0.1-20 MG-MCG | 1 | MO |
| VYFEMLA ORAL TABLET 0.4-35 MG-MCG | 2 | MO |
| VYLIBRA ORAL TABLET 0.25-35 MG-MCG | 1 | MO |
| ZOVIA 1/35 (28) ORAL TABLET 1-35 MG-MCG | 1 | MO |
| <i>Progestins</i> | | |
| CAMILA ORAL TABLET 0.35 MG | 1 | MO |
| DEBLITANE ORAL TABLET 0.35 MG | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SUSPENSION PREFILLED SYRINGE 104 MG/0.65ML | 2 | MO |
| ERRIN ORAL TABLET 0.35 MG | 1 | MO |
| INCASSIA ORAL TABLET 0.35 MG | 1 | MO |
| LYLEQ ORAL TABLET 0.35 MG | 1 | MO |
| LYZA ORAL TABLET 0.35 MG | 1 | MO |
| <i>medroxyprogesterone acetate intramuscular suspension 150 mg/ml</i> | 2 | MO |
| <i>medroxyprogesterone acetate intramuscular suspension prefilled syringe 150 mg/ml</i> | 2 | MO |
| <i>medroxyprogesterone acetate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 1 | MO |
| <i>megestrol acetate oral suspension 40 mg/ml</i> | 2 | MO |
| <i>megestrol acetate oral suspension 625 mg/5ml</i> | 4 | MO |
| <i>megestrol acetate oral tablet 20 mg, 40 mg</i> | 1 | MO |
| NORA-BE ORAL TABLET 0.35 MG | 1 | MO |
| <i>norethindrone acetate oral tablet 5 mg</i> | 2 | MO |
| <i>norethindrone oral tablet 0.35 mg</i> | 1 | MO |
| <i>progesterone oral capsule 100 mg, 200 mg</i> | 2 | MO |
| SHAROBEL ORAL TABLET 0.35 MG | 1 | MO |
| HORMONAL AGENTS, STIMULANT/ REPLACEMENT/ MODIFYING (THYROID) | | |
| <i>Hormonal Agents, Stimulant/ Replacement/ Modifying (Thyroid)</i> | | |
| EUTHYROX ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| <i>levothyroxine sodium oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 300 mcg, 50 mcg, 75 mcg, 88 mcg</i> | 1 | MO |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | 1 | MO |
| <i>liothyronine sodium oral tablet 25 mcg, 5 mcg, 50 mcg</i> | 1 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SYNTHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | MO |
| UNITHROID ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 300 MCG, 50 MCG, 75 MCG, 88 MCG | 3 | MO |
| HORMONAL AGENTS, SUPPRESSANT (PITUITARY) | | |
| <i>Hormonal Agents, Suppressant (Pituitary)</i> | | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | MO |
| ELIGARD SUBCUTANEOUS KIT 22.5 MG, 30 MG, 45 MG, 7.5 MG | 4 | PA; MO |
| FIRMAGON (240 MG DOSE) SUBCUTANEOUS SOLUTION RECONSTITUTED 120 MG/VIAL | 5 | PA |
| FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG | 4 | PA; MO |
| <i>leuprolide acetate (3 month) intramuscular injectable 22.5 mg</i> | 4 | PA; MO |
| <i>leuprolide acetate injection kit 1 mg/0.2ml</i> | 4 | PA; MO |
| LUPRON DEPOT (1-MONTH) INTRAMUSCULAR KIT 3.75 MG, 7.5 MG | 5 | PA |
| LUPRON DEPOT (3-MONTH) INTRAMUSCULAR KIT 11.25 MG, 22.5 MG | 5 | PA |
| LUPRON DEPOT (4-MONTH) INTRAMUSCULAR KIT 30 MG | 5 | PA |
| LUPRON DEPOT (6-MONTH) INTRAMUSCULAR KIT 45 MG | 5 | PA |
| LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 7.5 MG | 5 | PA |
| LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG (PED) | 5 | PA |
| LUPRON DEPOT-PED (6-MONTH) INTRAMUSCULAR KIT 45 MG | 5 | PA |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml</i> | 2 | PA; MO |
| <i>octreotide acetate injection solution 1000 mcg/ml, 500 mcg/ml</i> | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>octreotide acetate injection solution 200 mcg/ml</i> | 4 | PA; MO |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML, 0.6 MG/ML, 0.9 MG/ML | 5 | PA; QL (60 ML per 30 days) |
| SOMAVERT SUBCUTANEOUS SOLUTION RECONSTITUTED 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; QL (60 EA per 30 days) |
| SYNAREL NASAL SOLUTION 2 MG/ML | 5 | PA |
| TRELSTAR MIXJECT INTRAMUSCULAR SUSPENSION RECONSTITUTED 11.25 MG, 22.5 MG, 3.75 MG | 4 | PA; MO |
| HORMONAL AGENTS, SUPPRESSANT (THYROID) | | |
| <i>Antithyroid Agents</i> | | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | MO |
| <i>propylthiouracil oral tablet 50 mg</i> | 1 | MO |
| IMMUNOLOGICAL AGENTS | | |
| <i>Angioedema Agents</i> | | |
| <i>icatibant acetate subcutaneous solution prefilled syringe 30 mg/3ml</i> | 5 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2ML | 5 | PA |
| TAKHZYRO SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 300 MG/2ML | 5 | PA |
| <i>Immunoglobulins</i> | | |
| PANZYGA INTRAVENOUS SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML | 5 | BvD |
| PRIVIGEN INTRAVENOUS SOLUTION 20 GM/200ML | 5 | BvD |
| <i>Immunological Agents, Other</i> | | |
| ARCALYST SUBCUTANEOUS SOLUTION RECONSTITUTED 220 MG | 5 | PA |
| COSENTYX (300 MG DOSE) SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| COSENTYX SENSOREADY (300 MG) SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 5 | PA |
| COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML | 5 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PEN-INJECTOR 200 MG/1.14ML, 300 MG/2ML | 5 | PA |
| DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML, 200 MG/1.14ML, 300 MG/2ML | 5 | PA |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> | 2 | MO |
| OTEZLA ORAL TABLET 30 MG | 5 | PA |
| OTEZLA ORAL TABLET THERAPY PACK 10 & 20 & 30 MG | 5 | PA |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG, 45 MG | 5 | PA |
| SKYRIZI PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 150 MG/ML | 5 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION CARTRIDGE 180 MG/1.2ML, 360 MG/2.4ML | 5 | PA |
| SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML | 5 | PA |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML | 5 | PA |
| STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 45 MG/0.5ML, 90 MG/ML | 5 | PA |
| TAVNEOS ORAL CAPSULE 10 MG | 5 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML, 75 MG/0.5ML | 5 | PA |
| XOLAIR SUBCUTANEOUS SOLUTION RECONSTITUTED 150 MG | 5 | PA |
| <i>Immunostimulants</i> | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 2000000 UNIT/0.5ML | 5 | PA |
| BESREMI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 500 MCG/ML | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA |
| PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 180 MCG/0.5ML | 5 | PA |
| <i>Immunosuppressants</i> | | |
| <i>azathioprine oral tablet 100 mg, 75 mg</i> | 3 | BvD; MO |
| <i>azathioprine oral tablet 50 mg</i> | 2 | BvD; MO |
| BENLYSTA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/ML | 5 | PA |
| BENLYSTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 200 MG/ML | 5 | PA |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | BvD; MO |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | 2 | BvD; MO |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | 2 | BvD; MO |
| ENBREL MINI SUBCUTANEOUS SOLUTION CARTRIDGE 50 MG/ML | 5 | PA |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML | 5 | PA |
| ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML | 5 | PA |
| ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR 50 MG/ML | 5 | PA |
| ENSPRYNG SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 120 MG/ML | 5 | PA |
| ENVARUSUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG | 4 | BvD; MO |
| <i>everolimus oral tablet 0.25 mg, 0.75 mg, 1 mg</i> | 5 | BvD; QL (60 EA per 30 days) |
| <i>everolimus oral tablet 0.5 mg</i> | 5 | BvD; QL (120 EA per 30 days) |
| GENGRAF ORAL CAPSULE 100 MG, 25 MG | 2 | BvD; MO |
| GENGRAF ORAL SOLUTION 100 MG/ML | 2 | BvD; MO |
| HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML | 5 | PA |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML | 5 | PA |
| HUMIRA PEN-CD/UC/HS STARTER SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML, 80 MG/0.8ML | 5 | PA |
| HUMIRA PEN-PEDIATRIC UC START SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML | 5 | PA |
| HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML | 5 | PA |
| HUMIRA PEN-PSOR/UEIT STARTER SUBCUTANEOUS PEN-INJECTOR KIT 80 MG/0.8ML & 40MG/0.4ML | 5 | PA |
| HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML | 5 | PA |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/0.67ML | 5 | PA |
| LUPKYNIS ORAL CAPSULE 7.9 MG | 5 | PA; QL (180 EA per 30 days) |
| <i>methotrexate sodium (pf) injection solution 50 mg/2ml</i> | 1 | BvD; MO |
| <i>methotrexate sodium injection solution 50 mg/2ml</i> | 1 | BvD; MO |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | BvD; MO |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 4 | BvD; MO |
| <i>mycophenolate mofetil oral suspension reconstituted 200 mg/ml</i> | 5 | BvD |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | BvD; MO |
| <i>mycophenolate sodium oral tablet delayed release 180 mg, 360 mg</i> | 2 | BvD; MO |
| PROGRAF ORAL PACKET 0.2 MG, 1 MG | 4 | BvD; MO |
| REZUROCK ORAL TABLET 200 MG | 5 | PA |
| <i>sirolimus oral solution 1 mg/ml</i> | 5 | BvD |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 4 | BvD; MO |
| <i>tacrolimus oral capsule 0.5 mg</i> | 2 | BvD; MO |
| <i>tacrolimus oral capsule 1 mg, 5 mg</i> | 4 | BvD; MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| TREXALL ORAL TABLET 10 MG, 15 MG, 5 MG, 7.5 MG | 4 | BvD; MO |
| Vaccines | | |
| ACTHIB INTRAMUSCULAR SOLUTION RECONSTITUTED | 3 | MO |
| ADACEL INTRAMUSCULAR SUSPENSION 5-2-15.5 (PREFILLED SYRINGE), 5-2-15.5 LF-MCG/0.5 | 4 | MO |
| <i>bcg vaccine injection solution reconstituted 50 mg</i> | 4 | MO |
| BEXSERO INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | MO |
| BOOSTRIX INTRAMUSCULAR SUSPENSION 5-2.5-18.5 LF-MCG/0.5 | 3 | MO |
| BOOSTRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 5-2.5-18.5 LF-MCG/0.5 | 3 | MO |
| DAPTACEL INTRAMUSCULAR SUSPENSION 23-15-5 | 4 | MO |
| <i>diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml</i> | 4 | BvD; MO |
| ENGERIX-B INJECTION SUSPENSION 20 MCG/ML | 3 | BvD; MO |
| ENGERIX-B INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/0.5ML, 20 MCG/ML | 3 | BvD; MO |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION | 3 | MO |
| GARDASIL 9 INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | MO |
| HAVRIX INTRAMUSCULAR SUSPENSION 1440 EL U/ML, 720 EL U/0.5ML | 3 | MO |
| HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML | 3 | BvD; MO |
| HIBERIX INJECTION SOLUTION RECONSTITUTED 10 MCG | 3 | MO |
| IMOVAX RABIES INTRAMUSCULAR SUSPENSION RECONSTITUTED 2.5 UNIT/ML | 3 | BvD; MO |
| INFANRIX INTRAMUSCULAR SUSPENSION 25-58-10 | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| IPOL INJECTION INJECTABLE | 3 | MO |
| IXIARO INTRAMUSCULAR SUSPENSION | 3 | MO |
| JYNNEOS SUBCUTANEOUS SUSPENSION 0.5 ML | 3 | MO |
| KINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | 4 | MO |
| MENACTRA INTRAMUSCULAR SOLUTION | 3 | MO |
| MENQUADFI INTRAMUSCULAR SOLUTION | 3 | MO |
| MENVEO INTRAMUSCULAR SOLUTION RECONSTITUTED | 3 | MO |
| M-M-R II INJECTION SOLUTION RECONSTITUTED | 3 | MO |
| PEDIARIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 4 | MO |
| PEDVAX HIB INTRAMUSCULAR SUSPENSION 7.5 MCG/0.5ML | 3 | MO |
| PENTACEL INTRAMUSCULAR SUSPENSION RECONSTITUTED | 4 | MO |
| <i>prehevbrio intramuscular suspension 10 mcg/ml</i> | 3 | BvD; MO |
| PRIORIX SUBCUTANEOUS SUSPENSION RECONSTITUTED | 3 | MO |
| PROQUAD SUBCUTANEOUS SUSPENSION RECONSTITUTED | 3 | MO |
| QUADRACEL INTRAMUSCULAR SUSPENSION , (58 UNT/ML) | 4 | MO |
| QUADRACEL INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 0.5 ML | 4 | MO |
| RABAERT INTRAMUSCULAR SUSPENSION RECONSTITUTED | 3 | BvD; MO |
| RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5ML | 3 | BvD; MO |
| RECOMBIVAX HB INJECTION SUSPENSION PREFILLED SYRINGE 10 MCG/ML, 5 MCG/0.5ML | 3 | BvD; MO |
| ROTARIX ORAL SUSPENSION | 3 | MO |
| ROTARIX ORAL SUSPENSION RECONSTITUTED | 3 | MO |
| ROTATEQ ORAL SOLUTION | 3 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| SHINGRIX INTRAMUSCULAR SUSPENSION RECONSTITUTED 50 MCG/0.5ML | 3 | MO |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML | 3 | BvD; MO |
| TENIVAC INTRAMUSCULAR INJECTABLE 5-2 LFU, 5-2 LFU (INJECTION) | 3 | BvD; MO |
| TICOVAC INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 1.2 MCG/0.25ML, 2.4 MCG/0.5ML | 3 | MO |
| TRUMENBA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE | 3 | MO |
| TWINRIX INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 720-20 ELU-MCG/ML | 3 | MO |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5ML | 3 | MO |
| TYPHIM VI INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 25 MCG/0.5ML | 3 | MO |
| VAQTA INTRAMUSCULAR SUSPENSION 25 UNIT/0.5ML, 25 UNIT/0.5ML 0.5 ML, 50 UNIT/ML, 50 UNIT/ML 1 ML | 3 | MO |
| VARIVAX SUBCUTANEOUS INJECTABLE 1350 PFU/0.5ML | 3 | MO |
| YF-VAX SUBCUTANEOUS INJECTABLE , (2.5 ML IN 1 VIAL, MULTI-DOSE) | 3 | MO |

INFLAMMATORY BOWEL DISEASE AGENTS

Aminosalicylates

| | | |
|---|---|----|
| <i>balsalazide disodium oral capsule 750 mg</i> | 2 | MO |
| LIALDA ORAL TABLET DELAYED RELEASE 1.2 GM | 3 | MO |
| <i>mesalamine er oral capsule extended release 24 hour 0.375 gm</i> | 4 | MO |
| <i>mesalamine oral capsule delayed release 400 mg</i> | 4 | MO |
| <i>mesalamine oral tablet delayed release 800 mg</i> | 4 | MO |
| <i>mesalamine rectal enema 4 gm</i> | 4 | MO |
| <i>sulfasalazine oral tablet 500 mg</i> | 1 | MO |
| <i>sulfasalazine oral tablet delayed release 500 mg</i> | 1 | MO |

Glucocorticoids

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| <i>budesonide er oral tablet extended release 24 hour 9 mg</i> | 5 | |
| <i>budesonide oral capsule delayed release particles 3 mg</i> | 4 | MO |
| <i>hydrocortisone rectal enema 100 mg/60ml</i> | 4 | MO |
| METABOLIC BONE DISEASE AGENTS | | |
| <i>Metabolic Bone Disease Agents</i> | | |
| <i>alendronate sodium oral tablet 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>alendronate sodium oral tablet 35 mg, 70 mg</i> | 1 | MO; QL (4 EA per 28 days) |
| <i>calcitonin (salmon) nasal solution 200 unit/act</i> | 2 | BvD; MO; QL (4 ML per 28 days) |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 1 | BvD; MO |
| <i>calcitriol oral solution 1 mcg/ml</i> | 4 | BvD; MO |
| <i>cinacalcet hcl oral tablet 30 mg, 60 mg</i> | 4 | BvD; MO; QL (60 EA per 30 days) |
| <i>cinacalcet hcl oral tablet 90 mg</i> | 5 | BvD; QL (120 EA per 30 days) |
| <i>ibandronate sodium oral tablet 150 mg</i> | 1 | MO; QL (1 EA per 30 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG, 25 MCG, 50 MCG, 75 MCG | 5 | PA |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg, 4 mcg</i> | 4 | BvD; MO |
| PROLIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 60 MG/ML | 4 | MO; QL (1 ML per 180 days) |
| <i>raloxifene hcl oral tablet 60 mg</i> | 2 | MO |
| <i>risedronate sodium oral tablet 150 mg</i> | 2 | MO; QL (1 EA per 28 days) |
| <i>risedronate sodium oral tablet 30 mg, 5 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>risedronate sodium oral tablet 35 mg, 35 mg (12 pack), 35 mg (4 pack)</i> | 2 | MO; QL (4 EA per 28 days) |
| <i>risedronate sodium oral tablet delayed release 35 mg</i> | 2 | MO; QL (4 EA per 28 days) |
| <i>teriparatide (recombinant) subcutaneous solution pen-injector 620 mcg/2.48ml</i> | 5 | PA; QL (2.48 ML per 28 days) |
| TYMLOS SUBCUTANEOUS SOLUTION PEN- INJECTOR 3120 MCG/1.56ML | 5 | PA; QL (1.56 ML per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7ML | 5 | PA; QL (2 ML per 28 days) |

OPHTHALMIC AGENTS

Ophthalmic Agents, Other

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>atropine sulfate ophthalmic solution 1 %</i> | 2 | MO |
| <i>bacitra-neomycin-polymyxin-hc ophthalmic ointment 1 %</i> | 2 | MO |
| <i>cyclosporine ophthalmic emulsion 0.05 %</i> | 2 | MO; QL (60 EA per 30 days) |
| CYSTADROPS OPHTHALMIC SOLUTION 0.37 % | 5 | PA |
| CYSTARAN OPHTHALMIC SOLUTION 0.44 % | 5 | PA |
| <i>neomycin-polymyxin-dexameth ophthalmic ointment 3.5-10000-0.1</i> | 2 | MO |
| <i>neomycin-polymyxin-dexameth ophthalmic suspension 3.5-10000-0.1</i> | 1 | MO |
| <i>neomycin-polymyxin-gramicidin ophthalmic solution 1.75-10000-.025</i> | 2 | MO |
| <i>neomycin-polymyxin-hc ophthalmic suspension 3.5-10000-1</i> | 2 | MO |
| <i>polymyxin b-trimethoprim ophthalmic solution 10000-0.1 unit/ml-%</i> | 1 | MO |
| <i>sulfacetamide-prednisolone ophthalmic solution 10-0.23 %</i> | 2 | MO |
| <i>tobramycin-dexamethasone ophthalmic suspension 0.3-0.1 %</i> | 2 | MO |
| <i>Ophthalmic Anti-Allergy Agents</i> | | |
| <i>azelastine hcl ophthalmic solution 0.05 %</i> | 2 | MO |
| <i>cromolyn sodium ophthalmic solution 4 %</i> | 1 | MO |
| <i>olopatadine hcl ophthalmic solution 0.1 %</i> | 3 | MO |
| <i>Ophthalmic Anti-Infectives</i> | | |
| AZASITE OPHTHALMIC SOLUTION 1 % | 4 | MO |
| <i>bacitracin ophthalmic ointment 500 unit/gm</i> | 2 | MO |
| <i>bacitracin-polymyxin b ophthalmic ointment 500-10000 unit/gm</i> | 2 | MO |
| <i>erythromycin ophthalmic ointment 5 mg/gm</i> | 1 | MO |
| <i>gatifloxacin ophthalmic solution 0.5 %</i> | 2 | MO |
| <i>gentamicin sulfate ophthalmic solution 0.3 %</i> | 1 | MO |
| <i>moxifloxacin hcl ophthalmic solution 0.5 %</i> | 2 | MO |
| NATACYN OPHTHALMIC SUSPENSION 5 % | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>neomycin-bacitracin zn-polymyx ophthalmic ointment 5-400-10000</i> | 2 | MO |
| <i>ofloxacin ophthalmic solution 0.3 %</i> | 2 | MO |
| <i>sulfacetamide sodium ophthalmic solution 10 %</i> | 2 | MO |
| <i>tobramycin ophthalmic solution 0.3 %</i> | 1 | MO |
| <i>Ophthalmic Anti-Inflammatories</i> | | |
| <i>bromfenac sodium (once-daily) ophthalmic solution 0.09 %</i> | 2 | MO |
| BROMSITE OPHTHALMIC SOLUTION 0.075 % | 4 | MO |
| <i>dexamethasone sodium phosphate ophthalmic solution 0.1 %</i> | 2 | MO |
| <i>diclofenac sodium ophthalmic solution 0.1 %</i> | 2 | MO |
| DUREZOL OPHTHALMIC EMULSION 0.05 % | 3 | MO |
| <i>fluorometholone ophthalmic suspension 0.1 %</i> | 2 | MO |
| <i>flurbiprofen sodium ophthalmic solution 0.03 %</i> | 1 | MO |
| ILEVRO OPHTHALMIC SUSPENSION 0.3 % | 3 | MO |
| <i>ketorolac tromethamine ophthalmic solution 0.4 %, 0.5 %</i> | 2 | MO |
| <i>loteprednol etabonate ophthalmic suspension 0.5 %</i> | 2 | MO |
| <i>prednisolone acetate ophthalmic suspension 1 %</i> | 2 | MO |
| <i>prednisolone sodium phosphate ophthalmic solution 1 %</i> | 2 | MO |
| <i>Ophthalmic Beta-Adrenergic Blocking Agents</i> | | |
| <i>betaxolol hcl ophthalmic solution 0.5 %</i> | 2 | MO |
| <i>carteolol hcl ophthalmic solution 1 %</i> | 1 | MO |
| <i>levobunolol hcl ophthalmic solution 0.5 %</i> | 1 | MO |
| <i>timolol maleate (once-daily) ophthalmic solution 0.5 %</i> | 2 | MO |
| <i>timolol maleate ophthalmic gel forming solution 0.25 %, 0.5 %</i> | 2 | MO |
| <i>timolol maleate ophthalmic solution 0.25 %, 0.5 %</i> | 1 | MO |
| <i>Ophthalmic Intraocular Pressure Lowering Agents, Other</i> | | |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>acetazolamide er oral capsule extended release 12 hour 500 mg</i> | 2 | MO |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | MO |
| ALPHAGAN P OPHTHALMIC SOLUTION 0.1 % | 3 | MO |
| <i>apraclonidine hcl ophthalmic solution 0.5 %</i> | 2 | MO |
| AZOPT OPHTHALMIC SUSPENSION 1 % | 3 | MO |
| <i>brimonidine tartrate ophthalmic solution 0.15 %, 0.2 %</i> | 2 | MO |
| <i>brimonidine tartrate-timolol ophthalmic solution 0.2-0.5 %</i> | 3 | MO |
| COMBIGAN OPHTHALMIC SOLUTION 0.2-0.5 % | 4 | MO |
| <i>dorzolamide hcl ophthalmic solution 2 %</i> | 1 | MO |
| <i>dorzolamide hcl-timolol mal ophthalmic solution 22.3-6.8 mg/ml</i> | 2 | MO |
| <i>dorzolamide hcl-timolol mal pf ophthalmic solution 2-0.5 %</i> | 2 | MO |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 4 | MO |
| <i>pilocarpine hcl ophthalmic solution 1 %, 2 %, 4 %</i> | 2 | MO |
| RHOPRESSA OPHTHALMIC SOLUTION 0.02 % | 4 | MO |
| ROCKLATAN OPHTHALMIC SOLUTION 0.02-0.005 % | 4 | MO |
| SIMBRINZA OPHTHALMIC SUSPENSION 1-0.2 % | 4 | MO |
| <i>Ophthalmic Prostaglandin And Prostanamide Analogs</i> | | |
| <i>latanoprost ophthalmic solution 0.005 %</i> | 2 | MO |
| LUMIGAN OPHTHALMIC SOLUTION 0.01 % | 3 | MO |
| <i>travoprost (bak free) ophthalmic solution 0.004 %</i> | 3 | MO |
| VYZULTA OPHTHALMIC SOLUTION 0.024 % | 4 | MO |
| OTIC AGENTS | | |
| <i>Otic Agents</i> | | |
| <i>acetic acid otic solution 2 %</i> | 1 | MO |
| <i>ciprofloxacin hcl otic solution 0.2 %</i> | 4 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ciprofloxacin-dexamethasone otic suspension 0.3-0.1 %</i> | 3 | MO |
| <i>ciprofloxacin-fluocinolone pf otic solution 0.3-0.025 %</i> | 4 | MO |
| <i>fluocinolone acetonide otic oil 0.01 %</i> | 2 | MO |
| <i>neomycin-polymyxin-hc otic solution 1 %</i> | 2 | MO |
| <i>neomycin-polymyxin-hc otic suspension 3.5-10000-1</i> | 2 | MO |
| <i>ofloxacin otic solution 0.3 %</i> | 4 | MO |
| RESPIRATORY TRACT/ PULMONARY AGENTS | | |
| Antihistamines | | |
| <i>azelastine hcl nasal solution 0.1 %</i> | 2 | MO; QL (30 ML per 25 days) |
| <i>cetirizine hcl oral solution 1 mg/ml</i> | 1 | MO |
| <i>cyproheptadine hcl oral syrup 2 mg/5ml</i> | 4 | MO |
| <i>cyproheptadine hcl oral tablet 4 mg</i> | 4 | MO |
| <i>levocetirizine dihydrochloride oral solution 2.5 mg/5ml</i> | 2 | MO |
| <i>levocetirizine dihydrochloride oral tablet 5 mg</i> | 1 | MO |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ARNUITY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | MO; QL (30 EA per 30 days) |
| ASMANEX (120 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/ACT | 3 | MO; QL (2 EA per 30 days) |
| ASMANEX (30 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 110 MCG/ACT, 220 MCG/ACT | 3 | MO; QL (2 EA per 30 days) |
| ASMANEX (60 METERED DOSES) INHALATION AEROSOL POWDER BREATH ACTIVATED 220 MCG/ACT | 3 | MO; QL (2 EA per 30 days) |
| ASMANEX HFA INHALATION AEROSOL 100 MCG/ACT, 200 MCG/ACT, 50 MCG/ACT | 3 | MO; QL (26 GM per 30 days) |
| <i>budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml</i> | 4 | BvD; MO |
| <i>flunisolide nasal solution 25 mcg/act (0.025%)</i> | 2 | MO; QL (50 ML per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>fluticasone propionate hfa inhalation aerosol 110 mcg/act, 220 mcg/act</i> | 3 | MO; QL (24 GM per 30 days) |
| <i>fluticasone propionate hfa inhalation aerosol 44 mcg/act</i> | 3 | MO; QL (10.6 GM per 30 days) |
| <i>fluticasone propionate nasal suspension 50 mcg/act</i> | 1 | MO; QL (16 GM per 30 days) |
| <i>mometasone furoate nasal suspension 50 mcg/act</i> | 2 | MO; QL (34 GM per 30 days) |
| Antileukotrienes | | |
| <i>montelukast sodium oral packet 4 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet 10 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>montelukast sodium oral tablet chewable 4 mg, 5 mg</i> | 1 | MO; QL (30 EA per 30 days) |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | 2 | MO; QL (60 EA per 30 days) |
| Bronchodilators, Anticholinergic | | |
| ATROVENT HFA INHALATION AEROSOL SOLUTION 17 MCG/ACT | 4 | MO; QL (26 GM per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | BvD; MO |
| <i>ipratropium bromide nasal solution 0.03 %</i> | 2 | MO; QL (60 ML per 30 days) |
| <i>ipratropium bromide nasal solution 0.06 %</i> | 2 | MO; QL (30 ML per 30 days) |
| SPIRIVA HANDIHALER INHALATION CAPSULE 18 MCG | 3 | MO; QL (30 EA per 30 days) |
| SPIRIVA RESPIMAT INHALATION AEROSOL SOLUTION 1.25 MCG/ACT, 2.5 MCG/ACT | 3 | MO; QL (4 GM per 30 days) |
| Bronchodilators, Sympathomimetic | | |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act</i> | 2 | MO; QL (17 GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020503)</i> | 2 | MO; QL (13.4 GM per 30 days) |
| <i>albuterol sulfate hfa inhalation aerosol solution 108 (90 base) mcg/act (nda020983)</i> | 2 | MO; QL (36 GM per 30 days) |
| <i>albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml</i> | 2 | BvD; MO |
| <i>albuterol sulfate oral syrup 2 mg/5ml</i> | 2 | MO |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | MO |
| <i>epinephrine injection solution 0.3 mg/0.3ml</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>epinephrine injection solution auto-injector 0.15 mg/0.15ml, 0.15 mg/0.3ml, 0.3 mg/0.3ml</i> | 2 | MO |
| SEREVENT DISKUS INHALATION AEROSOL POWDER BREATH ACTIVATED 50 MCG/ACT | 3 | MO; QL (60 EA per 30 days) |
| <i>terbutaline sulfate oral tablet 2.5 mg, 5 mg</i> | 4 | MO |
| VENTOLIN HFA INHALATION AEROSOL SOLUTION 108 (90 BASE) MCG/ACT | 3 | MO; QL (36 GM per 30 days) |
| <i>Cystic Fibrosis Agents</i> | | |
| BRONCHITOL INHALATION CAPSULE 40 MG | 5 | PA |
| CAYSTON INHALATION SOLUTION RECONSTITUTED 75 MG | 5 | PA |
| KALYDECO ORAL PACKET 13.4 MG, 25 MG, 50 MG, 75 MG | 5 | PA |
| KALYDECO ORAL TABLET 150 MG | 5 | PA |
| ORKAMBI ORAL PACKET 100-125 MG, 150-188 MG, 75-94 MG | 5 | PA |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA |
| PULMOZYME INHALATION SOLUTION 2.5 MG/2.5ML | 5 | BvD |
| SYMDEKO ORAL TABLET THERAPY PACK 100-150 & 150 MG, 50-75 & 75 MG | 5 | PA |
| TOBI PODHALER INHALATION CAPSULE 28 MG | 5 | PA |
| <i>tobramycin inhalation nebulization solution 300 mg/5ml</i> | 5 | BvD |
| TRIKAFTA ORAL TABLET THERAPY PACK 100-50-75 & 150 MG, 50-25-37.5 & 75 MG | 5 | PA |
| TRIKAFTA ORAL THERAPY PACK 100-50-75 & 75 MG, 80-40-60 & 59.5 MG | 5 | PA |
| <i>Phosphodiesterase Inhibitors, Airways Disease</i> | | |
| <i>roflumilast oral tablet 250 mcg, 500 mcg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>theophylline er oral tablet extended release 12 hour 300 mg, 450 mg</i> | 2 | MO |
| <i>theophylline er oral tablet extended release 24 hour 400 mg, 600 mg</i> | 2 | MO |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>Pulmonary Antihypertensives</i> | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; QL (90 EA per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | 5 | PA; QL (30 EA per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | 5 | PA; QL (60 EA per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; QL (90 EA per 30 days) |
| <i>sildenafil citrate oral tablet 20 mg</i> | 2 | PA; MO; QL (90 EA per 30 days) |
| <i>Pulmonary Fibrosis Agents</i> | | |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA |
| <i>pirfenidone oral capsule 267 mg</i> | 5 | PA |
| <i>pirfenidone oral tablet 267 mg, 534 mg, 801 mg</i> | 5 | PA |
| <i>Respiratory Tract Agents, Other</i> | | |
| <i>acetylcysteine inhalation solution 10 %, 20 %</i> | 2 | BvD; MO |
| ADVAIR HFA INHALATION AEROSOL 115-21 MCG/ACT, 230-21 MCG/ACT, 45-21 MCG/ACT | 3 | MO; QL (12 GM per 30 days) |
| ANORO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 62.5-25 MCG/ACT | 3 | MO; QL (60 EA per 30 days) |
| BREO ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-25 MCG/ACT, 200-25 MCG/ACT | 3 | MO; QL (60 EA per 30 days) |
| BREZTRI AEROSPHERE INHALATION AEROSOL 160-9-4.8 MCG/ACT | 3 | MO; QL (10.7 GM per 30 days) |
| <i>budesonide-formoterol fumarate inhalation aerosol 160-4.5 mcg/act, 80-4.5 mcg/act</i> | 3 | MO; QL (10.2 GM per 30 days) |
| COMBIVENT RESPIMAT INHALATION AEROSOL SOLUTION 20-100 MCG/ACT | 4 | MO; QL (4 GM per 20 days) |
| <i>cromolyn sodium inhalation nebulization solution 20 mg/2ml</i> | 2 | BvD; MO |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act</i> | 3 | MO; QL (60 EA per 30 days) |
| <i>fluticasone-salmeterol inhalation aerosol powder breath activated 113-14 mcg/act, 232-14 mcg/act, 55-14 mcg/act</i> | 3 | MO; QL (1 EA per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------|
| <i>ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml</i> | 2 | BvD; MO |
| NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 100 MG/ML | 5 | PA |
| NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML | 5 | PA |
| NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 100 MG | 5 | PA |
| TRELEGY ELLIPTA INHALATION AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT, 200-62.5-25 MCG/ACT | 3 | MO; QL (60 EA per 30 days) |

SKELLETAL MUSCLE RELAXANTS

Skeletal Muscle Relaxants

| | | |
|--|---|----|
| <i>chlorzoxazone oral tablet 250 mg, 375 mg, 500 mg, 750 mg</i> | 2 | MO |
| <i>cyclobenzaprine hcl oral tablet 10 mg, 5 mg</i> | 2 | MO |
| <i>cyclobenzaprine hcl oral tablet 7.5 mg</i> | 4 | MO |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | MO |
| <i>orphenadrine citrate er oral tablet extended release 12 hour 100 mg</i> | 2 | MO |

SLEEP DISORDER AGENTS

Sleep Promoting Agents

| | | |
|--|---|-----------------------------|
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 4 | MO; QL (30 EA per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> | 3 | MO; QL (30 EA per 30 days) |
| <i>temazepam oral capsule 22.5 mg</i> | 4 | MO; QL (30 EA per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> | 4 | MO; QL (120 EA per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 2 | MO; QL (30 EA per 30 days) |
| <i>zolpidem tartrate oral tablet 10 mg, 5 mg</i> | 2 | MO; QL (30 EA per 30 days) |

Wakefulness Promoting Agents

| | | |
|--|---|--------------------------------|
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | 3 | PA; MO; QL (30 EA per 30 days) |
| <i>modafinil oral tablet 100 mg, 200 mg</i> | 4 | PA; MO; QL (60 EA per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> | 5 | PA; QL (540 ML per 30 days) |

You can find information on the symbols and abbreviations on this table by going to page 3 of the introduction. 2024 Sonder Standard MAPD 5-Tier, Formulary ID 24457, Version 6, effective 01/01/2024. Last updated 08/25/2023.

Index of Drugs/Alphabetical Listing

| | | |
|---|--------|---|
| A | | |
| <i>abacavir sulfate</i> | 39 | |
| <i>abacavir sulfate-lamivudine</i> | 39 | |
| ABELCET | 21 | |
| ABILIFY ASIMTUFII | 34 | |
| ABILIFY MAINTENA | 34 | |
| <i>abiraterone acetate</i> | 24 | |
| <i>acamprosate calcium</i> | 6 | |
| <i>acarbose</i> | 42 | |
| ACCUTANE | 58 | |
| <i>acebutolol hcl</i> | 49 | |
| <i>acetaminophen-codeine</i> | 5 | |
| <i>acetazolamide</i> | 86 | |
| <i>acetazolamide er</i> | 86 | |
| <i>acetic acid</i> | 87 | |
| <i>acetylcysteine</i> | 90 | |
| <i>acitretin</i> | 58 | |
| ACTHIB | 80 | |
| ACTIMMUNE | 78 | |
| <i>acyclovir</i> | 38 | |
| <i>acyclovir sodium</i> | 38 | |
| ADACEL | 80 | |
| <i>adefovir dipivoxil</i> | 37 | |
| ADEMPAS | 90 | |
| ADVAIR HFA | 90 | |
| <i>albendazole</i> | 32 | |
| <i>albuterol sulfate</i> | 89 | |
| <i>albuterol sulfate hfa</i> | 89 | |
| <i>alclometasone dipropionate</i> | 58 | |
| ALECENSA | 27 | |
| <i>alendronate sodium</i> | 83 | |
| <i>alfuzosin hcl er</i> | 68 | |
| <i>aliskiren fumarate</i> | 51 | |
| <i>allopurinol</i> | 22 | |
| <i>alosepron hcl</i> | 65 | |
| ALPHAGAN P | 86 | |
| <i>alprazolam</i> | 41 | |
| ALPRAZOLAM INTENSOL | 41 | |
| ALTAVERA | 71 | |
| ALUNBRIG | 27 | |
| <i>alyacen 1/35</i> | 71 | |
| <i>amantadine hcl</i> | 32 | |
| AMBISOME | 21 | |
| <i>ambrisentan</i> | 90 | |
| <i>amcinonide</i> | 58 | |
| <i>amikacin sulfate</i> | 7 | |
| <i>amiloride hcl</i> | 53 | |
| <i>amiloride-hydrochlorothiazide</i> | 51 | |
| <i>amiodarone hcl</i> | 49 | |
| <i>amitriptyline hcl</i> | 19 | |
| <i>amlodipine besy-benazepril hcl</i> | 51 | |
| <i>amlodipine besylate</i> | 50 | |
| <i>amlodipine besylate-valsartan</i> | 51 | |
| <i>amlodipine-atorvastatin</i> | 52 | |
| <i>amlodipine-olmesartan</i> | 52 | |
| <i>ammonium lactate</i> | 58, 59 | |
| AMNESTEEM | 58 | |
| <i>amoxapine</i> | 19 | |
| <i>amoxicillin</i> | 10 | |
| <i>amoxicillin-pot clavulanate</i> .. | 10 | |
| <i>amoxicillin-pot clavulanate er</i> | 10 | |
| <i>amphetamine-</i> | | |
| <i>dextroamphetamine</i> | 56 | |
| <i>amphotericin b</i> | 21 | |
| <i>ampicillin</i> | 10 | |
| <i>ampicillin sodium</i> | 10 | |
| <i>ampicillin-sulbactam sodium</i> .. | 11 | |
| <i>anagrelide hcl</i> | 47 | |
| <i>anastrozole</i> | 27 | |
| ANORO ELLIPTA | 91 | |
| <i>apraclonidine hcl</i> | 86 | |
| <i>aprepitant</i> | 20 | |
| APRI | 71 | |
| APTIOM | 16 | |
| APTIVUS | 40 | |
| ARANELLE | 71 | |
| ARCALYST | 77 | |
| ARIKAYCE | 7 | |
| <i>aripiprazole</i> | 34, 35 | |
| <i>armodafinil</i> | 92 | |
| ARNUITY ELLIPTA | 88 | |
| <i>asenapine maleate</i> | 35 | |
| ASMANEX (120 METERED DOSES) | 88 | |
| ASMANEX (30 METERED DOSES) | 88 | |
| ASMANEX (60 METERED DOSES) | 88 | |
| ASMANEX HFA | 88 | |
| <i>aspirin-dipyridamole er</i> | 47 | |
| | | |
| | | ASSURE ID INSULIN |
| | | SAFETY SYR |
| | | 44 |
| | | <i>atazanavir sulfate</i> |
| | | 40 |
| | | <i>atenolol</i> |
| | | 49 |
| | | <i>atenolol-chlorthalidone</i> |
| | | 52 |
| | | <i>atomoxetine hcl</i> |
| | | 56 |
| | | <i>atorvastatin calcium</i> |
| | | 54 |
| | | <i>atovaquone</i> |
| | | 32 |
| | | <i>atovaquone-proguanil hcl</i> |
| | | 32 |
| | | <i>atropine sulfate</i> |
| | | 84 |
| | | ATROVENT HFA |
| | | 88 |
| | | AUBRA EQ |
| | | 71 |
| | | AURYXIA |
| | | 64 |
| | | AUSTEDO |
| | | 56 |
| | | AUSTEDO XR |
| | | 56 |
| | | AUVELITY |
| | | 17 |
| | | AVIANE |
| | | 71 |
| | | AVONEX PEN |
| | | 57 |
| | | AVONEX PREFILLED |
| | | 57 |
| | | AYVAKIT |
| | | 27 |
| | | AZASITE |
| | | 85 |
| | | <i>azathioprine</i> |
| | | 78 |
| | | <i>azelastine hcl</i> |
| | | 85, 87 |
| | | <i>azithromycin</i> |
| | | 12 |
| | | AZOPT |
| | | 86 |
| | | <i>aztreonam</i> |
| | | 7 |
| | | B |
| | | <i>bacitracin</i> |
| | | 85 |
| | | <i>bacitracin-polymyxin b</i> |
| | | 85 |
| | | <i>bacitra-neomycin-polymyxin-</i> |
| | | <i>hc</i> |
| | | 84 |
| | | <i>baclofen</i> |
| | | 37 |
| | | <i>balsalazide disodium</i> |
| | | 83 |
| | | BALVERSA |
| | | 27 |
| | | BALZIVA |
| | | 71 |
| | | BAQSIMI ONE PACK |
| | | 44 |
| | | BARACLUDGE |
| | | 37 |
| | | <i>bcg vaccine</i> |
| | | 80 |
| | | BELSOMRA |
| | | 92 |
| | | <i>benazepril hcl</i> |
| | | 48 |
| | | <i>benazepril-hydrochlorothiazide</i> |
| | | 52 |
| | | BENLYSTA |
| | | 78, 79 |
| | | <i>benznidazole</i> |
| | | 32 |
| | | <i>benzoyl peroxide-erythromycin</i> |
| | | 58 |
| | | <i>benztropine mesylate</i> |
| | | 32 |
| | | BESREMI |
| | | 78 |

| | | | | | |
|--|--------|---|-------|--|--------|
| <i>betaine</i> | 67 | BYLVAY | 65 | <i>cephalexin</i> | 10 |
| <i>betamethasone dipropionate</i> | 59 | BYLVAY (PELLETS) | 65 | <i>cetirizine hcl</i> | 87 |
| <i>betamethasone dipropionate</i> | | C | | <i>chlordiazepoxide hcl</i> | 42 |
| <i>aug</i> | 59 | <i>cabergoline</i> | 76 | <i>chlorhexidine gluconate</i> | 58 |
| <i>betamethasone valerate</i> | 59 | CABLIVI | 47 | <i>chloroquine phosphate</i> | 32 |
| BETASERON | 57 | CABOMETYX | 27 | <i>chlorpromazine hcl</i> | 33 |
| <i>betaxolol hcl</i> | 49, 86 | <i>calcipotriene</i> | 60 | <i>chlorthalidone</i> | 54 |
| <i>bethanechol chloride</i> | 68 | <i>calcitonin (salmon)</i> | 83 | <i>chlorzoxazone</i> | 91 |
| <i>bexarotene</i> | 31 | <i>calcitriol</i> | 83 | <i>cholestyramine</i> | 55 |
| BEXSERO | 80 | <i>calcium acetate</i> | 64 | <i>cholestyramine light</i> | 55 |
| <i>bicalutamide</i> | 24 | <i>calcium acetate (phos binder)</i> | | <i>ciclopirox</i> | 61 |
| BICILLIN L-A | 11 | | 64 | <i>ciclopirox olamine</i> | 21 |
| BIKTARVY | 38 | CALQUENCE | 27 | <i>cilostazol</i> | 48 |
| <i>bisoprolol fumarate</i> | 49 | CAMILA | 74 | CIMDUO | 39 |
| <i>bisoprolol-hydrochlorothiazide</i> | | CAMZYOS | 52 | <i>cinacalcet hcl</i> | 84 |
| | 52 | <i>candesartan cilexetil</i> | 48 | <i>ciprofloxacin hcl</i> | 12, 87 |
| BLISOVI FE 1.5/30 | 71 | <i>candesartan cilexetil-hctz</i> | 52 | <i>ciprofloxacin in d5w</i> | 12 |
| BOOSTRIX | 81 | CAPLYTA | 35 | <i>ciprofloxacin-dexamethasone</i> | |
| <i>bosentan</i> | 90 | CAPRELSA | 27 | | 87 |
| BOSULIF | 27 | <i>captopril</i> | 48 | <i>ciprofloxacin-fluocinolone pf87</i> | |
| BRAFTOVI | 27 | <i>carbamazepine</i> | 16 | <i>citalopram hydrobromide</i> | 18 |
| BREO ELLIPTA | 91 | <i>carbamazepine er</i> | 16 | CLARAVIS | 58 |
| BREZTRI AEROSPHERE .. | 91 | <i>carbidopa</i> | 33 | <i>clarithromycin</i> | 12 |
| <i>brillyn</i> | 71 | <i>carbidopa-levodopa</i> | 33 | <i>clarithromycin er</i> | 12 |
| BRILINTA | 47 | <i>carbidopa-levodopa er</i> | 33 | CLENPIQ | 66 |
| <i>brimonidine tartrate</i> | 86 | <i>carbidopa-levodopa-</i> | | <i>clindamycin hcl</i> | 7, 8 |
| <i>brimonidine tartrate-timolol</i> .. | 86 | <i>entacapone</i> | 33 | <i>clindamycin palmitate hcl</i> | 8 |
| BRIVIACT | 13 | CARDURA XL | 68 | <i>clindamycin phos-benzoyl</i> | |
| <i>bromfenac sodium (once-daily)</i> | | <i>carglumic acid</i> | 62 | <i>perox</i> | 58 |
| | 85 | <i>carteolol hcl</i> | 86 | <i>clindamycin phosphate</i> | 8, 61 |
| <i>bromocriptine mesylate</i> | 33 | CARTIA XT | 50 | <i>clindamycin phosphate in d5w8</i> | |
| BROMSITE | 85 | <i>carvedilol</i> | 49 | CLINIMIX E/DEXTROSE | |
| BRONCHITOL | 89 | <i>carvedilol phosphate er</i> | 49 | (2.75/5) | 63 |
| BRUKINSA | 27 | <i>caspofungin acetate</i> | 21 | CLINIMIX E/DEXTROSE | |
| <i>budesonide</i> | 83, 88 | CAYSTON | 89 | (4.25/10) | 63 |
| <i>budesonide er</i> | 83 | <i>cefaclor</i> | 9 | CLINIMIX E/DEXTROSE | |
| <i>budesonide-formoterol</i> | | <i>cefaclor er</i> | 9 | (4.25/5) | 63 |
| <i>fumarate</i> | 91 | <i>cefadroxil</i> | 9 | CLINIMIX E/DEXTROSE | |
| <i>bumetanide</i> | 53 | <i>cefazolin sodium</i> | 9 | (5/15) | 64 |
| <i>buprenorphine hcl</i> | 6 | <i>cefdinir</i> | 9 | CLINIMIX E/DEXTROSE | |
| <i>buprenorphine hcl-naloxone</i> | | <i>cefepime hcl</i> | 9 | (5/20) | 64 |
| <i>hcl</i> | 6 | <i>cefixime</i> | 9 | CLINIMIX/DEXTROSE | |
| <i>bupropion hcl</i> | 17, 18 | <i>cefotetan disodium</i> | 9 | (4.25/10) | 64 |
| <i>bupropion hcl er (smoking det)</i> | | <i>cefoxitin sodium</i> | 9 | CLINIMIX/DEXTROSE | |
| | 7 | <i>cefpodoxime proxetil</i> | 9 | (4.25/5) | 64 |
| <i>bupropion hcl er (sr)</i> | 17 | <i>cefprozil</i> | 9 | CLINIMIX/DEXTROSE | |
| <i>bupropion hcl er (xl)</i> | 17 | <i>ceftazidime</i> | 9, 10 | (5/15) | 64 |
| <i>buspirone hcl</i> | 41 | <i>ceftriaxone sodium</i> | 10 | CLINIMIX/DEXTROSE | |
| <i>butalbital-apap-caffeine</i> | 4 | <i>cefuroxime axetil</i> | 10 | (5/20) | 64 |
| <i>butalbital-asa-caff-codeine</i> | 4 | <i>cefuroxime sodium</i> | 10 | <i>clobazam</i> | 15 |
| <i>butalbital-aspirin-caffeine</i> | 4 | <i>celecoxib</i> | 4 | <i>clobetasol propionate</i> | 59 |

| | |
|---|------------|
| <i>clobetasol propionate e</i> | 59 |
| <i>clomipramine hcl</i> | 20 |
| <i>clonazepam</i> | 42 |
| <i>clonidine</i> | 48 |
| <i>clonidine hcl</i> | 48 |
| <i>clopidogrel bisulfate</i> | 48 |
| <i>clorazepate dipotassium</i> | 42 |
| <i>clotrimazole</i> | 21 |
| <i>clotrimazole-betamethasone</i> | 60 |
| <i>clozapine</i> | 37 |
| COARTEM | 32 |
| <i>codeine sulfate</i> | 5 |
| <i>colchicine</i> | 22 |
| <i>colchicine-probenecid</i> | 22 |
| <i>colestipol hcl</i> | 55 |
| <i>colistimethate sodium (cba)</i> ... | 8 |
| COMBIGAN | 86 |
| COMBIVENT RESPIMAT | 91 |
| COMETRIQ (100 MG DAILY DOSE) | 27 |
| COMETRIQ (140 MG DAILY DOSE) | 27 |
| COMETRIQ (60 MG DAILY DOSE) | 27 |
| COMFORT ASSIST INSULIN SYRINGE | 44 |
| COMPLERA | 38 |
| <i>constulose</i> | 65 |
| COPAXONE | 57 |
| COPIKTRA | 27 |
| CORLANOR | 52 |
| COSENTYX | 77 |
| COSENTYX (300 MG DOSE) | 77 |
| COSENTYX SENSOREADY (300 MG) | 77 |
| COTELLIC | 27 |
| CREON | 67 |
| <i>cromolyn sodium</i> | 67, 85, 91 |
| CRYSELLE-28 | 71 |
| <i>cvs gauze sterile</i> | 44 |
| <i>cyclobenzaprine hcl</i> | 91 |
| <i>cyclophosphamide</i> | 24 |
| <i>cyclosporine</i> | 79, 84 |
| <i>cyclosporine modified</i> | 79 |
| <i>cyproheptadine hcl</i> | 87 |
| CYRED EQ | 71 |
| CYSTADROPS | 84 |
| CYSTAGON | 67 |
| CYSTARAN | 84 |
| D | |
| <i>dalfampridine er</i> | 57 |
| <i>danazol</i> | 70 |
| <i>dapsone</i> | 24 |
| DAPTACEL | 81 |
| <i>daptomycin</i> | 8 |
| <i>darifenacin hydrobromide er</i> | 68 |
| <i>darunavir</i> | 40 |
| DAURISMO | 28 |
| DEBLITANE | 74 |
| <i>deferasirox</i> | 63 |
| <i>deferasirox granules</i> | 63 |
| <i>deferiprone</i> | 63 |
| DELSTRIGO | 39 |
| DEPO-SUBQ PROVERA | 104 |
| DESCOVY | 39 |
| <i>desipramine hcl</i> | 20 |
| <i>desmopressin acetate</i> | 69 |
| <i>desmopressin acetate spray</i> | 69 |
| <i>desogestrel-ethinyl estradiol</i> | 71 |
| <i>desonide</i> | 59 |
| <i>desoximetasone</i> | 59 |
| <i>desvenlafaxine er</i> | 18 |
| <i>desvenlafaxine succinate er</i> | 18 |
| <i>dexamethasone</i> | 69 |
| <i>dexamethasone sodium phosphate</i> | 85 |
| <i>dexlansoprazole</i> | 66 |
| <i>dexmethylphenidate hcl</i> | 56 |
| <i>dextroamphetamine sulfate</i> | 56 |
| <i>dextroamphetamine sulfate er</i> | 56 |
| <i>dextrose</i> | 64 |
| <i>dextrose-nacl</i> | 64 |
| DIACOMIT | 13 |
| <i>diazepam</i> | 15, 42 |
| DIAZEPAM INTENSOL | 42 |
| <i>diazoxide</i> | 44 |
| <i>diclofenac potassium</i> | 4 |
| <i>diclofenac sodium</i> | 4, 60, 85 |
| <i>diclofenac sodium er</i> | 4 |
| <i>dicloxacillin sodium</i> | 11 |
| <i>dicyclomine hcl</i> | 65 |
| DIFICID | 12 |
| <i>diflunisal</i> | 4 |
| <i>digoxin</i> | 52 |
| <i>dihydroergotamine mesylate</i> | 23 |
| DILANTIN | 16 |
| <i>diltiazem hcl</i> | 51 |
| <i>diltiazem hcl er</i> | 51 |
| <i>diltiazem hcl er beads</i> | 51 |
| <i>diltiazem hcl er coated beads</i> | 51 |
| <i>dilt-xr</i> | 51 |
| <i>dimethyl fumarate</i> | 57 |
| <i>dimethyl fumarate starter pack</i> | 57 |
| <i>diphenoxylate-atropine</i> | 65 |
| <i>diphtheria-tetanus toxoids dt</i> | 81 |
| <i>disopyramide phosphate</i> | 49 |
| <i>disulfiram</i> | 6 |
| <i>divalproex sodium</i> | 42 |
| <i>divalproex sodium er</i> | 42 |
| <i>dofetilide</i> | 49 |
| DOJOLVI | 64 |
| <i>donepezil hcl</i> | 17 |
| <i>dorzolamide hcl</i> | 86 |
| <i>dorzolamide hcl-timolol mal</i> | 86 |
| <i>dorzolamide hcl-timolol mal pf</i> | 87 |
| DOVATO | 38 |
| <i>doxazosin mesylate</i> | 48 |
| <i>doxepin hcl</i> | 20 |
| DOXY 100 | 13 |
| <i>doxycycline hyclate</i> | 13 |
| <i>doxycycline monohydrate</i> | 13 |
| <i>dronabinol</i> | 20 |
| <i>drospirenone-ethinyl estradiol</i> | 71 |
| DROXIA | 25 |
| <i>droxidopa</i> | 48 |
| DUAVEE | 70 |
| <i>duloxetine hcl</i> | 18 |
| DUPIXENT | 77 |
| DUREZOL | 85 |
| <i>dutasteride</i> | 68 |
| <i>dutasteride-tamsulosin hcl</i> | 68 |
| E | |
| <i>econazole nitrate</i> | 21 |
| EDURANT | 38 |
| <i>efavirenz</i> | 38 |
| <i>efavirenz-emtricitab-tenofo df</i> | 39 |
| <i>efavirenz-lamivudine-tenofovir</i> | 39 |
| ELIGARD | 76 |
| ELIQUIS | 46 |
| ELIQUIS DVT/PE STARTER PACK | 46 |
| ELMIRON | 68 |
| ELURYNG | 71 |

| | | | | |
|--|------------|---------------------------------------|--|--------|
| EMCYT..... | 25 | <i>etonogestrel-ethinyl estradiol</i> | <i>fludrocortisone acetate</i> | 69 |
| EMGALITY..... | 23 | | <i>flunisolide</i> | 88 |
| EMSAM..... | 18 | <i>etravirine</i> | <i>fluocinolone acetonide</i> | 59, 87 |
| <i>emtricitabine</i> | 39 | EUCRISA..... | <i>fluocinonide</i> | 59, 60 |
| <i>emtricitabine-tenofovir df</i> | 39 | EUTHYROX..... | <i>fluocinonide emulsified base</i> | 59 |
| EMTRIVA..... | 39 | <i>everolimus</i> | <i>fluorometholone</i> | 86 |
| EMVERM..... | 32 | EVOTAZ..... | <i>fluorouracil</i> | 61 |
| <i>enalapril maleate</i> | 48 | EVRYSDI..... | <i>fluoxetine hcl</i> | 19 |
| <i>enalapril-hydrochlorothiazide</i> | 52 | EXEL COMFORT POINT | <i>fluphenazine decanoate</i> | 34 |
| | 52 | PEN NEEDLE..... | <i>fluphenazine hcl</i> | 34 |
| ENBREL..... | 79 | <i>exemestane</i> | <i>flurbiprofen</i> | 4 |
| ENBREL MINI..... | 79 | EXKIVITY..... | <i>flurbiprofen sodium</i> | 86 |
| ENBREL SURECLICK..... | 79 | <i>ezetimibe</i> | <i>fluticasone propionate</i> | 60, 88 |
| ENDARI..... | 67 | <i>ezetimibe-simvastatin</i> | <i>fluticasone propionate hfa</i> | 88 |
| ENGERIX-B..... | 81 | F | <i>fluticasone-salmeterol</i> | 91 |
| <i>enoxaparin sodium</i> | 46 | FALMINA..... | <i>fluvastatin sodium</i> | 54 |
| ENPRESSE-28..... | 71 | <i>famciclovir</i> | <i>fluvastatin sodium er</i> | 54 |
| ENSKYCE..... | 71 | <i>famotidine</i> | <i>flvoxamine maleate</i> | 19 |
| ENSPRYNG..... | 79 | FANAPT..... | <i>fondaparinux sodium</i> | 46 |
| <i>entacapone</i> | 33 | FANAPT TITRATION PACK | <i>fosamprenavir calcium</i> | 40 |
| <i>entecavir</i> | 37 | | <i>fosinopril sodium</i> | 48 |
| ENTRESTO..... | 52 | <i>febuxostat</i> | <i>fosinopril sodium-hctz</i> | 52 |
| <i>enulose</i> | 65 | <i>felbamate</i> | FOTIVDA..... | 28 |
| ENVARUSUS XR..... | 79 | <i>felodipine er</i> | <i>furosemide</i> | 53 |
| EPIDIOLEX..... | 14 | <i>fenofibrate</i> | FUZEON..... | 40 |
| <i>epinephrine</i> | 89 | <i>fenofibrate micronized</i> | FYCOMPA..... | 14 |
| EPITOL..... | 16 | <i>fenofibric acid</i> | G | |
| <i>eplerenone</i> | 53 | <i>fentanyl</i> | <i>gabapentin</i> | 15 |
| EPRONTIA..... | 23 | <i>fentanyl citrate</i> | GALAFOLD..... | 67 |
| ERAXIS..... | 21 | FERRIPROX..... | <i>galantamine hydrobromide</i> .. | 17 |
| <i>ergotamine-caffeine</i> | 23 | FERRIPROX TWICE-A-DAY | <i>galantamine hydrobromide er</i> | 17 |
| ERIVEDGE..... | 28 | | | 17 |
| ERLEADA..... | 24 | <i>fesoterodine fumarate er</i> | GARDASIL 9..... | 81 |
| <i>erlotinib hcl</i> | 28 | FETZIMA..... | <i>gatifloxacin</i> | 85 |
| ERRIN..... | 74 | FETZIMA TITRATION..... | GATTEX..... | 66 |
| <i>ertapenem sodium</i> | 11 | FIASP..... | GAVILYTE-C..... | 66 |
| <i>ery</i> | 61 | FIASP FLEXTOUCH..... | GAVILYTE-G..... | 66 |
| ERYTHROCIN | | FIASP PENFILL..... | GAVRETO..... | 28 |
| LACTOBIONATE..... | 12 | FILSPARI..... | <i>gefitinib</i> | 28 |
| <i>erythromycin</i> | 12, 61, 85 | <i>finasteride</i> | <i>gemfibrozil</i> | 54 |
| <i>erythromycin base</i> | 12 | <i>fingolimod hcl</i> | <i>generlac</i> | 65 |
| <i>erythromycin ethylsuccinate</i> .. | 12 | FINTEPLA..... | GENGRAF..... | 79 |
| <i>escitalopram oxalate</i> | 18 | FIRMAGON..... | <i>gentamicin in saline</i> | 7 |
| <i>esomeprazole magnesium</i> | 66 | FIRMAGON (240 MG DOSE) | <i>gentamicin sulfate</i> | 7, 85 |
| ESTARYLLA..... | 71 | | GENVOYA..... | 38 |
| <i>estradiol</i> | 70 | FIRVANQ..... | GILOTRIF..... | 28 |
| <i>ethambutol hcl</i> | 24 | <i>flecainide acetate</i> | GLEOSTINE..... | 24 |
| <i>ethosuximide</i> | 15 | <i>fluconazole</i> | <i>glimepiride</i> | 42 |
| <i>ethynodiol diac-eth estradiol</i> | 71 | <i>fluconazole in sodium chloride</i> | <i>glipizide</i> | 43 |
| <i>etodolac</i> | 4 | | <i>glipizide er</i> | 42 |
| | | <i>flucytosine</i> | <i>glipizide-metformin hcl</i> | 43 |

| | | | | | |
|--|------------|--|--------|--|-------|
| <i>global alcohol prep ease</i> | 61 | <i>ibuprofen</i> | 4 | <i>isosorb dinitrate-hydralazine</i> | 52 |
| GLUCAGEN HYPOKIT | 44 | <i>icatibant acetate</i> | 77 | <i>isosorbide dinitrate</i> | 55 |
| <i>glyburide</i> | 43 | ICLEVIA | 71 | <i>isosorbide mononitrate</i> | 55 |
| <i>glyburide micronized</i> | 43 | ICLUSIG | 28 | <i>isosorbide mononitrate er</i> | 55 |
| <i>glyburide-metformin</i> | 43 | <i>icosapent ethyl</i> | 55 | <i>isotretinoin</i> | 58 |
| <i>glycopyrrolate</i> | 65 | IDHIFA | 25 | <i>isradipine</i> | 50 |
| <i>granisetron hcl</i> | 20 | ILEVRO | 86 | ISTURISA | 69 |
| <i>griseofulvin microsize</i> | 21 | <i>imatinib mesylate</i> | 28 | <i>itraconazole</i> | 21 |
| <i>griseofulvin ultramicrosize</i> ... | 21 | IMBRUVICA | 28 | <i>ivermectin</i> | 32 |
| <i>guanfacine hcl</i> | 48 | <i>imipenem-cilastatin</i> | 11 | IXIARO | 81 |
| <i>guanfacine hcl er</i> | 56 | <i>imipramine hcl</i> | 20 | J | |
| H | | <i>imiquimod</i> | 61 | JAKAFI | 28 |
| <i>halobetasol propionate</i> | 60 | IMOVAX RABIES | 81 | JANTOVEN | 47 |
| <i>haloperidol</i> | 34 | IMVEXXY MAINTENANCE | | JANUMET | 43 |
| <i>haloperidol decanoate</i> | 34 | PACK | 70 | JANUMET XR..... | 43 |
| <i>haloperidol lactate</i> | 34 | IMVEXXY STARTER PACK | | JANUVIA..... | 43 |
| HAVRIX | 81 | | 70 | JARDIANCE..... | 43 |
| <i>heparin sodium (porcine)</i> | 47 | INBRIJA..... | 33 | JASMIEL..... | 71 |
| HEPLISAV-B..... | 81 | INCASSIA..... | 74 | JAYPIRCA | 28 |
| HIBERIX..... | 81 | INCRELEX | 69 | JUBLIA | 21 |
| HUMIRA..... | 80 | <i>indapamide</i> | 54 | JULEBER | 72 |
| HUMIRA PEDIATRIC | | <i>indomethacin</i> | 4 | JULUCA..... | 39 |
| CROHNS START | 79 | <i>indomethacin er</i> | 4 | JUNEL 1.5/30..... | 72 |
| HUMIRA PEN | 79 | INFANRIX..... | 81 | JUNEL 1/20..... | 72 |
| HUMIRA PEN-CD/UC/HS | | INLYTA | 28 | JUNEL FE 1.5/30 | 72 |
| STARTER..... | 79 | INQOVI..... | 25 | JUNEL FE 1/20 | 72 |
| HUMIRA PEN-PEDIATRIC | | INREBIC | 28 | JUXTAPID | 55 |
| UC START..... | 79 | <i>insulin glargine</i> | 45 | JYNNEOS | 81 |
| HUMIRA PEN-PS/UV/ADOL | | <i>insulin glargine solostar</i> | 45 | K | |
| HS START | 79 | INTELENCE | 38 | KALYDECO | 89 |
| HUMIRA PEN-PSOR/UVEIT | | INTRALIPID..... | 64 | KARIVA..... | 72 |
| STARTER..... | 80 | INTRAROSA | 71 | KATERZIA | 50 |
| <i>hydralazine hcl</i> | 55 | INTROVALE | 71 | <i>kcl in dextrose-nacl</i> | 62 |
| <i>hydrochlorothiazide</i> | 54 | INVEGA HAFYERA..... | 35 | <i>kcl-lactated ringers-d5w</i> | 62 |
| <i>hydrocodone-acetaminophen</i> .5 | | INVEGA SUSTENNA..... | 35 | KELNOR 1/35..... | 72 |
| <i>hydrocodone-ibuprofen</i> | 5 | INVEGA TRINZA..... | 35 | KELNOR 1/50..... | 72 |
| <i>hydrocortisone</i> | 60, 69, 83 | INVOKAMET..... | 43 | KERENDIA..... | 53 |
| <i>hydrocortisone (perianal)</i> | 60 | INVOKAMET XR | 43 | KESIMPTA | 57 |
| <i>hydrocortisone ace-pramoxine</i> | | INVOKANA | 43 | <i>ketoconazole</i> | 22 |
| | 61 | IPOL | 81 | <i>ketorolac tromethamine</i> | 4, 86 |
| <i>hydrocortisone valerate</i> | 60 | <i>ipratropium bromide</i> | 88, 89 | KINERET | 80 |
| <i>hydromorphone hcl</i> | 5 | <i>ipratropium-albuterol</i> | 91 | KINRIX | 81 |
| <i>hydroxychloroquine sulfate</i> .. | 32 | <i>irbesartan</i> | 48 | KISQALI (200 MG DOSE).. | 29 |
| <i>hydroxyurea</i> | 25 | <i>irbesartan-hydrochlorothiazide</i> | | KISQALI (400 MG DOSE).. | 29 |
| <i>hydroxyzine hcl</i> | 41 | | 52 | KISQALI (600 MG DOSE).. | 29 |
| <i>hydroxyzine pamoate</i> | 41 | ISENTRESS | 38 | KISQALI FEMARA (200 MG | |
| HYFTOR..... | 60 | ISENTRESS HD | 38 | DOSE) | 26 |
| I | | ISIBLOOM..... | 71 | KISQALI FEMARA (400 MG | |
| <i>ibandronate sodium</i> | 84 | ISOLYTE-P IN D5W | 64 | DOSE) | 26 |
| IBRANCE | 28 | ISOLYTE-S PH 7.4..... | 62 | KISQALI FEMARA (600 MG | |
| IBU | 4 | <i>isoniazid</i> | 24 | DOSE) | 26 |

| | | | | | |
|---|--------|---|----|--------------------------------------|--------|
| KLOR-CON | 62 | LENVIMA (8 MG DAILY DOSE) | 29 | LORYNA | 72 |
| KLOR-CON 10 | 62 | LESSINA..... | 72 | <i>losartan potassium</i> | 48 |
| KLOR-CON M10..... | 62 | <i>letrozole</i> | 27 | <i>losartan potassium-hctz</i> | 52 |
| KLOR-CON M15..... | 62 | <i>leucovorin calcium</i> | 26 | <i>loteprednol etabonate</i> | 86 |
| KLOR-CON M20..... | 62 | LEUKERAN | 24 | <i>lovastatin</i> | 54 |
| KLOXXADO | 6 | LEUKINE..... | 47 | LOW-OGESTREL | 72 |
| KORLYM..... | 44 | <i>leuprolide acetate</i> | 76 | <i>loxapine succinate</i> | 34 |
| KOSELUGO | 29 | <i>leuprolide acetate (3 month)</i> 76 | | <i>lubiprostone</i> | 65 |
| KRAZATI | 26 | LEVEMIR | 45 | LUMAKRAS..... | 26 |
| KURVELO..... | 72 | LEVEMIR FLEXPEN..... | 45 | LUMIGAN | 87 |
| L | | <i>levetiracetam</i> | 14 | LUPKYNIS | 80 |
| <i>labetalol hcl</i> | 49 | <i>levetiracetam er</i> | 14 | LUPRON DEPOT (1-MONTH) | 76 |
| <i>lacosamide</i> | 16 | <i>levobunolol hcl</i> | 86 | LUPRON DEPOT (3-MONTH) | 76 |
| <i>lactulose</i> | 65 | <i>levocarnitine</i> | 64 | LUPRON DEPOT (4-MONTH) | 76 |
| <i>lamivudine</i> | 37, 39 | <i>levocetirizine dihydrochloride</i> | 88 | LUPRON DEPOT (6-MONTH) | 76 |
| <i>lamivudine-zidovudine</i> | 39 | <i>levofloxacin</i> | 13 | LUPRON DEPOT (6-MONTH) | 76 |
| <i>lamotrigine</i> | 14 | <i>levofloxacin in d5w</i> | 13 | LUPRON DEPOT-PED (1-MONTH) | 76 |
| <i>lamotrigine er</i> | 14 | LEVONEST | 72 | LUPRON DEPOT-PED (3-MONTH) | 76 |
| <i>lamotrigine starter kit-blue</i> .. | 14 | <i>levonorgest-eth estrad 91-day</i> | 72 | LUPRON DEPOT-PED (6-MONTH) | 76 |
| <i>lamotrigine starter kit-green</i> 14 | | <i>levonorgestrel-ethinyl estrad</i> 72 | | <i>lurasidone hcl</i> | 35 |
| <i>lamotrigine starter kit-orange</i> | 14 | <i>levonorg-eth estrad triphasic</i> 72 | | LUTERA | 72 |
| LAMPIT | 32 | LEVORA 0.15/30 (28)..... | 72 | LYBALVI..... | 35 |
| LANOXIN..... | 52 | <i>levothyroxine sodium</i> | 75 | LYLEQ | 74 |
| <i>lansoprazole</i> | 66 | LEVOXYL | 75 | LYNPARZA..... | 26 |
| LANTUS | 45 | LEXIVA | 40 | LYSODREN..... | 24 |
| LANTUS SOLOSTAR | 45 | LIALDA | 83 | LYTGOBI (12 MG DAILY DOSE) | 29 |
| <i>lapatinib ditosylate</i> | 29 | <i>lidocaine</i> | 6 | LYTGOBI (16 MG DAILY DOSE) | 29 |
| LARIN 1.5/30..... | 72 | <i>lidocaine hcl</i> | 6 | LYTGOBI (20 MG DAILY DOSE) | 29 |
| LARIN 1/20..... | 72 | <i>lidocaine viscous hcl</i> | 6 | LYZA | 75 |
| LARIN FE 1.5/30..... | 72 | <i>lidocaine-prilocaine</i> | 6 | M | |
| LARIN FE 1/20..... | 72 | <i>linezolid</i> | 8 | <i>magnesium sulfate</i> | 62 |
| <i>latanoprost</i> | 87 | LINZESS | 65 | <i>malathion</i> | 61 |
| LEENA..... | 72 | <i>liothyronine sodium</i> | 75 | <i>maraviroc</i> | 40 |
| <i>leflunomide</i> | 78 | <i>lisinopril</i> | 49 | <i>marlissa</i> | 72 |
| <i>lenalidomide</i> | 25 | <i>lisinopril-hydrochlorothiazide</i> | 52 | MARPLAN..... | 18 |
| LENVIMA (10 MG DAILY DOSE) | 29 | <i>lithium carbonate</i> | 42 | MATULANE..... | 24 |
| LENVIMA (12 MG DAILY DOSE) | 29 | <i>lithium carbonate er</i> | 42 | MATZIM LA..... | 51 |
| LENVIMA (14 MG DAILY DOSE) | 29 | LIVALO | 54 | MAVYRET | 37 |
| LENVIMA (18 MG DAILY DOSE) | 29 | LIVMARLI | 66 | MAYZENT..... | 57 |
| LENVIMA (20 MG DAILY DOSE) | 29 | LIVTENCITY | 37 | MAYZENT STARTER PACK | 57, 58 |
| LENVIMA (24 MG DAILY DOSE) | 29 | LOKELMA | 63 | <i>meclizine hcl</i> | 20 |
| LENVIMA (4 MG DAILY DOSE) | 29 | LONSURF..... | 26 | | |
| | | <i>loperamide hcl</i> | 65 | | |
| | | <i>lopinavir-ritonavir</i> | 40 | | |
| | | <i>lorazepam</i> | 42 | | |
| | | LORAZEPAM INTENSOL..... | 42 | | |
| | | LORBRENA | 29 | | |

| | | | | |
|---------------------------------------|--|--------|---|----|
| <i>medroxyprogesterone acetate</i> | M-M-R II..... | 81 | <i>niacin er (antihyperlipidemic)</i> | 55 |
| | <i>modafinil</i> | 92 | | |
| <i>mefloquine hcl</i> | <i>moexipril hcl</i> | 49 | <i>nicardipine hcl</i> | 50 |
| <i>megestrol acetate</i> | <i>molindone hcl</i> | 34 | NICOTROL..... | 7 |
| MEKINIST..... | <i>mometasone furoate</i> | 60, 88 | <i>nifedipine</i> | 50 |
| MEKTOVI..... | <i>montelukast sodium</i> | 88 | <i>nifedipine er</i> | 50 |
| <i>meloxicam</i> | <i>morphine sulfate</i> | 5 | <i>nifedipine er osmotic release</i> | 50 |
| <i>memantine hcl</i> | <i>morphine sulfate (concentrate)</i> | 5 | NIKKI..... | 73 |
| <i>memantine hcl er</i> | | 5 | <i>nilutamide</i> | 25 |
| MENACTRA..... | <i>morphine sulfate er</i> | 5 | NINLARO..... | 26 |
| MENEST..... | MOUNJARO..... | 43 | <i>nitazoxanide</i> | 32 |
| MENQUADFI..... | MOVANTIK..... | 65 | <i>nitisinone</i> | 67 |
| MENVEO..... | <i>moxifloxacin hcl</i> | 13, 85 | NITRO-BID..... | 55 |
| <i>mercaptapurine</i> | <i>moxifloxacin hcl in nacl</i> | 13 | <i>nitrofurantoin macrocrystal</i> ... | 8 |
| <i>meropenem</i> | MULTAQ..... | 49 | <i>nitrofurantoin monohyd macro</i> | 8 |
| <i>mesalamine</i> | <i>mupirocin</i> | 61 | | 8 |
| <i>mesalamine er</i> | <i>mupirocin calcium</i> | 61 | <i>nitroglycerin</i> | 55 |
| MESNEX..... | <i>mycophenolate mofetil</i> | 80 | <i>nizatidine</i> | 66 |
| <i>metformin hcl</i> | <i>mycophenolate sodium</i> | 80 | NOC DURNA..... | 69 |
| <i>metformin hcl er</i> | MYRBETRIQ..... | 68 | NORA-BE..... | 75 |
| <i>methadone hcl</i> | N | | <i>norethin ace-eth estrad-fe</i> | 73 |
| <i>methazolamide</i> | <i>na sulfate-k sulfate-mg sulf</i> .. | 66 | <i>norethindrone</i> | 75 |
| <i>methenamine hippurate</i> | <i>nabumetone</i> | 4 | <i>norethindrone acetate</i> | 75 |
| <i>methimazole</i> | <i>nadolol</i> | 50 | <i>norethindrone acet-ethinyl est</i> | 73 |
| <i>methocarbamol</i> | <i>nafcillin sodium</i> | 11 | | 73 |
| <i>methotrexate sodium</i> | <i>naloxone hcl</i> | 6, 7 | <i>norethindrone-eth estradiol</i> .. | 73 |
| <i>methotrexate sodium (pf)</i> | <i>naltrexone hcl</i> | 6 | <i>norgestimate-eth estradiol</i> | 73 |
| <i>methsuximide</i> | NAMZARIC..... | 17 | <i>norgestim-eth estrad triphasic</i> | 73 |
| <i>methylphenidate hcl</i> | <i>naproxen</i> | 4 | | 73 |
| <i>methylprednisolone</i> | <i>naproxen sodium</i> | 4 | NORTREL 0.5/35 (28)..... | 73 |
| <i>metoclopramide hcl</i> | <i>naratriptan hcl</i> | 23 | NORTREL 1/35 (21)..... | 73 |
| <i>metolazone</i> | NARCAN..... | 7 | NORTREL 1/35 (28)..... | 73 |
| <i>metoprolol succinate er</i> | NATACYN..... | 85 | NORTREL 7/7/7..... | 73 |
| <i>metoprolol tartrate</i> | <i>nateglinide</i> | 43 | <i>nortriptyline hcl</i> | 20 |
| <i>metoprolol-</i> | NATPARA..... | 84 | NORVIR..... | 40 |
| <i>hydrochlorothiazide</i> | NAYZILAM..... | 15 | NOVOLIN 70/30..... | 45 |
| <i>metronidazole</i> | <i>nebivolol hcl</i> | 50 | NOVOLIN 70/30 FLEXPEN | 45 |
| <i>metyrosine</i> | NECON 0.5/35 (28)..... | 73 | | 45 |
| <i>mexiletine hcl</i> | <i>nefazodone hcl</i> | 19 | NOVOLIN N..... | 45 |
| MICROGESTIN 1.5/30..... | <i>neomycin sulfate</i> | 7 | NOVOLIN N FLEXPEN..... | 45 |
| MICROGESTIN 1/20..... | <i>neomycin-bacitracin zn-</i> | | NOVOLIN R..... | 45 |
| MICROGESTIN FE 1.5/30.. | <i>polymyx</i> | 85 | NOVOLIN R FLEXPEN..... | 45 |
| MICROGESTIN FE 1/20.... | <i>neomycin-polymyxin-dexameth</i> | | NOVOLOG..... | 45 |
| <i>midodrine hcl</i> | | 84 | NOVOLOG FLEXPEN..... | 45 |
| <i>miglitol</i> | <i>neomycin-polymyxin-</i> | | NOVOLOG MIX 70/30..... | 45 |
| <i>miglustat</i> | <i>gramicidin</i> | 84 | NOVOLOG MIX 70/30 | |
| MILI..... | <i>neomycin-polymyxin-hc</i> .. | 85, 87 | FLEXPEN..... | 45 |
| <i>minocycline hcl</i> | NERLYNX..... | 30 | NOVOLOG PENFILL..... | 46 |
| <i>minoxidil</i> | NEUPRO..... | 33 | NOXAFIL..... | 22 |
| <i>mirtazapine</i> | <i>nevirapine</i> | 39 | NUBEQA..... | 25 |
| <i>misoprostol</i> | <i>nevirapine er</i> | 39 | NUCALA..... | 91 |

| | | | | |
|--|------------|--|--|--------|
| NUEDEXTA | 57 | P | PLASMA-LYTE A | 62 |
| NUPLAZID | 35 | <i>paliperidone er</i> | <i>podofilox</i> | 61 |
| NUTRILIPID | 64 | PANRETIN | <i>polymyxin b-trimethoprim</i> ... | 85 |
| NYAMYC | 22 | <i>pantoprazole sodium</i> | POMALYST | 25 |
| NYLIA 1/35 | 73 | PANZYGA | PORTIA-28 | 73 |
| NYLIA 7/7/7 | 73 | <i>paricalcitol</i> | <i>posaconazole</i> | 22 |
| NYMYO | 73 | <i>paromomycin sulfate</i> | <i>potassium chloride</i> | 62, 63 |
| <i>nystatin</i> | 22 | <i>paroxetine hcl</i> | <i>potassium chloride crys er</i> ... | 62 |
| <i>nystatin-triamcinolone</i> | 61 | PEDIARIX | <i>potassium chloride er</i> | 62 |
| NYSTOP | 22 | PEDVAX HIB | <i>potassium chloride in nacl</i> ... | 62 |
| O | | <i>peg 3350-kcl-na bicarb-nacl</i> 66 | <i>potassium citrate er</i> | 63 |
| OCELLA | 73 | <i>peg-3350/electrolytes</i> | <i>potassium cl in dextrose 5%</i> .63 | |
| <i>octreotide acetate</i> | 76 | PEGASYS | <i>pramipexole dihydrochloride</i> 33 | |
| ODEFSEY | 39 | PEMAZYRE | <i>prasugrel hcl</i> | 48 |
| ODOMZO | 30 | <i>penicillamine</i> | <i>pravastatin sodium</i> | 54 |
| OFEV | 90 | <i>penicillin g pot in dextrose</i> .. | <i>prazosin hcl</i> | 48 |
| <i>ofloxacin</i> | 13, 85, 87 | <i>penicillin g potassium</i> | <i>prednisolone</i> | 69 |
| <i>olanzapine</i> | 35 | <i>penicillin g procaine</i> | <i>prednisolone acetate</i> | 86 |
| <i>olanzapine-fluoxetine hcl</i> | 18 | <i>penicillin g sodium</i> | <i>prednisolone sodium</i> | |
| <i>olmesartan medoxomil</i> | 48 | <i>penicillin v potassium</i> | <i>phosphate</i> | 69, 86 |
| <i>olmesartan medoxomil-hctz</i> .. | 53 | PENTACEL..... | <i>prednisone</i> | 69 |
| <i>olmesartan-amlodipine-hctz</i> .. | 53 | <i>pentamidine isethionate</i> | PREDNISON INTENSOL | 69 |
| <i>olopatadine hcl</i> | 85 | <i>pentoxifylline er</i> | <i>preferred plus insulin syringe</i> | |
| <i>omega-3-acid ethyl esters</i> | 55 | <i>perindopril erbumine</i> | | 46 |
| <i>omeprazole</i> | 67 | PERIOGARD | <i>pregabalin</i> | 57 |
| OMNITROPE..... | 69, 70 | <i>permethrin</i> | <i>prehevbrio</i> | 82 |
| <i>ondansetron</i> | 20 | <i>perphenazine</i> | PREMARIN | 70 |
| <i>ondansetron hcl</i> | 20 | <i>phenelzine sulfate</i> | PREMASOL..... | 64 |
| ONUREG | 25 | <i>phenobarbital</i> | PREMPHASE..... | 73 |
| OPSUMIT | 90 | <i>phenytoin</i> | PREMPRO | 73 |
| ORGOVYX..... | 26 | <i>phenytoin sodium extended</i> .. | <i>prenatal</i> | 64 |
| ORKAMBI..... | 89, 90 | PIFELTRO | PREVYMIS | 37 |
| <i>orphenadrine citrate er</i> | 92 | <i>pilocarpine hcl</i> | PREZCOBIX..... | 40 |
| ORSERDU | 25 | <i>pimecrolimus</i> | PREZISTA | 40, 41 |
| <i>oseltamivir phosphate</i> | 41 | <i>pimozide</i> | PRIFTIN | 24 |
| OSPHENA | 73 | PIMTREA | <i>primaquine phosphate</i> | 32 |
| OTEZLA | 78 | <i>pindolol</i> | <i>primidone</i> | 14 |
| <i>oxacillin sodium</i> | 11 | <i>pioglitazone hcl</i> | PRIORIX | 82 |
| <i>oxacillin sodium in dextrose</i> . | 11 | <i>pioglitazone hcl-metformin hcl</i> | PRIVIGEN | 77 |
| <i>oxaprozin</i> | 4 | | <i>probenecid</i> | 22 |
| <i>oxazepam</i> | 41 | <i>piperacillin sod-tazobactam so</i> | <i>prochlorperazine</i> | 20 |
| <i>oxcarbazepine</i> | 16 | | <i>prochlorperazine maleate</i> | 20 |
| <i>oxybutynin chloride</i> | 68 | PIQRAY (200 MG DAILY | PROCTO-MED HC..... | 60 |
| <i>oxybutynin chloride er</i> | 68 | DOSE) | PROCTOSOL HC | 60 |
| <i>oxycodone hcl</i> | 5, 6 | PIQRAY (250 MG DAILY | PROCTOZONE-HC..... | 60 |
| <i>oxycodone hcl er</i> | 5 | DOSE) | <i>progesterone</i> | 75 |
| <i>oxycodone-acetaminophen</i> | 6 | PIQRAY (300 MG DAILY | PROGRAF..... | 80 |
| OZEMPIC (0.25 OR 0.5 | | DOSE) | PROLASTIN-C | 67 |
| MG/DOSE)..... | 43 | <i>pirfenidone</i> | PROLIA..... | 84 |
| OZEMPIC (1 MG/DOSE).... | 43 | <i>piroxicam</i> | PROMACTA..... | 47 |
| OZEMPIC (2 MG/DOSE).... | 43 | PLASMA-LYTE 148 | <i>promethazine hcl</i> | 20 |

| | | | | | |
|-------------------------------------|--------|--|--------|--|--------|
| <i>propafenone hcl</i> | 49 | <i>risedronate sodium</i> | 84 | <i>sodium polystyrene sulfonate</i> | 63 |
| <i>propranolol hcl</i> | 23, 50 | RISPERDAL CONSTA | 36 | <i>sofosbuvir-velpatasvir</i> | 37 |
| <i>propranolol hcl er</i> | 23, 50 | <i>risperidone</i> | 36 | <i>solifenacin succinate</i> | 68 |
| <i>propylthiouracil</i> | 77 | <i>ritonavir</i> | 41 | SOLQUA..... | 46 |
| PROQUAD..... | 82 | <i>rivastigmine</i> | 17 | SOLTAMOX..... | 25 |
| PROSOL..... | 64 | <i>rivastigmine tartrate</i> | 17 | SOMAVERT | 76 |
| <i>protriptyline hcl</i> | 20 | <i>rizatRIPTAN benzoate</i> | 23 | <i>sorafenib tosylate</i> | 30 |
| PULMOZYME..... | 90 | ROCKLATAN | 87 | <i>sotalol hcl</i> | 49 |
| PURIXAN | 25 | <i>roflumilast</i> | 90 | <i>sotalol hcl (af)</i> | 49 |
| <i>pyrazinamide</i> | 24 | <i>ropinirole hcl</i> | 33 | SPIRIVA HANDIHALER .. | 89 |
| <i>pyridostigmine bromide</i> | 24 | <i>rosuvastatin calcium</i> | 54 | SPIRIVA RESPIMAT..... | 89 |
| Q | | ROTARIX | 82 | <i>spironolactone</i> | 53 |
| QINLOCK..... | 30 | ROTATEQ..... | 82 | <i>spironolactone-hctz</i> | 53 |
| QUADRACEL | 82 | ROZLYTREK | 30 | SPRINTEC 28 | 74 |
| <i>quetiapine fumarate</i> | 36 | RUBRACA..... | 30 | SPRITAM..... | 14, 15 |
| <i>quetiapine fumarate er</i> | 36 | <i>rufinamide</i> | 16 | SPRYCEL..... | 30 |
| <i>quinapril hcl</i> | 49 | RUKOBIA..... | 40 | SPS | 63 |
| <i>quinidine sulfate</i> | 49 | RYBELSUS..... | 44 | SRONYX..... | 74 |
| <i>quinine sulfate</i> | 32 | RYDAPT | 30 | SSD..... | 61 |
| R | | RYTARY..... | 33 | STELARA | 78 |
| RABAVERT | 82 | S | | STIVARGA..... | 30 |
| <i>raloxifene hcl</i> | 84 | SANTYL | 61 | STRIBILD | 38 |
| <i>ramipril</i> | 49 | <i>sapropterin dihydrochloride</i> | 67 | SUBOXONE | 6 |
| <i>ranolazine er</i> | 53 | SAVELLA..... | 57 | <i>sucralfate</i> | 66 |
| <i>rasagiline mesylate</i> | 33 | SAVELLA TITRATION | | <i>sulfacetamide sodium</i> | 85 |
| RAVICTI..... | 67 | PACK | 57 | <i>sulfacetamide sodium (acne)</i> .. | 13 |
| RECLIPSEN..... | 74 | SCSEMBLIX..... | 30 | <i>sulfacetamide-prednisolone</i> .. | 85 |
| RECOMBIVAX HB | 82 | <i>scopolamine</i> | 20 | <i>sulfadiazine</i> | 13 |
| RECTIV | 55 | SECUADO..... | 36 | <i>sulfamethoxazole-trimethoprim</i> | 13 |
| REGRANEX | 61 | <i>selegiline hcl</i> | 33 | | 13 |
| RELENZA DISKHALER.... | 41 | <i>selenium sulfide</i> | 60 | <i>sulfasalazine</i> | 83 |
| RELI-ON INSULIN | | SELZENTRY | 40 | <i>sulindac</i> | 5 |
| SYRINGE..... | 46 | SEREVENT DISKUS | 89 | <i>sumatriptan</i> | 23 |
| <i>repaglinide</i> | 44 | <i>sertraline hcl</i> | 19 | <i>sumatriptan succinate</i> | 23 |
| REPATHA | 55 | SETLAKIN | 74 | <i>sumatriptan succinate refill</i> .. | 23 |
| REPATHA PUSHTRONEX | | <i>sevelamer carbonate</i> | 64, 65 | <i>sunitinib malate</i> | 30 |
| SYSTEM..... | 55 | SHAROBEL..... | 75 | SUNLENCA..... | 40 |
| REPATHA SURECLICK.... | 55 | SHINGRIX..... | 82 | SUTAB | 66 |
| RETACRIT | 47 | SIGNIFOR..... | 76 | SYEDA..... | 74 |
| RETEVMO..... | 30 | <i>sildenafil citrate</i> | 65, 90 | SYMDEKO | 90 |
| REXULTI..... | 36 | <i>silodosin</i> | 68 | SYMLINPEN 120 | 44 |
| REYATAZ | 41 | <i>silver sulfadiazine</i> | 61 | SYMLINPEN 60 | 44 |
| REZLIDHIA..... | 30 | SIMBRINZA | 87 | SYMPAZAN | 15 |
| REZUROCK | 80 | <i>simvastatin</i> | 54 | SYMTUZA..... | 38 |
| RHOPRESSA..... | 87 | <i>sirolimus</i> | 80 | SYNAREL..... | 76 |
| <i>ribavirin</i> | 37 | SIRTURO..... | 24 | SYNJARDY | 44 |
| <i>rifabutin</i> | 24 | SKYRIZI | 78 | SYNJARDY XR..... | 44 |
| <i>rifampin</i> | 24 | SKYRIZI PEN..... | 78 | SYNRIBO..... | 26 |
| <i>riluzole</i> | 57 | <i>sodium chloride</i> | 63 | SYNTHROID | 75 |
| <i>rimantadine hcl</i> | 41 | <i>sodium fluoride</i> | 63 | T | |
| RINVOQ | 78 | <i>sodium oxybate</i> | 92 | TABLOID..... | 25 |

| | | | | | |
|---------------------------------------|--------|--------------------------------------|--------|--------------------------------------|------|
| TABRECTA..... | 30 | TOBI PODHALER | 90 | TROPHAMINE..... | 64 |
| <i>tacrolimus</i> | 60, 80 | <i>tobramycin</i> | 85, 90 | <i>trospium chloride</i> | 68 |
| TAFINLAR..... | 30 | <i>tobramycin sulfate</i> | 7 | <i>trospium chloride er</i> | 68 |
| TAGRISSE | 30 | <i>tobramycin-dexamethasone</i> .. | 85 | TRULICITY | 44 |
| TAKHZYRO..... | 77 | <i>tolterodine tartrate</i> | 68 | TRUMENBA..... | 82 |
| TALZENNA..... | 31 | <i>tolterodine tartrate er</i> | 68 | TUKYSA..... | 31 |
| <i>tamoxifen citrate</i> | 25 | <i>tolvaptan</i> | 63 | TURALIO..... | 31 |
| <i>tamsulosin hcl</i> | 68 | <i>topiramate</i> | 23 | TWINRIX..... | 82 |
| TARINA FE 1/20 EQ..... | 74 | <i>topiramate er</i> | 23 | TYBOST..... | 40 |
| TASIGNA | 31 | <i>toremifene citrate</i> | 25 | TYMLOS..... | 84 |
| TAVNEOS | 78 | <i>torseamide</i> | 53 | TYPHIM VI..... | 83 |
| <i>tazarotene</i> | 58 | TOUJEO MAX SOLOSTAR | | U | |
| TAZORAC..... | 58 | | 46 | UBRELVY | 23 |
| TAZTIA XT | 51 | TOUJEO SOLOSTAR..... | 46 | UNITHROID..... | 75 |
| TAZVERIK..... | 31 | TPN ELECTROLYTES | 64 | <i>ursodiol</i> | 66 |
| TDVAX..... | 82 | <i>tramadol hcl</i> | 6 | V | |
| TEFLARO..... | 10 | <i>tramadol-acetaminophen</i> | 6 | <i>valacyclovir hcl</i> | 38 |
| TEGSEDI | 67 | <i>trandolapril</i> | 49 | VALCHLOR | 24 |
| <i>telmisartan</i> | 48 | <i>trandolapril-verapamil hcl er</i> | | <i>valganciclovir hcl</i> | 37 |
| <i>telmisartan-amlodipine</i> | 53 | | 53 | <i>valproic acid</i> | 15 |
| <i>telmisartan-hctz</i> | 53 | <i>tranexamic acid</i> | 47 | <i>valsartan</i> | 48 |
| <i>temazepam</i> | 92 | <i>tranylcypromine sulfate</i> | 18 | <i>valsartan-hydrochlorothiazide</i> | |
| TENIVAC | 82 | TRAVASOL..... | 64 | | 53 |
| <i>tenofovir disoproxil fumarate</i> | | <i>travoprost (bak free)</i> | 87 | VALTOCO 10 MG DOSE ... | 15 |
| | 39 | <i>trazodone hcl</i> | 19 | VALTOCO 15 MG DOSE ... | 15 |
| TEPMETKO..... | 31 | TRECTOR..... | 24 | VALTOCO 20 MG DOSE ... | 15 |
| <i>terazosin hcl</i> | 48 | TRELEGY ELLIPTA..... | 91 | VALTOCO 5 MG DOSE | 16 |
| <i>terbinafine hcl</i> | 22 | TRELSTAR MIXJECT | 77 | <i>vancomycin hcl</i> | 8, 9 |
| <i>terbutaline sulfate</i> | 89 | TRESIBA | 46 | VAQTA | 83 |
| <i>terconazole</i> | 22 | TRESIBA FLEXTOUCH..... | 46 | <i>varenicline tartrate</i> | 7 |
| <i>teriparatide (recombinant)</i> ... | 84 | <i>tretinoin</i> | 31, 58 | VARIVAX..... | 83 |
| <i>testosterone</i> | 70 | TREXALL..... | 80 | VARUBI (180 MG DOSE) .. | 20 |
| <i>testosterone cypionate</i> | 70 | <i>triamcinolone acetonide</i> . | 58, 60 | VASCEPA..... | 55 |
| <i>testosterone enanthate</i> | 70 | <i>triamterene-hctz</i> | 53 | VELIVET | 74 |
| <i>tetrabenazine</i> | 57 | <i>trientine hcl</i> | 63 | VELPHORO..... | 65 |
| <i>tetracycline hcl</i> | 13 | TRI-ESTARYLLA..... | 74 | VEMLIDY..... | 37 |
| THALOMID..... | 25 | <i>trifluoperazine hcl</i> | 34 | VENCLEXTA | 31 |
| <i>theophylline er</i> | 90 | <i>trifluridine</i> | 38 | VENCLEXTA STARTING | |
| <i>thioridazine hcl</i> | 34 | <i>trihexyphenidyl hcl</i> | 32 | PACK | 31 |
| <i>thiothixene</i> | 34 | TRIKAFTA | 90 | <i>venlafaxine besylate er</i> | 19 |
| TIADYLT ER | 51 | <i>trimethoprim</i> | 8 | <i>venlafaxine hcl</i> | 19 |
| <i>tiagabine hcl</i> | 15 | TRI-MILI..... | 74 | <i>venlafaxine hcl er</i> | 19 |
| TIBSOVO..... | 31 | <i>trimipramine maleate</i> | 20 | VENTOLIN HFA | 89 |
| TICOVAC..... | 82 | TRINTELLIX..... | 19 | <i>verapamil hcl</i> | 51 |
| <i>tigecycline</i> | 8 | TRI-NYMYO | 74 | <i>verapamil hcl er</i> | 51 |
| <i>timolol maleate</i> | 50, 86 | TRI-SPRINTEC | 74 | VERQUVO..... | 53 |
| <i>timolol maleate (once-daily)</i> | 86 | TRIUMEQ..... | 40 | VERSACLOZ..... | 37 |
| <i>tinidazole</i> | 8 | TRIUMEQ PD..... | 40 | VERZENIO | 31 |
| TIVICAY | 38 | TRIVORA (28)..... | 74 | VESTURA..... | 74 |
| TIVICAY PD | 38 | TRI-VYLIBRA | 74 | VICTOZA..... | 44 |
| <i>tizanidine hcl</i> | 37 | TRIZIVIR..... | 39 | VIENVA..... | 74 |

| | | | | | |
|------------------------------|----|------------------------------------|----|-----------------------------------|----|
| <i>vigabatrin</i> | 16 | XCOPRI (250 MG DAILY DOSE) | 15 | Y | |
| VIIBRYD STARTER PACK | 19 | XCOPRI (350 MG DAILY DOSE) | 15 | YF-VAX | 83 |
| VIJOICE | 67 | XERMELO | 65 | YONSA | 25 |
| <i>vilazodone hcl</i> | 19 | XGEVA | 84 | Z | |
| VIRACEPT | 41 | XIFAXAN | 9 | <i>zafirlukast</i> | 88 |
| VIREAD | 39 | XOFLUZA (40 MG DOSE) | 41 | <i>zaleplon</i> | 92 |
| VITRAKVI | 31 | XOFLUZA (80 MG DOSE) | 41 | ZARXIO | 47 |
| VIVITROL | 6 | XOLAIR | 78 | ZEJULA | 31 |
| VIZIMPRO | 31 | XOSPATA | 31 | ZELBORAF | 31 |
| VONJO | 31 | XPOVIO (100 MG ONCE WEEKLY) | 26 | ZEMDRI | 7 |
| <i>voriconazole</i> | 22 | XPOVIO (40 MG ONCE WEEKLY) | 26 | ZENPEP | 67 |
| VOSEVI | 37 | XPOVIO (40 MG TWICE WEEKLY) | 26 | <i>zidovudine</i> | 40 |
| VOTRIENT | 31 | XPOVIO (60 MG ONCE WEEKLY) | 26 | ZIEXTENZO | 47 |
| VRAYLAR | 36 | XPOVIO (60 MG TWICE WEEKLY) | 26 | ZIMHI | 7 |
| VYFEMLA | 74 | XPROVIO (80 MG ONCE WEEKLY) | 26 | <i>ziprasidone hcl</i> | 36 |
| VYLIBRA | 74 | XPROVIO (80 MG TWICE WEEKLY) | 26 | <i>ziprasidone mesylate</i> | 36 |
| VYNDAMAX | 67 | XTANDI | 25 | ZIRGAN | 37 |
| VYZULTA | 87 | XULTOPHY | 44 | ZOKINVY | 67 |
| W | | XURIDEN | 67 | ZOLINZA | 27 |
| <i>warfarin sodium</i> | 47 | | | <i>zolmitriptan</i> | 23 |
| WELIREG | 26 | | | <i>zolpidem tartrate</i> | 92 |
| X | | | | ZONISADE | 15 |
| XALKORI | 31 | | | <i>zonisamide</i> | 15 |
| XARELTO | 47 | | | ZOVIA 1/35 (28) | 74 |
| XARELTO STARTER PACK | 47 | | | ZTALMY | 15 |
| XATMEP | 26 | | | ZYDELIG | 31 |
| XCOPRI | 15 | | | ZYKADIA | 31 |
| | | | | ZYPREXA RELPREVV | 37 |

This formulary was updated on 08/25/2023. For more recent information or other questions, please contact us, Sonder Health Plans Member Service at 1-833-684-7263 (TTY users should call 711), 24 hours a day, 7 days a week, or visit www.sonderhealthplans.com.

Multi-Language Insert

Multi-language Interpreter Services

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at 1-888-428-4440. Someone who speaks English/Language can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al 1-888-428-4440. Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 1-888-428-4440。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 1-888-428-4440。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa 1-888-428-4440. Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au 1-888-428-4440. Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi 1-888-428-4440 sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí .

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter 1-888-428-4440. Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 대해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 1-888-428-4440 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону 1-888-428-4440. Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بالصحة أو جدول الأدوية لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على 1-888-428-4440. سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं. एक दुभाषिया प्राप्त करने के लिए, बस हमें 1-888-428-4440 पर फोन करें. कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है. यह एक मुफ्त सेवा है.

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero 1-888-428-4440. Un nostro incaricato che parla Italianovi fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número 1-888-428-4440. Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan 1-888-428-4440. Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer 1-888-428-4440. Ta usługa jest bezpłatna.

Japanese: 当社の健康 健康保険と薬品 処方薬プランに関するご質問にお答えするため、無料の通訳サービスがあります。通訳をご用命になるには、1-888-428-4440にお電話ください。日本語を話す人者が支援いたします。これは無料のサービスです。